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Chapter 1 
INTRODUCTION 
Monitoring the Future (MTF) is a long-term study of American adolescents, college students, and 
adult high school graduates through age 60. The study is supported under a series of investigator-
initiated, competing research grants from the National Institute on Drug Abuse and has been 
conducted annually by the University of Michigan’s Institute for Social Research since 1975. 
The present monograph focuses on a broad range of behaviors, including certain forms of 
substance use, related to the spread of the human immunodeficiency virus (HIV), which is 
responsible for acquired immunodeficiency syndrome (AIDS). The populations under study here 
includes high school graduates in the general population ages 21-30, surveyed annually since 2004; 
age 35, surveyed annually since 2008; and age 40, surveyed annually since 2010.  
HIV infection is clearly a serious public health concern. Worldwide, about 36.9 million people 
were living with AIDS at the end of 2017 (WHO, 2018). In the United States, about 1.1 million 
people were living with HIV in 2015, and 1 in 7 were unaware of their infection (CDC, 2018a). 
The rate of new HIV infections has been decreasing, albeit very gradually, in recent years; between 
2011 and 2015, the rate of new HIV infections dropped by 5% (CDC, 2018a). However, progress 
has been uneven, and some segments of the population continue to show increases in infections 
(CDC, 2018a). The present monograph addresses some of the factors that may be preventing 
further progress against HIV/AIDS.   
In this monograph, we track some of the key behaviors related to the spread of HIV/AIDS in the 
United States, some of which also relate to the spread of other sexually transmitted diseases (STD). 
In 2016, about 40,000 individuals became newly infected with HIV in the United States (CDC, 
2018a). MTF surveys assess both sexual risk behaviors and injection drug use (including needle 
sharing), which are two main sources of HIV infection. In addition to the particular risk of HIV, 
young adults are at high risk of contracting other sexually transmitted diseases and infections. 
Since 2013, there have been significant and sustained increases in the number of STD infections 
in the United States (CDC, 2018b). Nearly half of the approximately 20 million STDs occurring 
annually in the United States affect individuals aged 15 to 24 (CDC, 2017; Satterwhite et al., 2013).  
The present volume is the fourth monograph in the MTF series of annual reports, all available 
online from the MTF website. The first monograph, Overview of Key Findings, is published near 
the beginning of each year and provides early findings on the levels and trends in use of various 
substances by the nation’s 8th, 10th, and 12th grade students surveyed in the previous year 
(Johnston et al., 2018). Volume I, available at the beginning of June, provides more detailed and 
complete findings on the same population (Miech et al., 2018). Volume II, available at the 
beginning of August, provides similar prevalence and trend information on the substance-using 
behaviors of adult high school graduates through age 55, based on a series of follow-up surveys of 
representative samples of students from each high school graduating class (Schulenberg et al., 
2018). Volume II has provided findings specific to college students since 1980. HIV/AIDS risk 
and protective behaviors were introduced into the MTF follow-up surveys in 2004 and findings 
 
1
based on these measures were reported in Volume II from 2004 through 2008, after which they 
were published in separate volumes including the present one. 
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Chapter 2 
BACKGROUND 
HIV/AIDS remains an important and ongoing threat to public health. Behaviors of the general 
population, especially among young adults, are an important part of the problem. Questions about 
known risk and protective behaviors (i.e., needle sharing, multiple sex partners, men having sex 
with men, condom use, testing for HIV) were added to MTF in 2004.  
This monograph reports levels of these behaviors among three age bands: young adults 21–30 
years old, adults 35 years old, and those 40 years old; it also reports on the degree to which they 
intersect. In Chapters 9 and 10 we examine the time trends in these HIV/AIDS-related risk and 
protective behaviors (e.g., multiple sex partners, condom use) among respondents 21–40 years old. 
Over the years, we have found that the risk and protective behaviors were relatively stable early in 
the interval from 2004 to 2015, and at far from optimal levels. We had previously written that 
stability in these behaviors helped to explain the CDC finding that the reported incidence of new 
HIV cases was level from 1991 to 2014 (CDC, 2008; CDC, 2015a; CDC, 2015b; CDC, 2015c) 
with an estimated 50,000 new HIV infections per year, and with new diagnoses recently increasing 
among young adults (CDC, 2015c; CDC, 2015d). More recently, however, we are beginning to 
see some changes in some of the risk and protective factors that we track, as will be documented 
in this monograph.  
The CDC more recently issued revised analyses of the trends, estimating that there actually has 
been a 12% decline in new HIV infections between 2010 and 2015 (CDC, 2018a). This is a limited 
improvement over a six year period, but nonetheless an important one. The improvement has been 
greater among certain subgroups such as females, African Americans, and heterosexuals. 
However, new HIV infections were found to increase among other groups, particularly those aged 
25–34 (CDC, 2018a).  
The National HIV/AIDS Strategy (White House Office of National AIDS Policy, 2015) lists 
widespread testing and linkage to care as one of its four key areas of critical focus. Being tested 
for HIV/AIDS and securing the results have been shown to be protective behaviors for individuals 
testing positive as well as others (HIV.Gov, 2018). Obtaining testing results for those testing 
positive can enable (1) earlier treatment to reduce the progression of the disease and the likelihood 
of dying from it; and (2) reduced exposure of others to the disease by abstaining from sexual 
contact, using condoms, and not sharing needles. Obtaining results for those not testing positive is 
also protective, because it helps provide an opportunity for re-evaluation of current risks and 
prevention strategies (HIV.gov, 2018).  
Importantly, the CDC attributes the improvement to the number of people who know they are HIV 
positive and have their infection under control, making them less likely to spread the disease. This 
has been due largely to the use of antiretroviral medications which “dramatically reduce a person’s 
risk of transmitting the virus to others” (CDC, 2017, p.1). Also, they mention the use of PrEP, a 
pre-exposure prophylaxis for which the CDC issued interim clinical guidelines in 2012. It is a pill 
that, when taken daily by someone without HIV, can reduce their risk of infection by more than 
90%.  
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Despite these improvements, attributable largely to medical advances, there remains a need for the 
continued monitoring of the other known risk and protective behaviors in the general population. 
Several national studies provide important epidemiological data regarding HIV/AIDS, as is 
described in the Appendix to this volume; but none duplicate all of the contributions of MTF to 
understanding the epidemic. Thus, MTF is an important component of the nation's efforts to 
monitor and understand HIV/AIDS-related risk and protective behaviors in the general population. 
 
Some of the behaviors that put people at heightened risk of contracting and spreading HIV are 
connected to drug abuse—in particular, drug use by injection when it involves needle sharing. 
Other behaviors related to heightened risk involve sexual practices, including having multiple sex 
partners, which itself is a behavior correlated with drug use. Further, both drug use and having 
multiple sex partners tend to be more prevalent among young adults than in other age groups 
(Anderson & Dahlberg, 1992; Gavin et al., 2009; Lefkowitz & Gillen, 2006). Another major risk 
behavior is men having unprotected sex with men (CDC, 2018a).  
 
Using MTF data, Patrick et al. (2012) documented that the number of sexual partners is positively 
correlated with binge drinking, marijuana use, and other illicit drug use, and that these relationships 
vary across age. In addition, more frequent use of marijuana and other illicit drugs was associated 
with less frequent condom use. There was a moderation effect, indicating that the positive 
correlation between binge drinking and number of sexual partners was stronger for younger 
individuals (i.e., aged 21–24) than somewhat older individuals (i.e., aged 25–30).  
 
An important protective behavior is getting tested for HIV/AIDS, particularly given the advent of 
effective retroviral treatments for the disease (Fauci & Folkers, 2012; Steinbrook, 2013). Early 
detection can alert the infected individual to the potential of infecting others, particularly others 
with whom he or she is sexually active and/or shares needles. Early and sustained treatment can 
not only protect the treated individual but also reduce the odds of transmitting HIV to others. Many 
individuals do not know that they are infected, especially young people; it is estimated that 51% 
of adolescents and young adults who have HIV do not know that they are infected (CDC, 2018b). 
In order to reduce the number of new HIV infections, infected individuals need to be identified 
and then receive effective care (Gardner et al., 2011). 
 
A second main protective behavior is condom use. According to the CDC, “latex condoms, when 
used consistently and correctly, are highly effective in preventing the sexual transmission of HIV” 
and other sexually transmitted diseases (CDC, 2011). However, consistent condom use is not 
widespread. According to the CDC (2010), only 23% of women aged 15–44 who have never been 
married and are not cohabiting with a partner choose condoms as their method of contraception. 
Rates of dual-method contraceptive use (i.e., using the male condom plus an oral or other 
contraceptive method) to prevent both STDs and unintended pregnancy is low in the United States; 
recent estimates indicate 17% of contraceptive users combine two or more methods (Sonfield, 
2017). Condom use is an important way to prevent HIV and other STDs among sexually active 
individuals, and is a clear focus of HIV prevention efforts.  
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Other Relevant Studies of the General Population 
A considerable literature has evolved based on studies of particular high-risk populations, such as 
injection drug users and men who have sex with men, but there are fewer studies on the prevalence 
of risk and protective behaviors in the general population. To our knowledge, there are currently 
six data collection efforts in addition to the present one that provide some information on 
HIV/AIDS risk behaviors based on nationally representative surveys of the general population. 
These studies are described and compared to MTF in the Appendix to this volume. Each of these 
surveys provides some key HIV/AIDS risk behavior data; however, as discussed in the Appendix, 
none fully duplicates the type of HIV/AIDS-related information produced by the MTF study. 
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Chapter 3 
 
RESEARCH DESIGN 
 
MTF is uniquely suited to address key gaps in the literature concerning HIV/AIDS-related risk 
and protective behaviors. Most of the features that make MTF an important epidemiologic and 
etiologic study of drug use also apply to tracking and studying HIV/AIDS-related behaviors. MTF 
is population-based, prospective, cohort-sequential, and has especially rich measures of drug use 
with which to study how drug use relates to HIV transmission directly (through injection drug use 
and needle sharing) and indirectly (through engaging in risky sexual and other behaviors). 
 
The MTF research design is described in detail in Volume I (Miech et al., 2018), Volume II 
(Schulenberg et al., 2018), and in MTF Occasional Paper 82 (Bachman et al., 2015), so we limit 
the description here to a brief overview. 
 
Samples 
The MTF design has included a representative subsample of each 12th-grade class sample since 
1976, with 2,450 participants from each class selected in a stratified random procedure for follow-
up. The 2,450 are randomly split into two half samples of 1,225 each, one surveyed on even 
numbered years and the other surveyed on odd numbered years up to six times, through modal age 
29 or 30. After that, they are followed at five-year intervals, starting at age 35, and currently 
continuing up to age 60 this year, but reporting through age 55 here. With this design, it is possible 
to present data for each class every year while surveying each respondent only every other year 
through age 30; this schedule was judged to be less demanding, less repetitive and, therefore, more 
conducive to retention in the panels than an annual follow-up of each individual. In order to 
increase the numbers of drug users in these panels, certain groups are selected for the follow-up 
samples with a higher probability (by a factor of 3.0) than the remaining 12th graders. Those over-
sampled include high school seniors who report 20 or more occasions of marijuana use in the prior 
30 days (i.e., “daily or near-daily users”) in 12th grade and/or any use of other illicit drugs in the 
prior 30 days. Corrective weighting is then used in all subsequent analyses to adjust for these 
differential sampling probabilities. Those in the drug-using stratum receive a weight of 0.33 in the 
calculation of all statistics to correct for their overrepresentation in the selection stage. As a result, 
the actual numbers of follow-up respondents are larger than the weighted Ns given in the tables.  
 
The respondents included in the analyses presented in this volume were drawn from participants 
in the MTF follow-up surveys of 21- to 30-year-olds in 2004–2017 (representing graduates from 
the high school classes of 1992–2014); 35-year-olds in 2008–2017 (representing graduates from 
the classes of 1991–2000); and 40-year-olds in 2010–2017 (representing graduates from the 
classes of 1988–1995). 
 
The present monograph reports findings from respondents of modal ages 21 to 30, 35, and 40. For 
those ages 21 to 30, there are fourteen years of data (collected in 2003 through 2017; weighted N 
= 29,906 observations), but there are fewer individuals, because most provided two or more 
observations (N=10,322 individuals, as is discussed below). For those age 35 there are ten years 
of data (collected in 2008 through 2017; weighted N = 8,541 observations and individuals). For 
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those age 40 there are eight years of data (collected in 2010 through 2017; weighted N = 6,851 
observations and individuals). Because of the limited sample sizes, particularly at the older ages, 
certain subgroup estimates are not reliable and therefore are not reported. 
 
Measures 
Each 12th-grade respondent in recent years has been administered one of six different, randomly 
distributed, questionnaire forms in their senior year—a procedure adopted in order to cover much 
more material than would have been possible in one class period using a single form. Each 
individual selected for the young adult follow-up surveys receives a form of the questionnaire 
matching the one he or she completed in 12th grade; much of the content is the same, though some 
content is replaced with more age-appropriate topics such as family formation, experiences in 
higher education, and work history.  
 
In 2004, new questions covering risk and protective behaviors for HIV/AIDS were included in two 
of the questionnaire forms being mailed to people of modal ages 21–30. Beginning in 2007, this 
set of questions was added to a third questionnaire form in order to increase sample size. One 
reason for limiting the new HIV/AIDS-related questions to two forms initially was to determine 
whether the inclusion of the sensitive items on sexual practices would adversely affect follow-up 
response rates. Fortunately, no decrement was observed, so the same set of questions was added 
to an additional questionnaire form in the 2007 survey of young adults, raising the annual case 
count by half again what it had been in 2004–2006.1 
 
In 2008 the same set of questions was added to the single questionnaire form that went to a random 
half of the 35-year-olds, and response rates were compared that year between the half sample 
receiving the revised form and the half sample that received the original form. The response rates 
again were comparable for the two half samples, so the new set of questions was included in 
surveys of all 35-year-olds in 2009 and later. Because of concerns about whether the impact on 
response rates might rise with increasing age, we surveyed the age-35 stratum first, and finding no 
clear adverse effect, added the question set to the age-40 stratum beginning in 2010.  
 
Risk behavior variables include lifetime and 12-month frequency of injecting drugs without a 
doctor’s order; lifetime and 12-month prevalence of using a needle that the respondent “knew (or 
suspected) had been used by someone else” before they used it; number of sex partners during the 
12 months prior to the survey; and whether those partners had been exclusively opposite sex, same 
sex, or both male and female.  
 
Protective behavior variables include lifetime and 12-month prevalence of being tested for HIV; 
obtaining the results of the most recent HIV test; and frequency of condom use in the prior 12 
months.2 The exact questions measuring these different variables are included in the tables in this 
monograph. 
1 When we added this new form to the set containing questions on risk and protective behaviors for the transmission of HIV, we compared its results 
with those from the other two forms to make sure that there were no systematic differences across forms in the estimates derived. The results proved 
highly comparable across forms, which is reassuring for trend estimation based on the increasing number of forms used. 
2 In earlier surveys we also asked about lifetime and 12-month prevalence of donating blood or blood plasma, not because it is a behavior that puts 
the respondent at risk, but because it is a behavior that—depending on the risky behaviors of the respondent—could have posed a very small chance 
of putting others at risk. Because that risk is now estimated to be extremely small, we no longer report on blood donation in this series of 
monographs.  
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 Field Procedures 
The initial data collection from panel members occurs at 12th grade; they complete a self-
administered questionnaire in a group setting, usually their normal classroom but sometimes in 
larger groups. They are asked to complete the questionnaires during a usual class period (about 45 
minutes) and to complete a tear-off card providing contact information, which permits subsequent 
communication with the subsample selected for panel study follow-up. After the card is separated 
from the questionnaire, the identifying information on it can be matched to the questionnaire only 
by using a computer file at the University of Michigan, because the numbers printed on the back 
of the questionnaire and the card are long, randomly matched numbers. This, plus the facts that 
the questionnaires are machine-readable and that they are administered (and the cards are 
collected) separately by a field representative from the University of Michigan, helps to assure 
respondents that their confidentiality has been protected.  
 
The respondents subsequently selected into the panels are followed by mail—a highly cost-
effective method of data collection that helps make large sample sizes possible. Annually, each 
respondent receives an MTF newsletter with an address correction card enclosed; each respondent 
up to age 29/30 also receives an invitation letter sent prior to the questionnaire. A subsequent letter 
is printed on the front of the questionnaire. The questionnaire is sent with a check made out to the 
subject, currently in the amount of $20 in the case of the older panels (age 35 or over); the payment 
was raised to $25 per occasion for half of the class of 2006 and for all high school graduating 
classes thereafter to help offset the effects of inflation. Extensive efforts are made to secure 
location information on previous participants whom we are unable to locate by mail. Reminder 
postcards are sent about two weeks after the questionnaires, and telephone calls are made to 
attempt to contact those who have not responded after a reasonable interval in order to request 
their participation. No answers to the questionnaire are obtained by telephone; responses are 
obtained only by mail. Beginning with 2018 data collections, we include the option of web-based 
surveys with the young adult panel respondents. 
 
Panel Retention 
We summarize the nature of the panel attrition problem generally, the response rates for MTF 
panel surveys in recent years, and evidence relevant to assessing the impact of attrition on the 
study’s research results. 
 
Response Rates. Virtually all longitudinal studies—including MTF—experience attrition, which 
is often differential with respect to health risks including substance use (e.g., Booker et al., 2011; 
Brook et al., 2009; Galea & Tracy, 2007; McCabe & West, 2015; McGuigan et al., 1997). In 
addition, survey response rates in general have been declining in recent decades (e.g., Dillman et 
al., 2009; Groves, 2006; Groves et al., 2002; Massey & Tourangeau, 2013; Pew Research Center, 
2012; Wechsler et al., 2002), highlighting an important challenge in the conduct of all population-
based research. 
 
A vital feature of the MTF panel studies is the very low cost per respondent. There are many 
advantages to collecting panel data through low-cost surveys. Indeed, given the number of MTF 
questionnaires sent each year (roughly 18,000) across the entire coterminous U.S., we have viewed 
low-cost mail and web surveys as our best cost-effective options. One disadvantage of data 
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collection by mail or web surveys is that attrition rates tend to be higher than those that might be 
obtained with much more expensive methods, such as intensive personal tracking and face-to-face 
interviewing. There are a few large epidemiological/etiological surveys that have better retention 
rates, but their procedures are extremely expensive and not realistic for an ongoing effort like 
MTF. Our retention rates compare favorably with those of most longitudinal studies reported in 
the field, including interview studies. We are working to increase response rates (or at least stem 
the general response rate erosion mentioned below) based on results from an experiment in which 
we offered respondents the option of responding online to determine the extent to which web-
based data collection affects response rates, data quality, respondent composition, and cost per 
respondent. The early results look promising (Patrick et al., 2018). In an extension of that 
experiment, we have optimized the web surveys for mobile devices such as smart phones, which 
may be more convenient for responding for certain groups, and starting with 2018 data collections, 
we are now using web-based surveys for a subsample of panel respondents. 
 
Retention rates in the biennial follow-ups of respondents modal ages 19–30 (corresponding to the 
first six follow-ups) decline with the length of the follow-up interval. For the five surveys from 
2013 to 2017, the response rate in the first follow-up (corresponding to one to two years past high 
school) averaged 420%, and for the sixth follow-up (corresponding to 11–12 years past high 
school) response rates averaged 40% of the originally selected panels. (Among long-term 
respondents—the 35-, 40-, 45-, 50-, and 55-year-olds—retention rates are quite good, apparently 
because some of the decline over time in retention rates reflects cohort differences.) In sum, the 
response rates attained under the current design range from respectable to quite good, especially 
when the low-cost nature of the procedure, the long time-intervals, the modest payment, and the 
substantial length of the questionnaires are taken into account. More importantly, the evidence 
discussed next leaves us confident that the data resulting from these follow-up panels are 
reasonably accurate, which brings us to our adjustments for panel attrition and the comparison of 
our results with those from other sources.  
 
The Impact of Panel Attrition on Research Results. An important purpose of the MTF panel study 
is to allow estimation of drug prevalence levels among American high school graduates at various 
ages. Thus, we have always been concerned about making the appropriate adjustments to account 
for panel attrition. In essence, our standard adjustment process is a post-stratification procedure in 
which we reweight the data obtained from the follow-up samples in such a way that, when 
reweighted, the distribution of their 12th-grade answers on a given drug matches the original 
distribution of use observed for that drug based on all participating high school seniors in their 
graduating class. This procedure is carried out separately for cigarettes, alcohol, and marijuana, as 
well as other illicit drugs (combined). As expected, it produces prevalence estimates in the follow-
up data that are somewhat higher than those uncorrected for attrition, indicating a positive 
association between drug use and panel attrition. However, the adjustments are relatively modest. 
 
Attrition rates by levels of 12th grade substance use differ some, but less than one might expect. 
For example, in the classes of 1978–2008, among all respondents who had never used marijuana 
by 12th grade, an average of 74% participated in the first follow-up. The proportion responding 
was somewhat lower among those who had used marijuana once or twice in the last 12 months 
(67%). This proportion decreased gradually with increasing levels of marijuana use; but even 
among those who used marijuana on 20 or more occasions in the last 30 days in 12th grade, 60% 
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participated in the first follow-up. The corresponding participation rates for the same drug use 
strata at the fourth follow-up (i.e., at modal ages 25/26) were 64%, 57%, and 51%, respectively.  
 
Thus, even among those who were active heavy users of marijuana in high school, response rates 
at the fourth follow-up were only 13 percentage points lower than among those who had never 
used marijuana by 12th grade. That is not to say that we assume all types of drug users remain in 
the panels at comparably high rates. We believe that people who become dependent on or addicted 
to illicit drugs such as heroin, cocaine, or methamphetamine are less likely to be retained in 
reasonable proportions. That is why we are careful not to quantify or characterize these special 
segments of the population; but we note that they constitute very low proportions of the adult 
population. 
 
As a validation of our panel data on drug use, we compared MTF prevalence rates with those from 
the National Survey on Drug Use and Health (NSDUH); this survey provides the best available 
comparison data because it is also based on national samples and uses cross-sectional surveys that 
do not have panel attrition. Using the NSDUH data from 2014 (Center for Behavioral Health 
Statistics, 2015), we compared the prevalence rates on a set of drugs—cigarettes, alcohol, 
marijuana, and cocaine—for which there was reasonable similarity in question wording across the 
two studies. These comparisons showed a high degree of comparability in the prevalence estimates 
of the two studies, particularly with the post-stratification procedure applied to the MTF data 
(Miech et al., 2018; Schulenberg et al., 2018).  
 
In addition, attrition in the MTF panel is not necessarily as great a problem as nonresponse is in a 
cross-sectional study. In the MTF panel we know a great deal about each of the follow-up non-
respondents, including their prior substance use, based on a lengthy questionnaire administered in 
12th grade (and, for many, in subsequent years as well). Thus, adjustments can be made utilizing 
data that are highly informative about the missing individuals. 
 
Effects on Relational Analyses. While differential attrition (uncorrected) may contribute to some 
bias in point estimates and other univariate statistics, a considerable amount of empirical research 
has shown that such attrition tends to have less influence on associations among variables (Cordray 
& Polk, 1983; Galea & Tracey, 2007; Goudy, 1976; Groves, 2006; Groves & Peytcheva, 2008; 
Martikainen et al., 2007; Nohr & Olsen, 2013; Peytchev, 2013; Van Loon et al., 2003). With MTF 
samples, we have found that correlations among variables at base year are very similar across 
groups who remain in the longitudinal study and those who do not (Jager et al., 2013; Merline et 
al., 2008; Schulenberg et al., 1994; Schulenberg et al., 2005; Staff et al., 2010).  
 
Limitations 
Sample Coverage. There are certain limitations to the present study for attempting to quantify 
HIV/AIDS-related risk and protective behaviors in the general population. Perhaps the major 
limitation derives from the sample under study, because MTF does not include the 7% to 15% or 
so of each high school class cohort that leave high school without graduating (i.e., drop out). 
Although our coverage includes the great majority of the population of interest (young adults who 
recently entered their 20s), an important and on average somewhat more deviant segment of the 
population—high school dropouts—is not covered. In addition, panel attrition is a limitation, but 
techniques have been used here to help compensate for the effects; they are described below. 
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 These limitations likely lower the estimates of risk behaviors from what their values would be if 
the entire population of 21- through 30-year-olds, 35-year-olds, and 40-year-olds in the United 
States could be surveyed, but it is difficult to quantify by how much. (We believe that we do a 
better job of characterizing the original target population, which is high school graduates.) 
However, because the school dropout rates have added, and panel retention rates tend to change 
very slowly, we believe that the trend estimates changed only modestly since the questions on 
HIV/AIDS risk and protective factors were—which ultimately will be among the most important 
results for policy purposes—will be little affected by these omissions from the sample. This is 
particularly true given our procedures for compensating for panel loss.3  
 
Validity. The sensitive nature of questions about certain risk behaviors may affect the validity of 
the data reported. Recognizing this, we provide an introduction to the section of the questionnaire 
dealing with HIV/AIDS risk and protective factors explaining why these questions are important 
in helping us to increase our understanding of the HIV/AIDS epidemic. The protections of 
confidentiality are re-emphasized by reminding respondents that their answers are never connected 
with their names and by inviting respondents to leave blank any questions that they “do not wish 
to answer.” The decrement in response rates between the preceding non-sensitive questions and 
those in this section is very small—on the order of about one percentage point for five questions, 
and about 2 percentage points for two other questions—suggesting that the great majority of 
respondents feel willing and able to answer the potentially sensitive questions.  
 
Sample Sizes and Trend Estimation for Young Adults (Ages 21–30) 
The prevalence and, when available, the frequency of HIV/AIDS-related behaviors in the general 
population can now be established for the years of 2004 through 2017 combined. Having multiple 
years of data is valuable because they can be combined to increase the precision of low-prevalence 
estimates (in particular, for the intersection of some behaviors). Because the intersection of some 
of the behaviors is of particular importance, we report the bivariate associations among them, 
though the low numbers in some cases still limit the conclusions that can be reached. Over time 
the case counts continue to grow and allow more detailed analyses. 
 
Because individuals are surveyed every two years, some individuals complete multiple 
questionnaires across the years, and thus we draw a distinction between the number of observations 
and the number of unique individuals surveyed. For estimates based on one or two years of data, 
the number observations is equivalent to the number of individuals surveyed. However, for 
estimates based on all years combined, the number of unique individuals is lower than the number 
of observations. Thus, for estimates using data from 2004 through 2017, a single individual can 
contribute up to five waves of data containing information of relevance to these analyses. The total 
number of weighted observations of young adults for 2004 through 2017 is 29,906, but the total 
number of unique individuals is only a little more than one-third of that number at 10,322. The 
weighted Ns reported in each table refer to observations, and in the case of the young adults, that 
is not the same as individuals. As stated earlier, for the 35- and 40-year-olds, the number of 
3 According to U.S. Census data, high school completion rates had been quite constant at 85% between 1972 and 2002 for persons 20–-24 years 
old. (Younger age brackets are less appropriate to use because they include some young people who are still enrolled in high school.) However, 
since 2002 there has been a very gradual increase in completion rates, reaching 91.9% by 2016. U.S. Census (various years). Current population 
reports, Series P-20, various numbers. Washington, DC: U.S. Government Printing Office 
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observations and individuals are equivalent because each individual contributes only one 
observation at a given age. 
 
It should be noted that we also examine the data for each of the fourteen years (2004–2017) 
separately to look for signs of change in prevalence levels, and find only limited evidence of 
systematic trending in any of the risk or protective behaviors under study during this interval, as 
will be addressed in later chapters. It is encouraging, though, that the univariate distributions 
replicate quite well across years, which provides powerful evidence of estimate reliability. 
 
Sample Sizes for Respondents Ages 35 and 40 
For those of modal age 35, ten years of data have been collected—2008 through 2017 (weighted 
N = 8,541), and for those of modal age 40 there are eight years of data (2010–2017; weighted N = 
6,851). Because an individual respondent can contribute only one observation at each of these 
ages, the number of observations and the number of observations are the same. The shorter 
intervals and lower case counts at these ages make some prevalence estimation, and particularly 
trend estimation, more difficult. 
 
Adjusting for the Effects of Panel Attrition  
In chapter 3 of Volume II (Schulenberg et al., 2018) we described the procedures used to adjust 
the substance use estimates to reduce (insofar as possible) the effects of panel attrition. In the case 
of substance use estimates, we have data on the prevalence and frequency of the same behaviors 
among all respondents when they were in 12th grade. This permits a post-stratification procedure 
in which we reweight the obtained follow-up samples such that the reweighted distribution of their 
senior-year responses reproduces the original distribution obtained from the entire 12th-grade 
sample for the behavior under consideration. 
 
However, the measures of non-drug-using variables under consideration in this monograph 
(primarily related to sexual behavior) were not included in the 12th-grade surveys, so this form of 
post-stratification is unworkable. Instead, we have implemented a different post-stratification 
reweighting procedure for the follow-up respondents, one in which we attempt to correct for their 
differential retention in the panels as a function of demographic and other characteristics that were 
measured in 12th grade. For example, males have a somewhat lower retention rate than females, 
which means that their proportion in the attained follow-up sample is lower than it was in the 
original 12th-grade in-school survey. We are able to correct for that difference by up-weighting 
the data from all males who did continue in the panel study, so that males will remain in the same 
proportion in the reweighted panel as they were when the panel was first selected. 
 
Using this strategy, we simultaneously correct for differential attrition using multiple variables 
identified as being related to attrition. To do so, we calculate the retention rate for the various cells 
defined by the intersection of these variables and then weight the respondents in each cell by the 
reciprocal of the retention rate found for the people who belong in that cell. These adjustments 
generate a newly weighted panel with frequency distributions on the variables used in this 
reweighting procedure (e.g., gender or grade point average in high school) that reproduce the 
distributions observed in the original 12th-grade sample. As a practical matter, the number of 
variables used in this procedure must be limited to some extent by the total sample size, lest certain 
cells become too small to be reliably reweighted. 
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 The variables that we use for defining the cells are as follows: gender (male/female), ethnicity 
(White/non-White), grade point average in 12th grade (low/medium/high), and past 12-month 
illicit drug use reported in 12th grade (none/marijuana only/any other illicit drug). The first two 
variables were pre-specified, while the latter two were chosen from a larger set entered into a 
regression analysis in which they emerged as the strongest predictors of retention rate. 
 
These four variables generate 36 non-overlapping categories (or cells) of individuals that can be 
reweighted to adjust for differential rates of attrition. Retention rates in each of the 36 cells are 
then calculated based on the number of people in each cell in the original panel and the number 
who subsequently provided data at the follow-up; the participating members of each cell are 
assigned a new weight that is the reciprocal of the retention rate in that cell—that is, one divided 
by the retention rate. (For example, if White males with low grades and illegal drug use other than 
marijuana are represented in the retained panel at a 50% retention rate, each of the respondents in 
that cell would be given a weight of two.) This new weight is then multiplied by a separate 
individual weight that corrects for any differential probability in being selected into the panel 
originally. A particular advantage to using this procedure is that it takes into account any 
interactions among the predictor variables, such as an interaction between gender and 
race/ethnicity. 
 
With the resulting weight, we have a total weighted N (sample size) equal to the original panel 
size, not the actual retained panel, which means that we would be overstating the accuracy with 
which we are making prevalence estimates. Thus, in a final step, all individual weights are then 
multiplied by the overall sample retention rate to bring the weighted sum of cases down to the 
actual total number of individually weighted cases still in the panel. This entire correction 
procedure is carried out separately for each year of follow-up data collection. 
 
We consider this correction procedure to be appropriate in this circumstance, but we caution the 
reader that it is not possible to correct entirely for the effects of panel attrition for two reasons. 
First, specific to our relatively small sample for these measures, we cannot adjust for all measured 
variables that might predict retention, because we are limited as to the number of cells that can 
reasonably be generated to which to assign weights. Second, and more generally, even with a 
prediction model that accounts for nearly all of the variance in retention, there still could be some 
unmeasured characteristics that differentiate the people in each cell who do and do not remain in 
the study. As we stated earlier, one of the most important uses of these data will be to track 
historical changes in the major HIV/AIDS risk and protective behaviors in the general population, 
a purpose for which these data are well suited, because such uncorrected factors are likely to be 
fairly constant across time. 
 
Significance Testing Protocol 
All significance tests referred to in this monograph are based on standard testing procedures that 
do not take account of the complex sampling design used in the initial sampling of 12th-grade 
students. Because the follow-up samples represent only a small sub-sample of the original 
clustered samples, design effects are quite small and generally ignorable. Significance tests on 
trends do account for multiple responses from individuals. Also, nominal significance levels are 
used with no correction for multiple tests. Thus, nominal levels may be overstated; however, we 
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take care to ascertain that any findings cited as statistically significant appear valid by examining 
multiple years, multiple cohorts, and general internal consistency. 
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Chapter 4 
 
PREVALENCE/FREQUENCY OF FOUR RISK BEHAVIORS 
 
In this chapter we report the prevalence and frequency of four HIV/AIDS-related risk behaviors 
among respondents aged 21 to 40 in the MTF follow-up surveys combined across all available 
survey years.1 Results are presented in Tables 4-1 and 4-2. The 'a' tables (i.e., 4-1a, 4-2a) provide 
the data for young adults aged 21 to 30 based on data from the 2004–2017 period. The 'b' tables 
provide the data for 35-year-olds based on data from 2008–2017. The 'c' tables provide the data 
for 40-year-olds based on data from 2010–2017. We present the 'a,' 'b,' and 'c' versions of each 
table together to facilitate comparisons across age groups. In those comparisons, it is important to 
recognize that the data for the three age groups come from different ranges of years, and also from 
different class cohorts. 
 
We present data on the combined samples for each age group and for males and females separately 
within each age group. The young adult sample from 2004 through 2017 has a total weighted N of 
29,906 observations. The sample of 35-year-old respondents from 2008 through 2017 has a total 
weighted N of 8,541, and for those of modal age 40 from 2010–2017, the total weighted N is 6,851. 
As noted earlier, the number of observations in the young adult (ages 21-30) sample is larger than 
the number of different individuals because some participants were surveyed more than once and 
thus account for more than one observation. Because the 35-year-old and 40-year-old samples each 
are based on only one survey age, the data from each individual are included only once, thus the 
number of individuals and number of observations are the same.  
 
Results are included for four behaviors related to HIV-risk to the respondent (and potentially to 
others2): injection drug use, needle sharing, having sex with multiple partners, and men having sex 
with men (MSM).  
 
Injection Drug Use 
While not itself a vector of HIV transmission, the amount of illicit injection drug use determines 
the pool of eligible persons from which the high-risk behavior of needle sharing is drawn. The 
question to respondents reads, “On how many occasions (if any) have you taken any drugs by 
injection with a needle (like heroin, cocaine, amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor’s orders.” Note that this refers to more than just heroin 
use. A sequel question asks about such behavior in the prior 12-months. Trends in the prevalence 
of these behaviors would be indicative of changes in the pool of persons at risk. 
 
1 Combining all available years of data provides a much needed increase in total numbers of cases, compared with reporting just the most recent 
year or two. As will be seen in the later section on trends, the results are sufficiently stable to warrant combining the data across years. In 
Chapters 9 and 10, trends across years are shown. 
2 According to recent statistics from CDC (http://www.cdc.gov/hiv/library/reports/surveillance/), the estimated number of cases of new HIV 
infections in the U.S. in 2014 (44,073) by transmission category was as follows: 29,529 (67%) for MSM, 10,578 (24%) for heterosexual contact, 
2,644 (6%) for injection drug use, 1,322 (3%) for both MSM and injection drug use, and 276 (< 1%) for other transmission routes including blood 
transfusion, hemophilia, and perinatal exposure. 
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• In the fourteen-year (2004–2017) combined samples of young adults aged 21–30, 1.5% 
report having ever used any drug by injection not under a doctor’s orders, and 0.5% 
reported doing so on 40 or more occasions (Table 4-1a). Thus, about 1 in every 67 
respondents has ever used an illicit drug by injection, and about 1 in every 200 respondents 
reports an extended pattern of use as indicated by use on 40 or more occasions. There are 
appreciable gender differences—2.2% of males vs. 0.9% of females indicate ever injecting 
a drug (p<.001), and the percentages saying they injected on 40 or more occasions are 0.7% 
for males and 0.3% for females (p<.001). The percentages of young adults who have 
injected drugs during the past 12 months without medical supervision are considerably 
smaller: 0.5% overall—1 in every 200 respondents—including 0.8% of males and 0.3% of 
females (p<.001). The percentages using 40 or more times in the past 12 months are 0.2% 
overall—0.3% for males and 0.1% for females 
 
• Tables 4-1b and 4-1c provide data for the two older age groups included in this report, 35- 
and 40-year-olds, respectively. The lifetime prevalence of ever injecting drugs does not 
vary much with age: 1.5%, 1.7%, and 1.5% for 21-30, 35, and 40, respectively. Annual 
prevalence declines with age: 0.5%, 0.4%, and 0.3% for 21-30, 35, and 40, respectively. 
Males report higher levels than females. (The difference between the three age groups is 
confounded by the years of measurement and the class cohorts involved, which means that 
any differences across the three age groups could be due to factors other than just age.) 
 
Needle Sharing 
The risk of catching or transmitting a number of blood-borne diseases, including HIV, emerges 
when injection drug use is combined with the sharing of needles. Immediately following the MTF 
survey questions about injecting drugs not under a doctor’s orders, just discussed, the question 
about needle sharing is asked: “Have you ever taken such drugs using a needle that you knew (or 
suspected) had been used by someone else before you used it?” Response alternatives are “Yes, in 
the last 12 months”, “Yes, but not in the last 12 months”, and “No, never.” The first response 
provides an estimate of annual prevalence, and the sum of the first two responses provides an 
estimate of lifetime prevalence.  
 
• The proportions of 21- to 30-year-olds who say they have ever shared needles in this way 
during their lifetime are 0.5% overall—0.6% of males and 0.4% of females (Table 4-1a). 
As noted in the previous section, 1.5% of the full samples say they have ever injected a 
drug, so this indicates that a minority—but still a third—of the people injecting any of the 
several drug classes mentioned in the question (heroin, cocaine, amphetamines, and/or 
steroids) shared a needle at some time. 
 
• The proportion of 21- to 30-year-olds who reported that they shared needles in the prior 12 
months is 0.2%, with no significant gender difference. This compares to 0.5% who said 
that they have injected a drug in the prior 12 months, so about two fifths of past year 
injectors shared a needle during that interval.  
 
• Of respondents age 21-30, almost half of females who have injected in their lifetime 
reported having shared needles (0.4%/0.9%), compared to a little more than one-fourth of 
male injectors (0.6%/2.2%), suggesting that young adult female injectors are more at risk 
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of needle sharing. The lifetime prevalence for needle sharing is lower among the 35- and 
40-year-olds than among the young adults. Lifetime prevalence is estimated to be 0.3% 
among the 35- and 40-year-olds, compared to 0.5% among young adults (Tables 4-1b and 
4-1c). This could be due to cohort-effects—lasting differences between class cohorts—
different years of measurement, and/or to attrition from the panel. In sum, needle-sharing 
behavior appears to have a very low prevalence among high school graduates ages 21 to 
30, and even lower among 35- and 40-year-olds. (In fact, among the 35- and 40-year-olds, 
past year prevalence is below 0.5%.) It seems likely that the rates are an underestimate for 
the entire population in these age groups due to the omission of high school dropouts, the 
likelihood that drug-addicted users would be more likely than average to leave the study, 
and the possibility of some underreporting of this behavior. But while the prevalence of 
needle sharing is low, it can still translate to sizable numbers of people engaging in shared 
needle use. An estimated 45 million Americans were between ages 20 and 29 in 2017 (US 
Census Bureau, 2018); just 0.5% of this group would be approximately 225,000 
individuals. 
 
• As was true for young adults, men in the two older age groups are a bit more likely than 
women to engage in needle sharing. 
 
• To summarize this section, while young adult men are more likely to inject drugs than their 
female counterparts, they are only slightly more likely to share needles. These dangerous 
practices appear to decline with age, but among the 35- and 40-year-olds slightly more men 
indicate having shared needles in the past than do women. 
 
Sex with Multiple Partners 
Having sex with multiple partners is another behavior that increases the risk of HIV transmission 
and infection. The question to respondents is, “During the last 12 months, how many sex partners 
have you had? (This includes vaginal, oral, or anal sex.)” All three types of sexual activity are 
specifically mentioned in this question because all can involve the transmission of HIV, though 
they vary in the degree of risk involved.3 Results are provided in Tables 4-2a, 4-2b, and 4-2c. 
 
• Roughly one quarter (24%) of the sample of young adults aged 21 to 30 reported that they 
have had multiple (two or more) sex partners in the prior 12 months—26% of males and 
22% of females (Table 4-2a). 
 
• About one-sixth (16%) of 21- to 30-year-old respondents reported having no sex partners 
during the prior 12 months (i.e., sexual abstinence)—18% of males and 14% of females. 
 
• The most common answer by far to this question was having one partner during the year 
(60% overall); a lower proportion of males (56%) than females (64%) gave this answer. 
 
• While having even one sex partner is not without risk, the risk of acquiring or transmitting 
HIV rises with an increased number of partners. About 10% of young adults reported that 
they had a total of two partners during the past 12 months (9.2% of males and 9.9% of 
3 The CDC reports that there is little to no risk of getting or transmitting HIV through oral sex. https://www.cdc.gov/hiv/risk/oralsex.html  
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females); 5.6% reported three partners (5.9% of males and 5.3% of females); and about 
one in eleven (8.7%) reported having four or more partners (11% of males and 6.6% of 
females). Very few reported having more than 20 partners in the prior 12 months (0.7% of 
males and 0.1% of females). Overall, while males were slightly more likely to be abstinent 
than females, males were more likely to have multiple sex partners and substantially more 
likely to have had a large number of partners during the year. 
 
• The reported numbers of sex partners among 35- and 40-year-olds (Tables 4-2b and 4-2c) 
were substantially lower than they were among young adults. The proportion reporting 
having had more than one partner during the past 12 months was 24.0% among young 
adults (ages 21-30), 12.0% among 35-year-olds, and 10.6% among 40-year-olds. The 
proportions reporting four or more sex partners during the year fell from 8.7% among 
young adults to 4.2% among 35-year-olds and 3.4% among 40-year-olds. These numbers 
strongly suggest that potential exposure to HIV infection through multiple sexual contacts 
declines sharply between ages 21 and 35—a finding that replicates a similar one from the 
National Survey of Family Growth (Chandra et al., 2012; Chandra et al., 2011). 
 
• In these older age strata, males continued to be more likely than females to report multiple 
sex partners (14.0% vs. 10.3%, respectively at age 35, and 12.4% vs. 8.8% at age 40). They 
also remained more likely to report four or more partners in the prior year (6.1% vs. 2.5% 
at age 35, and 5.0% vs. 2.0% at age 40).  
 
Men Having Sex with Men, and Sex across Both Genders  
Because males who have sexual contact with other males have been at particular risk of contracting 
and transmitting HIV, we also looked at subgroups by the different gender combinations. We 
distinguished six configurations: males with females exclusively, males with males exclusively, 
males with partners of both genders, females with males exclusively, females with females 
exclusively, and females with partners of both genders. For both male and female respondents, the 
case counts are fairly limited in the two categories that involve sexual contact with partners of the 
same gender, as will be detailed below, so the reader is cautioned to pay particular attention to the 
numbers of observations for these groups (Tables 4-2a, 4-2b, and 4-2c). Only people reporting that 
they have had sexual contact with one or more partners in the prior 12 months were asked the 
question: “During the last 12 months, have your sex partner or partners been . . . .” The answer 
alternatives are: “exclusively male,” “both male and female,” and “exclusively female.” (See 
Tables 4-2a, 4-2b, and 4-2c for the proportions in each of the three categories.) Recall that these 
findings are based on data combined across years. 
 
•  Of the young adult respondents reporting one or more sex partners in the prior 12 months 
(representing 84% of the total sample, 82% of all males, and 86% of all females), about 1 
in 20 (5.4%) males indicated some sexual contact with other males during the last 12 
months—4.5% saying that their partners were males exclusively and 0.9% saying that they 
had both male and female partners (Table 4-2a). 
 
Note that because of the low prevalence for these behaviors, the weighted number of cases 
is limited: a total of 606 observations from male respondents who reported having sexual 
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contact with other males—505 observations of men having sex exclusively with other 
males and 101 observations of men having sex with both genders.  
 
• Among young adult females, 4.5% reported having any female sex partners—2.5% 
indicated female partners exclusively and 2.0% indicated that their partners were of both 
genders—almost an even split, unlike the case for males (Table 4-2a). Thus bisexual 
behavior is more common among females in this population—about twice as common, in 
fact (2.0% vs. 0.9% for males), and having sex only with the same gender is about twice 
as common among men (4.5% vs. 2.5%). 
 
Again, note that the numbers of reports available for study are limited: 601 reports of 
females having any sexual contact with other females, 334 reports of females having sexual 
contact exclusively with other females, and 267 reports of having sex with both female and 
male partners.  
 
• Of the young adult respondents reporting one or more sex partners in the prior 12 months, 
95% of males reported that their partners were exclusively female, and 96% of females 
indicated that their partners were exclusively male (Table 4-2a). 
 
• As noted previously, males with same-gender sexual contact are at greater risk of acquiring 
or transmitting HIV than females because male-to-male sex carries a greater likelihood of 
HIV transmission than female-to-female (or heterosexual) sex.  
 
Among the 35- and 40-year-olds who reported sex with one or more partners, the 
proportions of males reporting sex exclusively with males in the past 12 months were 
similar to those observed among 21- to 30-year-olds (3.7% and 3.8% respectively for 35- 
and 40-year-olds, compared to 4.5% among the young adults). The proportion of both 35- 
and 40-year-old males reporting sex with partners of both genders (0.7% and 0.7% 
respectively) was slightly lower than for the young adult males (0.9%)—a non-significant 
difference.  
 
Among females, there was very little difference in the proportions reporting sex in the prior 
year exclusively with female partners among 35-year-olds (2.2%) and 40-year-olds (2.0%), 
compared with the young adults (2.5%). The proportion of females reporting having sex 
with partners of both genders was 0.9% and 1.1% in these two older age groups, 
respectively, compared to 2.0% among young adults. There appears to be some decline in 
the reporting of female-to-female and bisexual sex in the older groups.   
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Total Male Female
Lifetime Frequency of Injecting Drugs
    0 Occasions 98.5 97.8 99.1
    1–2  0.4  0.5  0.3
    3–5  0.2  0.3  0.1
    6–9  0.1  0.2  0.1
    10–19  0.2  0.3  0.1
    20–39  0.1  0.2 *
    40+ Occasions  0.5  0.7  0.3
Weighted N = 29,341 13,715 15,625
Annual Frequency of Injecting Drugs
    0 Occasions 99.5 99.2 99.7
    1–2  0.1  0.2  0.1
    3–5  0.1  0.1 *
    6–9  0.1  0.1 *
    10–19 * 0.1 *
    20–39  0.1 0.1 *
    40+ Occasions  0.2 0.3  0.1
Weighted N = 29,339 13,711 15,628
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months  0.2  0.2  0.1
    Yes, but not in the last 12 months  0.3  0.4  0.3
    No, never 99.5 99.4 99.6
Weighted N = 29,097 13,599 15,498
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were  
added to a third questionnaire form.
On how many occasions (if any) have you 
taken any drugs by injection with a needle (like 
heroin, cocaine, amphetamines, or steroids) in 
your lifetime? Do not include anything you took 
under a doctor’s orders.
On how many occasions (if any) have you 
taken any drugs by injection with a needle (like 
heroin, cocaine, amphetamines, or steroids) 
during the last 12 months? Do not include 
anything you took under a doctor’s orders.
Have you ever taken such drugs using a 
needle that you knew (or suspected) had been 
used by someone else before you used it?
(Entries are percentages.)
TABLE 4-1a
Injection Drug Use and Needle Sharing
Total and by Gender
among Respondents of Modal Ages 21–30 
in 2004–2017 a Combined
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Lifetime Frequency of Injecting Drugs Total Male Female
0 Occasions 98.3 97.5 99.0
1–2  0.7  0.8  0.5
3–5  0.1  0.2  0.1
6–9  0.1  0.2 *
10–19  0.2  0.4  0.1
20–39  0.1  0.2 *
40+ Occasions  0.5  0.7  0.3
Weighted N = 8,030 3,826 4,204
Annual Frequency of Injecting Drugs
0 Occasions 99.6 99.5 99.8
1–2 * 0.1 *
3–5 * * *
6–9  0.1  0.2 *
10–19 * * *
20–39  0.1  0.1  0.1
40+ Occasions  0.1  0.2  0.1
Weighted N = 8,034 3,829 4,206
Lifetime and Annual Needle Sharing
Yes, in the last 12 months * *  0.1
Yes, but not in the last 12 months  0.3  0.4  0.2
No, never 99.6 99.5 99.7
Weighted N = 8,023 3,824 4,198
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old 
respondents. In 2009 and after, these questions were included in all questionnaires for this group.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor’s 
orders.
Have you ever taken such drugs using a needle that 
you knew (or suspected) had been used by someone 
else before you used it?
(Entries are percentages.)
TABLE 4-1b
Injection Drug Use and Needle Sharing
Total and by Gender
among Respondents of Modal Age 35
in 2008–2017 a Combined
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Lifetime Frequency of Injecting Drugs Total Male Female
0 Occasions 98.5 97.8 99.2
1–2  0.6  0.8  0.4
3–5  0.2  0.3  0.1
6–9  0.2  0.3  0.1
10–19  0.1  0.2 *
20–39  0.1  0.1 *
40+ Occasions  0.4  0.6  0.2
Weighted N = 6,808 3,293 3,516
Annual Frequency of Injecting Drugs
0 Occasions 99.7 99.5 99.9
1–2  0.1  0.1 *
3–5 * * *
6–9 * * *
10–19 * 0.1 *
20–39 * 0.1 *
40+ Occasions  0.1 0.2  0.1
Weighted N = 6,811 3,294 3,517
Lifetime and Annual Needle Sharing
Yes, in the last 12 months * * *
Yes, but not in the last 12 months  0.3  0.4  0.2
No, never 99.7 99.6 99.8
Weighted N = 6,796 3,291 3,504
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) in your 
lifetime? Do not include anything you took under 
a doctor’s orders.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) during the 
last 12 months? Do not include anything you took 
under a doctor’s orders.
Have you ever taken such drugs using a needle 
that you knew (or suspected) had been used by 
someone else before you used it?
(Entries are percentages.)
TABLE 4-1c
Injection Drug Use and Needle Sharing
Total and by Gender
among Respondents of Modal Age 40
in 2010–2017 a Combined 
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Total Male Female
Number of Partners in Last 12 Months
    None 15.9 18.0 14.1
    One 60.1 55.7 64.0
    Two  9.6  9.2  9.9
    Three  5.6  5.9  5.3
    Four  3.6  4.0  3.3
    5–10  4.0  5.3  2.9
    11–20  0.7  1.2  0.3
    21–100  0.3  0.5  0.1
    More than 100  0.1  0.2 *
Weighted N = 29,279 13,683 15,596
Gender of Partners in Last 12 Months b
    Exclusively male? 54.0  4.5 95.5
    Both male and female?  1.5  0.9  2.0
    Exclusively female? 44.5 94.5  2.5
Weighted N = 24,584 11,213 13,371
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added 
to a third questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting  
no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
(Entries are percentages.)
TABLE 4-2a
Number of Sex Partners and Gender of Sex Partners
Total and by Gender
among Respondents of Modal Ages 21–30 
in 2004–2017 a Combined
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Number of Partners in Last 12 Months Total Male Female
None  9.4  9.4  9.4
One 78.6 76.6 80.3
Two  5.0  4.8  5.1
Three  2.8  3.0  2.6
Four  1.7  2.3  1.1
5–10  1.8  2.5  1.1
11–20  0.5  0.8  0.2
21–100  0.2  0.4  0.1
More *  0.1 *
Weighted N = 8,001 3,811 4,190
Gender of Partners in Last 12 Months b
Exclusively male? 52.4  3.7 96.9
Both male and female?  0.8  0.7  0.9
Exclusively female? 46.8 95.6  2.2
Weighted N = 7,212 3,446 3,766
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old
respondents. In 2009 and after, these questions were included in all questionnaires for this group.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those 
reporting  no partners are omitted.
During the LAST 12 MONTHS, how many sex partners 
have you had? (This includes vaginal, oral, or anal 
sex.)
During the LAST 12 MONTHS, have your sex partner 
or partners been …
(Entries are percentages.)
TABLE 4-2b
Number of Sex Partners and Gender of Sex Partners
Total and by Gender
among Respondents of Modal Age 35
in 2008–2017 a Combined
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Number of Partners in Last 12 Months Total Male Female
None 10.5  9.5 11.5
One 78.9 78.1 79.7
Two  4.8  4.6  5.0
Three  2.3  2.8  1.9
Four  1.2  1.5  1.0
5–10  1.5  2.3  0.8
11–20  0.3  0.5  0.2
21–100  0.3  0.6 *
More than 100  0.1  0.1 *
Weighted N = 6,787 3,285 3,502
Gender of Partners in Last 12 Months b
Exclusively male? 51.3  3.8 96.8
Both male and female?  0.9  0.7  1.1
Exclusively female? 47.8 95.5  2.0
Weighted N = 6,040 2,958 3,083
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bPercentages based on those reporting sex with one or more partners during the last 12 months.   
Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
(Entries are percentages.)
TABLE 4-2c
Number of Sex Partners and Gender of Sex Partners
Total and by Gender
among Respondents of Modal Age 40 
in 2010–2017 a Combined 
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Chapter 5 
INTERSECTION OF RISK BEHAVIORS 
One goal of the MTF panel study is to determine to what extent the various HIV-related risk 
behaviors overlap with one another, and to determine what proportion of the population is at 
heightened risk of HIV transmission as a result. In this chapter, we report several pair-wise 
combinations of risk factors. 
Needle Sharing by Gender of Sex Partners 
Needle sharing and male-to-male sex are known to be among the most important risk behaviors 
for the spread of HIV. 
• Table 5-1a provides information on young adults’ (age 21−30) injection drug use and
needle sharing by the six categories of gender of partners in the prior 12 months—men who
had sex exclusively with females, exclusively with males, or with both males and females;
and women who had sex exclusively with males, exclusively with females, or with both
males and females. As noted earlier, the limited numbers of cases in the groups reporting
same-gender or both-gender sexual contact make any results somewhat tentative. See
Tables 5-1a, 5-1b, and 5-1c for numbers of cases in each of the six categories.
• Keeping in mind the small sample sizes, it appears that among young adults the annual
prevalence of injecting drugs and of needle sharing both tend to be highest among those
who engage in sex with both genders. This holds true for both male and female respondents,
but especially among males (Table 5-1a).
• Young adult males who report having exclusively male partners have the same lifetime
prevalence of injection drug use as males having exclusively female partners (2.4%) and
an annual prevalence that is only slightly higher at 1.2% vs. 0.8% (Table 5-1a). However,
they have a significantly higher lifetime and annual prevalence of needle sharing (1.3% vs.
0.4% lifetime [p<.01]; 0.8% vs. 0.1% annual [p<.001]). So, among young adult males there
is some compounding of these two types of risk—needle sharing and men having sex with
me.
• Among young adult females the lifetime but not annual prevalence of injecting drugs is
significantly higher for those having exclusively female partners than for those with
exclusively male partners (3.3% vs. 0.8% for lifetime [p<.001], and 0.7% vs 0.2% for
annual [ns]). More importantly, their lifetime prevalence of needle sharing is also
significantly higher (2.4% vs. 0.3% [p<.001]). Interestingly, there is no significant
difference between these two groups in the prevalence of injecting drugs or needle sharing
in the prior 12 months, so much of the heightened risk from needle sharing for women who
have exclusively female partners appears to have occurred when they were younger.
• The case counts are still too low to make such comparisons among the 35- and 40-year-old
respondents, primarily because fewer years of data have accumulated so far for them
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(Tables 5-1b and 5-1c), a situation that will be remedied in future years as more young 
cohorts in the study reach ages 35 and 40.  
Injection Drug Use and Needle Sharing by Number of Sex Partners 
• Among young adults, the prevalence of having injected drugs either over a lifetime or in
the prior 12 months rises considerably with the number of sex partners reported in the prior
12 months (Table 5-2a). For example, those who report zero, one, or two partners during
the prior 12 months report a prevalence of injecting a drug in the prior 12 months of 0.3%,
0.3%, and 0.5%, respectively, whereas those reporting five or more partners have a
prevalence of 3.0%. Although the association holds for both males and females, it is much
stronger for males: 6.4% of males reporting five or more sex partners in the prior 12 months
have injected drugs at some time in their lifetime. A similar relationship exists for annual
prevalence of injecting drugs.
• At ages 35 and 40 (Tables 5-2b and 5-2c) a similar positive association holds between
number of sex partners in the prior 12 months and both lifetime and annual injection drug
use, and the association is due largely to males. Females report little injecting in the prior
12 months and in their lifetime.
• Among the young adults, the dangerous practice of sharing needles relates positively to the
number of sex partners; prior-12-month sharing was 0.1% or less among those who had
two or fewer partners in the prior 12 months, and 0.9% among those reporting five or more
partners in that period (Table 5-2a, bottom panel). This means that needle sharers, who are
at particular risk of contracting HIV, are more likely than others to have been exposing
somewhat larger numbers of partners to that risk through sexual contact; and this is true
for both genders.
• There are lower levels of reported needle sharing among the age 35 and 40 respondents
(Tables 5-2b and 5-2c), but lifetime needle sharing rates have some positive association
with number of sex partners in the prior 12 months. Among the 35-year-olds those
reporting three or more partners in the prior 12 months are most likely to have ever shared
needles. Among 40-year-olds, it is difficult to say with any certainty, given the limitations
of sample sizes; but it appears that males with three or more partners are also the ones most
likely to share needles. There is no association for females at age 40. Insofar as needle
sharing is associated with number of sex partners in the previous 12 months, it appears that
the needle sharing occurred in previous years, not the most recent one.
Number of Sex Partners by Gender of Sex Partners 
• We examined the number of sex partners reported by the genders of those partners (Table
5-3a). Among sexually active young adult males, of those who had sex exclusively with
other males during the prior 12 months (N = 510 observations), about half (53%) reported
that they had more than one sex partner, compared to 31% among those males who reported
that they had sexual contact exclusively with females. About one-fifth (22%) of males with
exclusively male partners reported sexual contact with five or more partners, compared to
8% of males with exclusively female partners. The proportions of the two groups having
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more than ten sex partners during the year were 10.2% vs. 1.7%, respectively. Thus, 
although their proportion of the total population is small, and these particular findings are 
thus based on a limited subsample, it appears that appreciable numbers of young adult 
males are potentially placing themselves and others at greater risk by having multiple sex 
partners, and this is especially true for males who have had sex exclusively with other 
males during the year. These two risk behaviors—men having sex with men and having a 
large number of sex partners—are positively correlated, as others also have found 
(Ashenhurst et al., 2017; CDC, 2013).  
 
• The finding that young adult males whose sex partners are exclusively male tend to have 
more sex partners is also seen among 35- and 40-year-old male respondents (N = 125 and 
112 observations, respectively; see Tables 5-3b and 5-3c). Indeed, across ages only about 
half of males who reported having sex exclusively with men also reported sex with only 
one partner. What differs by age is the percent of males who had sex exclusively with 
females and who had only one partner—among young adults it is 70%, but among both 35- 
and 40-year-olds it is 87% and 88%, respectively, no doubt reflecting in part the larger 
proportion of the two older age groups who are married to women.  
 
• Among sexually active young adult females who had sex exclusively with other females 
during the year (N = 328), 75% reported having only one partner, indicating a considerably 
higher level of monogamy than among males having sex exclusively with other males. This 
rate of monogamy is about the same (76%) as it is among females who had male partners 
exclusively. Again, these estimates are only suggestive, given the limited sample sizes 
involved. However, the results suggest that females who have sex exclusively with other 
females are at lower risk of contracting or transmitting HIV than are males who have sex 
exclusively with other males or females who have sex with males, based on the number of 
sex partners they have as well as on the relatively lower risks associated with female-to-
female sex. 
 
• There were insufficient numbers of 35- and 40-year-old females reporting same sex 
partners to provide reliable estimates (Tables 5-3b and 5-3c). 
 
• Individuals who have sex partners of both genders carry the risk of spreading HIV across 
genders, making their behavior of particular importance. The numbers of cases collected 
to date are limited; young adult weighted Ns = 273 observations for females and 104 for 
males reporting sex partners of both genders in the prior 12 months. Given these small 
numbers, the results can be considered only tentative and suggestive. Nevertheless, based 
on the 377 cases that report partners of both genders, the proportions reporting five or more 
sex partners appear to be quite high for both genders—40% for males and 29% for females 
(Table 5-3a).  
 
• There are currently insufficient numbers of cases among those ages 35 and 40 who report 
having sex partners of both genders in the prior 12 months to provide estimates (Tables 5-
3b and 5-3c).  
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Lifetime Frequency of Injecting Drugs
    0 Occasions 97.6 97.6 87.6 99.2 96.7 93.8
    1–2 0.6 0.5 1.9 0.3 1.0 2.3
    3–5 0.3 0.9 1.3 0.1 1.2 1.1
    6–9 0.2 0.3 2.7 0.1 * 0.6
    10–19 0.3 0.1 * 0.1 * 0.4
    20–39 0.2 0.1 1.1 * * *
    40+ Occasions 0.7 0.5 5.3 0.3 1.1 1.9
Weighted N = 10,555 505 102 12,721 328 273
Annual Frequency of Injecting Drugs
    0 Occasions  99.2  98.8  89.4  99.8  99.3  96.5
    1–2  0.1  0.5  2.5 * * 1.6
    3–5  0.1  0.3  0.7 * 0.1 0.3
    6–9  0.1 * 2.3 * * *
    10–19  0.1 * 1.1 * 0.3  0.1
    20–39  0.1 * 0.9 * * 0.1
    40+ Occasions  0.3  0.4 2.9  0.1 0.3  1.3
Weighted N = 10,559 505 102 12,724 328 273
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months 0.1 0.8 3.0 0.1 0.3 1.5
    Yes, but not in the last 12 months 0.3 0.5 3.1 0.2 2.1 1.5
    No, never 99.5 98.7 93.9 99.7 97.6 97.0
Weighted N = 10,474 504 97 12,627 328 272
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
On how many occasions (if any) have you taken any drugs by 
injection with a needle (like heroin, cocaine, amphetamines, or 
steroids) in your lifetime? Do not include anything you took under a 
doctor’s orders.
On how many occasions (if any) have you taken any drugs by 
injection with a needle (like heroin, cocaine, amphetamines, or 
steroids) during the last 12 months? Do not include anything you 
took under a doctor’s orders.
Have you ever taken such drugs using a needle that you knew (or 
suspected) had been used by someone else before you used it?
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
by Gender of Sex Partners in Last 12 Months 
Injection Drug Use and Needle Sharing  
TABLE 5-1a
Gender of Partner(s)Gender of Partner(s)
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
 
37
Female Male Male and Male Female Male and
Only Only Female Only Only Female
Lifetime Frequency of Injecting Drugs
0 Occasions 97.5 99.3 † 99.1 † †
1–2 0.8 0.3 † 0.4 † †
3–5 0.2 * † 0.1 † †
6–9 0.2 * † * † †
10–19 0.4 0.4 † 0.1 † †
20–39 0.2 * † * † †
40+ Occasions 0.7 * † 0.2 † †
Weighted N = 3,284 127 24 3,636 83 33
Annual Frequency of Injecting Drugs
0 Occasions  99.5  99.6 †  99.7 † †
1–2 * * † * † †
3–5  0.1 * † * † †
6–9  0.1  0.4 † * † †
10–19 * * † * † †
20–39  0.1 * † * † †
40+ Occasions  0.1 * †  0.1 † †
Weighted N = 3,286 127 24 3,637 83 33
Lifetime and Annual Needle Sharing
Yes, in the last 12 months * * † 0.1 † †
Yes, but not in the last 12 months 0.3 0.3 † 0.2 † †
No, never 99.6 99.7 † 99.7 † †
Weighted N = 3,281 127 24 3,632 82 33
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' † ' indicates that the sample size is too limited to provide reliable estimates. ' * ' indicates a prevalence rate of less than 0.05%. 
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. In 2009
and after, these questions were included in all questionnaires for this group.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor’s orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
MALE RESPONDENTS FEMALE RESPONDENTS
among Respondents of Modal Age 35 in 2008–2017 a Combined
by Gender of Sex Partners in Last 12 Months 
Injection Drug Use and Needle Sharing  
TABLE 5-1b
Gender of Partner(s)Gender of Partner(s)
(Entries are percentages.)
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Lifetime Frequency of Injecting Drugs
0 Occasions 97.9 95.3 † 99.1 † †
1–2 0.7 3.1 † 0.4 † †
3–5 0.2 0.3 † 0.1 † †
6–9 0.3 0.8 † 0.1 † †
10–19 0.2 * † * † †
20–39 0.1 * † * † †
40+ Occasions 0.5 0.6 † 0.2 † †
Weighted N = 2,807 112 20 2,975 63 35
Annual Frequency of Injecting Drugs
0 Occasions  99.6  98.9 †  99.9 † †
1–2  0.1  0.8 † * † †
3–5 * 0.3 † * † †
6–9 * * † * † †
10–19  0.1 * † * † †
20–39  0.1 * † * † †
40+ Occasions  0.2 * †  0.1 † †
Weighted N = 2,809 112 20 2,976 63 35
Lifetime and Annual Needle Sharing
Yes, in the last 12 months * * † * † †
Yes, but not in the last 12 months 0.4 0.8 † 0.2 † †
No, never 99.6 99.2 † 99.8 † †
Weighted N = 2,807 111 20 2,966 63 35
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' † ' indicates that the sample size is too limited to provide reliable estimates. ' * ' indicates a prevalence rate of less 
than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 
months? Do not include anything you took under a 
doctor’s orders.
Have you ever taken such drugs using a needle that 
you knew (or suspected) had been used by someone 
else before you used it?
among Respondents of Modal Age 40 in 2010–2017 a Combined
by Gender of Sex Partners in Last 12 Months 
Injection Drug Use and Needle Sharing  
TABLE 5-1c
Gender of Partner(s)Gender of Partner(s)
(Entries are percentages.)
FEMALE RESPONDENTSMALE RESPONDENTS 
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Three  Five   
Lifetime Frequency of Injecting Drugs None One Two or Four or More
Total
    0 Occasions 99.4 98.8 98.2 97.0 94.9
    1+ Occasions 0.6 1.2 1.8 3.0 5.1
Weighted N = 4,643 17,540 2,790 2,691 1,492
Male
    0 Occasions 99.0 98.3 97.6 95.6 93.6
    1+ Occasions 1.0 1.7 2.4 4.4 6.4
Weighted N = 2,451 7,598 1,249 1,346 974
Female
    0 Occasions 99.8 99.2 98.7 98.5 97.5
    1+ Occasions 0.2 0.8 1.3 1.5 2.5
Weighted N = 2,192 9,943 1,541 1,344 518
Annual Frequency of Injecting Drugs
Total
    0 Occasions 99.7 99.7 99.5 98.7 97.0
    1+ Occasions 0.3 0.3 0.5 1.3 3.0
Weighted N = 4,636 17,544 2,790 2,692 1,492
Male
    0 Occasions 99.7 99.6 99.5 98.0 96.2
    1+ Occasions 0.3 0.4 0.5 2.0 3.8
Weighted N = 2,444 7,600 1,248 1,347 973
Female
    0 Occasions 99.8 99.9 99.5 99.4 98.5
    1+ Occasions 0.2 0.1 0.5 0.6 1.5
Weighted N = 2,192 9,944 1,542 1,344 518
Lifetime and Annual Needle Sharing
Total
    Yes, in the last 12 months 0.1 0.1 0.1 0.5 0.9
    Yes, but not in the last 12 months 0.3 0.2 0.4 0.8 0.4
    No, never 99.6 99.7 99.5 98.7 98.6
Weighted N = 4,592 17,418 2,766 2,667 1,478
Male
    Yes, in the last 12 months 0.1 0.1 * 0.6 1.0
    Yes, but not in the last 12 months 0.5 0.2 0.4 1.0 0.3
    No, never 99.3 99.7 99.6 98.4 98.6
Weighted N = 2,425 7,550 1,231 1,336 962
Female
    Yes, in the last 12 months 0.1 0.1 0.1 0.4 0.7
    Yes, but not in the last 12 months * 0.2 0.5 0.5 0.6
    No, never 99.9 99.7 99.4 99.1 98.7
Weighted N = 2,167 9,868 1,535 1,331 516
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added 
to a third questionnaire form.
On how many occasions (if any) have you taken any drugs 
by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not include 
anything you took under a doctor’s orders.
On how many occasions (if any) have you taken any drugs 
by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? Do 
not include anything you took under a doctor’s orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
Number of Partners in Last 12 Months
TABLE 5-2a
Injection Drug Use and Needle Sharing 
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
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Three  Five   
Lifetime Frequency of Injecting Drugs None One Two or Four or More
Total
0 Occasions 98.6 98.6 97.4 95.2 95.6
1+ Occasions 1.4 1.4 2.6 4.8 4.4
Weighted N = 752 6,262 397 358 205
Males
0 Occasions 97.5 98.0 96.2 94.1 94.4
1+ Occasions 2.5 2.0 3.8 5.9 5.6
Weighted N = 357 2,909 184 202 146
Females
0 Occasions 99.6 99.1 98.5 96.7 98.5
1+ Occasions 0.4 0.9 1.5 3.3 1.5
Weighted N = 394 3,353 213 157 59
Annual Frequency of Injecting Drugs
Total
0 Occasions 99.6 99.8 98.4 98.4 98.9
1+ Occasions 0.4 0.2 1.6 1.6 1.1
Weighted N = 752 6,266 397 358 205
Males
0 Occasions 99.1 99.7 97.3 98.5 98.6
1+ Occasions 0.9 0.3 2.7 1.5 1.4
Weighted N = 357 2,911 184 202 146
Females
0 Occasions 100.0 99.8 99.4 98.2 99.6
1+ Occasions * 0.2 0.6 1.8 0.4
Weighted N = 394 3,355 213 157 59
Lifetime and Annual Needle Sharing
Total
Yes, in the last 12 months * * * 0.2 *
Yes, but not in the last 12 months 0.2 0.3 0.2 1.2 1.3
No, never 99.8 99.7 99.8 98.7 98.7
Weighted N = 750 6,257 397 357 205
Males
Yes, in the last 12 months * * * 0.3 *
Yes, but not in the last 12 months 0.3 0.3 * 1.9 1.7
No, never 99.7 99.7 100.0 97.8 98.3
Weighted N = 358 2,908 183 202 146
Females
Yes, in the last 12 months * 0.1 * * *
Yes, but not in the last 12 months 0.1 0.2 0.4 0.3 0.5
No, never 99.9 99.7 99.6 99.7 99.5
Weighted N = 392 3,350 214 155 59
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) in your 
lifetime? Do not include anything you took under a 
doctor’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) during the last 
12 months? Do not include anything you took under 
a doctor’s orders.
Have you ever taken such drugs using a needle that 
you knew (or suspected) had been used by 
someone else before you used it?
Number of Partners in Last 12 Months
TABLE 5-2b
Injection Drug Use and Needle Sharing 
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
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Three  Five   
Lifetime Frequency of Injecting Drugs None One Two or Four or More
Total
0 Occasions 98.2 98.7 99.2 96.1 95.3
1+ Occasions 1.8 1.3 0.8 3.9 4.7
Weighted N = 713 5,332 325 239 147
Males
0 Occasions 96.7 98.1 98.5 95.0 93.9
1+ Occasions 3.3 1.9 1.5 5.0 6.1
Weighted N = 313 2,549 151 140 113
Females
0 Occasions 99.3 99.1 99.9 97.7 100.0
1+ Occasions 0.7 0.9 0.1 2.3 *
Weighted N = 400 2,783 174 99 34
Annual Frequency of Injecting Drugs
Total
0 Occasions 99.6 99.8 99.6 99.1 97.7
1+ Occasions 0.4 0.2 0.4 0.9 2.3
Weighted N = 713 5,334 325 239 147
Males
0 Occasions 99.5 99.7 99.0 99.3 97.0
1+ Occasions 0.5 0.3 1.0 0.7 3.0
Weighted N = 313 2,551 151 140 113
Females
0 Occasions 99.7 99.9 100.0 98.7 100.0
1+ Occasions 0.3 0.1 * 1.3 *
Weighted N = 400 2,783 174 99 34
Lifetime and Annual Needle Sharing
Total
Yes, in the last 12 months * * * * *
Yes, but not in the last 12 months 0.3 0.3 0.2 1.1 0.9
No, never 99.7 99.7 99.8 98.9 99.1
Weighted N = 711 5,330 323 238 144
Males
Yes, in the last 12 months . * . * . * . * . *
Yes, but not in the last 12 months 0.1 0.4 0.3 1.7 1.2
No, never 99.9 99.6 99.7 98.3 98.8
Weighted N = 312 2,556 149 140 110
Females
Yes, in the last 12 months . * . * . * . * . *
Yes, but not in the last 12 months 0.4 0.2 * 0.3 *
No, never 99.6 99.8 100.0 99.7 100.0
Weighted N = 399 2,773 174 99 34
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
Have you ever taken such drugs using a needle that you knew (or suspected) 
had been used by someone else before you used it?
On how many occasions (if any) have you taken any drugs by injection with a 
needle (like heroin, cocaine, amphetamines, or steroids) during the last 12 
months? Do not include anything you took under a doctor’s orders.
On how many occasions (if any) have you taken any drugs by injection with a 
needle (like heroin, cocaine, amphetamines, or steroids) in your lifetime? Do 
not include anything you took under a doctor’s orders.
Number of Partners in Last 12 Months
TABLE 5-2c
Injection Drug Use and Needle Sharing 
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Number of Partners in Last 12 Months
    None — — — — — —
    One 69.5 47.2 9.4 76.0 74.8 5.1
    Two 11.1 12.0 15.8 11.3 11.8 25.1
    Three 7.0 10.3 13.5 5.8 7.8 23.2
    Four 4.6 8.7 21.6 3.6 2.9 18.0
    5–10 6.1 11.6 24.3 2.9 2.4 22.4
    11–20 1.1 6.3 8.4 0.3 * 4.8
    21 or more partners 0.6 3.9 7.0 0.1 0.3 1.4
Weighted N = 10,561 510 104 12,741 328 273
Source. The Monitoring the Future study, the University of Michigan.
Notes ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 5-3a
Number of Sex Partners by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Number of Partners in Last 12 Months
None — — † — † †
One 86.7 46.0 † 89.5 † †
Two 5.2 6.1 † 5.4 † †
Three 2.9 7.7 † 2.5 † †
Four  2.3 7.7 † 1.1 † †
5–10 2.0 24.1 † 1.2 † †
11–20 0.6 4.4 † 0.2 † †
21 or more partners 0.4 4.1 † 0.1 † †
Weighted N = 3,281 125 24 3,648 82 33
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' † ' indicates that the sample size is too limited to provide reliable estimates. ' — ' indicates not applicable. 
' * ' indicates a prevalence rate of less than 0.05%.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 5-3b
Number of Sex Partners by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Number of Partners in Last 12 Months
None — — † — † †
One 88.3 49.8 † 91.0 † †
Two 4.5 13.5 † 5.3 † †
Three 2.9 7.8 † 2.0 † †
Four 1.4 6.3 † 0.8 † †
5–10 1.9 15.4 † 0.7 † †
11–20 0.5 1.9 † 0.2 † †
21 or more partners 0.4 5.2 † * † †
Weighted N = 2,820 112 20 2,977 63 35
Source. The Monitoring the Future study, the University of Michigan.
Notes.  ' †  '  indicates that the sample size is too limited to provide reliable estimates. ' — ' indicates not applicable. 
' * ' indicates a prevalence rate of less than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 5-3c
Number of Sex Partners by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Chapter 6 
 
PREVALENCE OF PROTECTIVE BEHAVIORS 
 
Various precautions can diminish the likelihood of contracting and/or transmitting HIV. One, of 
course, is simply to avoid the high-risk behaviors already discussed (e.g., having multiple sex 
partners, sharing needles). Another is to use condoms during intercourse to protect against viral 
transmission. A third—getting tested for HIV—increases the likelihood that an infected individual 
will (a) be identified as infected and receive appropriate treatment that may save his or her life, 
and (b) refrain from behaviors that put others at risk of contracting the virus or alerting an ongoing 
partner to take preventive measures. We consider prevalence of these two protective behaviors 
(i.e., condom use and HIV testing) in three age groups: young adults (ages 21−30), 35-year-olds, 
and 40-year-olds. 
 
Condom Use 
Respondents who indicate that they have had one or more sex partners during the prior 12 months 
are asked, “When you had sexual intercourse during the last 12 months, how often were condoms 
used? (This includes vaginal and anal sex, but not oral sex.)” The answer alternatives are: “never, 
seldom, sometimes, most times, and always.” Both genders respond to this question. (Respondents 
who report no sex partners in the prior 12 months are not included in the data presented here.) 
 
• Just over half (55%) of sexually active young adult respondents report that they “seldom” 
or “never” used condoms during the past 12 months—with 50% of males and 59% of 
females giving these answers (Table 6-1a). Indeed, a large proportion (41%) indicate that 
they did not use condoms at all during the past 12 months—36% of the sexually active 
males and 46% of the sexually active females. Higher rates of monogamy among females 
(documented in the previous chapter) may help to explain their lower rate of condom use; 
however, if their male partners are not monogamous, the risk to women increases, quite 
possibly without their awareness. Women having sex with other women are unlikely to 
report condom use. 
 
• Only about one third (33%) of sexually active young adults say that they used a condom 
“most times” or “always”—37% of males and 29% of females. 
 
• An examination of two-year age groups among 21- to 30-year-olds shows that the 
prevalence of condom use declines steadily with age (Table 6-1d). Three quarters (75%) 
of 21- to 22-year-olds report some condom use in the last 12 months, compared to only 
46% of 29- to 30-year-olds. And while 45% of the 21- to 22-year-old group report using 
condoms “most times” or “always,” only 22% of 29- to 30-year-olds say that. One plausible 
explanation for these age-related declines in condom use is an increase with age in the 
proportions who are married, cohabiting, monogamous, and/or trying to conceive children; 
however, Table 6-1e shows that even among young adults who were not married at the 
time of the surveys, proportions reporting any condom use decline with age across the 20s 
by 17 percentage points (from 77% of 21- to 22-year-olds to 60% of 29- to 30-year-olds). 
Among those who report being married, the prevalence of condom use is indeed lower at 
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each age, but there is also a 16 percentage point decline with age (from 50% of the married 
21- to 22-year-olds reporting any condom use to 34% among married 29- to 30-year-olds)
(Table 6-1f). Thus, the decline with age is only partially explainable by an increased
proportion being married.
• Condom use is lower among sexually active 35-year-olds than among the young adults,
with 61% of the 35-year-old males and 70% of the females saying that they never used
condoms in the prior 12 months (Table 6-1b). And condom use is lower still among the
sexually active 40-year-olds, with 72% of the males and 78% of the females saying that
they never used condoms in the prior 12 months (Table 6-1c). Changes in marital and
cohabiting status likely account for much of this change with age as well (see Tables 6-1b,
and 6-1c).
Getting Tested for HIV 
Respondents were asked if they had ever been tested for HIV/AIDS; the question instructed them 
not to include any testing that may have occurred when they were donating blood. The results may 
be found in Tables 6-2a, 6-2b, and 6-2c. 
• Less than half (43%) of all young adults ages 21 to 30 indicate that they have ever been 
tested for HIV outside of blood donation screening (Table 6-2a). Despite the fact that males 
are at considerably higher risk of contracting HIV (CDC, 2018), females are more likely 
to report having been tested than are males (50% versus 35%). The higher rate of being 
tested among females may be partly due to being tested during pregnancy.
• Lifetime prevalence of HIV testing rises with age among young adults (Table 6-2d). 
Summing across the surveys from 2004 to 2017 (see the far right hand column), 28% of
21- to 22-year-olds report some testing in their lifetime compared to 51% of 29- to 30-year-
olds.
• About one fifth (21%) of young adults say they have been tested in the last 12 months, and 
as with lifetime prevalence, a higher percentage of females than males report being tested 
(26% versus 16%, Table 6-2a).
• The great majority (93%) of those who have been tested receive the results of their most 
recent HIV/AIDS test, with little difference by gender.
• Among both 35- and 40-year-olds, the lifetime prevalence of being tested for HIV/AIDS 
(55% and 54%, respectively) is higher than among young adults ages 21 to 30 (43%). 
Lifetime rates are higher among females than among males in all three age groups. Unlike 
the lifetime rates, the rates of being tested in the past 12 months decline some with age 
(21% in ages 21-30, 17% at age 35, and 12% at age 40). (See Tables 6-2a, 6-2b, and 6-2c.) 
Again, the higher proportions of older respondents who are married or in a monogamous 
relationship no doubt contribute to their lower rates of getting tested, just as it helped to 
account for their lower use of condoms. 
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Frequency of Condom Use in Last 12 Monthsb Total Male Female Total Male Female Total Male Female
    Never 41.1 35.9 45.5 60.9 57.5 63.4 31.7 26.5 36.3
    Seldom 13.7 13.8 13.7 12.8 14.4 11.6 14.2 13.5 14.7
    Sometimes 12.6 13.1 12.2 10.9 11.9 10.2 13.5 13.7 13.3
    Most times 14.8 16.6 13.2  7.9  9.1  7.1 18.1 19.9 16.4
    Always 17.8 20.6 15.4  7.5  7.2  7.8 22.7 26.5 19.3
Weighted N = 24,388 11,147 13,241 7,846 3,374 4,472 16,416 7,718 8,698
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting  no partners are omitted.
TABLE 6-1a
Frequency of Condom Use 
Total and by Gender and Marital Status
among Respondents of Modal Ages 21–30 
in 2004–2017 a Combined
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This includes 
vaginal and anal sex, but not oral sex.)
Total Sample Married Not Married
(Entries are percentages.)
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Frequency of Condom Use in Last 12 Months b Total Male Female Total Male Female Total Male Female
Never 65.8 61.4 69.8 74.4 70.8 77.6 45.2 38.8 51.0
Seldom  8.6 10.3  7.0  7.0  8.5  5.5 12.4 14.4 10.5
Sometimes  8.0  9.0  7.1  6.6  7.8  5.6 11.3 11.9 10.7
Most times  8.0  9.2  7.0  5.5  6.4  4.7 14.0 15.8 12.5
Always  9.7 10.2  9.2  6.5  6.5  6.6 17.2 19.1 15.4
Weighted N = 7,132 3,404 3,729 5,030 2,399 2,632 2,102 1,005 1,097
Source. The Monitoring the Future study, the University of Michigan.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting  no partners are omitted.
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This includes 
vaginal and anal sex, but not oral sex.)
TABLE 6-1b
Frequency of Condom Use 
Total and by Gender and Marital Status
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
Total Sample Married Not Married
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Frequency of Condom Use in Last 12 Months b Total Male Female Total Male Female Total Male Female
Never 74.9 72.2 77.5 81.4 79.3 83.5 53.3 48.4 57.8
Seldom  5.4  6.1  4.7  4.1  4.6  3.7  9.7 11.2  8.3
Sometimes  5.8  6.6  5.0  4.2  5.0  3.3 10.7 11.1 10.5
Most times  5.9  6.6  5.2  4.5  5.0  4.1 10.6 12.9  8.4
Always  8.0  8.5  7.6  5.7  6.0  5.4 15.7 16.4 15.1
Weighted N = 6,002 2,936 3,066 4,499 2,206 2,293 1,356 656 700
Source. The Monitoring the Future study, the University of Michigan.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting  no partners are omitted.
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This includes 
vaginal and anal sex, but not oral sex.)
TABLE 6-1c
Frequency of Condom Use 
Total and by Gender
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
Total Sample Married Not Married
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Frequency of Condom Use in Last 12 Months 21–22 23–24 25–26 27–28 29–30
Never 25.4 33.6 40.9 49.4 54.1
Seldom 14.6 15.3 13.9 13.1 11.9
Sometimes 14.8 12.7 12.9 11.5 11.4
Most times 19.4 17.4 15.1 11.9 10.7
Always 25.8 20.9 17.1 14.2 11.9
Weighted N = 4,495 4,871 4,866 5,006 5,149
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third questionnaire form.
Age of Respondent
TABLE 6-1d
Use of Condoms in Past Year by 2-Year Age Groups 
(Entries are percentages.)
among Young Adults 2004–2017 a Combined
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Frequency of Condom Use in Last 12 Months 21–22 23–24 25–26 27–28 29–30
Never 23.0 29.0 33.3 39.5 40.0
Seldom 14.4 15,5 13.7 13.4 12.9
Sometimes 14.7 13.0 13.8 12.1 13.1
Most times 20.4 18.9 17.9 15.3 15.8
Always 27.4 23.6 21.2 19.7 18.3
Weighted N = 4,102 3,985 3,308 2,725 2,297
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third questionnaire form.
TABLE 6-1e
among Respondents who Report NOT Being Married 
among Young Adults 2004–2017 a Combined
(Entries are percentages.)
Age of Respondent
Use of Condoms in Past Year by 2-Year Age Groups  
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Frequency of Condom Use in Last 12 Months 21–22 23–24 25–26 27–28 29–30
Never 50.1 54.7 57.3 61.5 65.6
Seldom 16.3 15.0 14.3 12.6 11.0
Sometimes 16.6 11.6 11.0 10.7 10.1
Most times 9.2 10.2 9.0 7.8 6.6
Always 7.9 8.5 8.4 7.4 6.7
Weighted N = 367 854 1,529 2,261 2,834
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third questionnaire form.
TABLE 6-1f
among Respondents who Report Being Married 
among Young Adults 2004–2017 a Combined
(Entries are percentages.)
Age of Respondent
Use of Condoms in Past Year by 2-Year Age Groups  
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Test for HIV: Lifetime and Last 12 Months Total Male Female
    Yes, in the last 12 months 21.0 15.9 25.5
    Yes, but not in the last 12 months 21.6 18.7 24.1
    No, never 57.3 65.4 50.3
Weighted N = 29,436 13,771 15,665
Received HIV Test Results b
    Yes 93.4 92.2 94.1
    No  6.6  7.8  5.9
Weighted N = 12,411 4,705 7,706
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added 
to a third questionnaire form.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not include tests 
that you may have had when donating blood or blood plasma.)
Did you receive the results of your most recent HIV/AIDS test? 
(We don’t want to know your test results.)
TABLE 6-2a
Test for HIV, Lifetime and Last 12 Months
Total and by Gender
among Respondents of Modal Ages 21–30 
(Entries are percentages.)
in 2004–2017 a Combined
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Test for HIV: Lifetime and Last 12 Months Total Male Female
Yes, in the last 12 months 16.9 14.3 19.4
Yes, but not in the last 12 months 38.1 32.8 42.9
No, never 45.0 53.0 37.7
Weighted N = 8,021 3,822 4,199
Received HIV Test Results b
Yes 94.7 92.4 96.3
No  5.3  7.6  3.7
Weighted N = 4,340 1,768 2,572
Source. The Monitoring the Future study, the University of Michigan.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
TABLE 6-2b
Test for HIV, Lifetime and Last 12 Months
Total and by Gender
among Respondents of Modal Age 35 
(Entries are percentages.)
in 2008–2017 a Combined
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Test for Total Male Female
Yes, in the last 12 months 12.0 11.9 12.0
Yes, but not in the last 12 months 41.9 35.7 47.8
No, never 46.1 52.4 40.2
Weighted N = 6,794 3,287 3,507
Received HIV Test Results b
Yes 94.0 91.9 95.5
No  6.0  8.1  4.5
Weighted N = 3,584 1,538 2,047
Source. The Monitoring the Future study, the University of Michigan.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not include 
tests that you may have had when donating blood or 
blood plasma.)
Did you receive the results of your most recent HIV/AIDS 
test? (We don’t want to know your test results.)
TABLE 6-2c
Test for HIV, Lifetime and Last 12 Months
Total and by Gender
among Respondents of Modal Age 40 
(Entries are percentages.)
in 2010–2017 a Combined
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 2004–
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2017
Age 21–22 33.2 29.7 29.5 32.9 28.8 31.2 26.4 27.5 28.8 27.1 26.9 23.5 21.1 28.9 28.3
Weighted N = 404 360 357 493 531 565 548 506 489 438 450 388 374 375 6,278
Age 23–24 37.8 38.0 39.3 39.9 39.1 41.2 41.9 41.4 37.6 32.6 31.9 34.0 33.9 35.2 36.7
Weighted N = 392 373 354 475 490 477 473 495 508 466 453 375 379 375 6,084
Age 25–26 45.0 46.6 43.0 45.6 43.8 48.0 46.5 46.3 46.2 40.7 37.2 44.7 41.0 38.7 42.6
Weighted N = 378 349 320 468 468 441 478 420 427 424 435 397 374 343 5,723
Age 27–28 54.5 50.5 52.6 48.2 53.7 51.3 50.2 45.6 54.4 45.7 52.7 45.1 46.6 47.5 48.2
Weighted N = 343 366 344 468 467 436 449 414 429 397 372 361 376 398 5,619
Age 29–30 56.8 54.2 54.3 52.5 54.3 52.1 53.3 52.6 53.3 53.4 56.1 49.0 58.5 48.7 51.3
Weighted N = 369 330 305 514 509 470 453 422 425 407 418 336 342 359 5,658
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third questionnaire form.
TABLE 6-2d
Percentage of Respondents Who Have Had an HIV Test in Their Lifetime a
 by 2-Year Age Groups 
(Entries are percentages.)
Year of Administration
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Chapter 7 
INTERSECTION OF PROTECTIVE BEHAVIORS 
To the extent that people who use one type of protection against HIV transmission are more (or 
less) likely to use another type, it is useful to consider a broader construct of individual differences 
in avoidance of HIV infection in general. We look here at the degree of association between the 
two protective behaviors of getting tested and using condoms in the three age groups including 
young adults (ages 21-30 year olds), 35 year olds, and 40 year olds. 
Frequency of Condom Use by Getting Tested for HIV 
• Are people who take the precaution of using condoms also the ones who are getting tested
for HIV? The answer appears to be somewhat complicated (Table 7-1a); the association is
slightly curvilinear among both male and female young adults (ages 21-30). Of those who
say they “always” used condoms in the last 12 months, 19% indicate getting tested for HIV
in that period, compared to the 27%–30% who say they seldom, sometimes, or most times
use condoms. Perhaps those who always use condoms consider themselves to be at less
risk of contracting HIV. Sexually active respondents who say they never use condoms are
also slightly less likely to have been tested in the last 12 months (22%) than the middle
groups, perhaps because many of them simply are not concerned about HIV and/or in a
monogamous relationship attempting to conceive. The chart below shows the curvilinear
association.
• Among the 35- and 40-year-olds the same curvilinear relationship between HIV testing
and condom use appears to hold (Tables 7-1b and 7-1c). The differences in testing as a
function of how often sexually active respondents use condoms are fairly consistent with
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those for the young adults. For example, among 35-year-olds who reported not using 
condoms at all in the past 12 months, 16% were tested in the past 12 months. That 
proportion rises to 23% among those who seldom use condoms and to 25% among those 
who sometimes use condoms; it then declines back to 23% among those who use condoms 
most times, and falls further to 16% among those who always use condoms. 
• As noted in the previous chapter, marital status is related to the likelihood of using
condoms, and perhaps for some similar reasons (e.g., assumptions of fidelity), marriage is
also negatively related to the prevalence of testing in the prior 12 months. A comparison
of Tables 7-1d and 7-1e shows that indeed young adults who are married are somewhat
less likely to have been tested for HIV in the last 12 months than those who are not married,
especially among females; but the relationship between testing and condom use remains
curvilinear even after controlling for whether or not the respondent is married.
• Tables 7-1d and 7-1e also show that the frequency of condom use in the past year is
considerably higher among those who are not married than among those who are, as would
be expected.
There appears to be little association between condom use and the proportion of those
getting tested for HIV who actually receive the results of their tests. As Tables 7-1a, 7-1b,
and 7-1c illustrate, nearly all respondents (93%–96%) receive their test results, regardless
of how often they have used condoms in the last 12 months.
• In sum, there is little evidence that the two protective behaviors discussed here—condom
use and getting tested for HIV—are positively correlated. Rather, the association is
curvilinear; those least likely to get tested are those who never use condoms and those who
always use condoms.
 
60
Test for HIV: Lifetime and Last 12 Months Never Seldom Sometimes Most Times Always
Total
 Yes, in the last 12 months 22.2 27.7 29.5 26.9 19.1
 Yes, but not in the last 12 months 28.2 23.2 22.9 21.9 17.4
 No, never 49.6 49.1 47.5 51.2 63.6
Weighted N = 10,007 3,340 3,069 3,596 4,321
Male
Yes, in the last 12 months 15.6 19.8 22.0 21.5 17.2
Yes, but not in the last 12 months 24.2 21.7 21.8 20.8 15.0
No, never 60.2 58.5 56.2 57.7 67.8
Weighted N = 3,991 1,535 1,458 1,852 2,286
Female
Yes, in the last 12 months 26.6 34.5 36.3 32.6 21.2
Yes, but not in the last 12 months 30.8 24.4 24.0 23.1 20.0
No, never 42.6 41.1 39.7 44.3 58.8
Weighted N = 6,016 1,805 1,611 1,744 2,035
Received HIV Test Resultsc
Total
Yes 93.6 93.0 93.9 94.7 93.0
No 6.4 7.0 6.1 5.3 7.0
Weighted N = 4,977 1,675 1,593 1,736 1,567
Male
Yes 92.6 92.1 91.8 93.4 92.9
No 7.4 7.9 8.2 6.6 7.1
Weighted N = 1,573 623 625 770 733
Female
Yes 94.1 93.6 95.2 95.7 93.0
No 5.9 6.4 4.8 4.3 7.0
Weighted N = 3,403 1,053 968 965 835
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners 
are omitted.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Condom Use in Last 12 Months b
TABLE 7-1a
Test for HIV, Lifetime and Last 12 Months
by Frequency of Condom Use
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
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Test for HIV: Lifetime and Last 12 Months Never Seldom Sometimes Most Times Always
Total
Yes, in the last 12 months 15.8 23.3 24.7 23.3 16.4
Yes, but not in the last 12 months 40.3 36.8 34.7 37.7 40.0
No, never 43.9 39.9 40.6 39.0 43.6
Weighted N = 4,712 609 576 579 690
Males
Yes, in the last 12 months 12.4 18.4 22.0 20.0 14.6
Yes, but not in the last 12 months 34.6 31.3 32.7 34.9 37.5
No, never 53.0 50.3 45.3 45.0 48.0
Weighted N = 2,102 348 311 316 348
Females
Yes, in the last 12 months 18.5 29.8 27.8 27.2 18.3
Yes, but not in the last 12 months 44.9 44.1 37.1 41.0 42.7
No, never 36.5 26.1 35.1 31.8 39.1
Weighted N = 2,610 261 265 263 342
Received HIV Test Results c
Total
Yes 94.7 94.8 94.6 95.2 94.8
No 5.3 5.2 5.4 4.8 5.2
Weighted N = 2,608 359 338 351 388
Males
Yes 91.7 91.9 93.4 93.6 95.2
No 8.3 8.1 6.6 6.4 4.8
Weighted N = 965 170 170 172 181
Females
Yes 96.5 97.4 95.7 96.8 94.4
No 3.5 2.6 4.3 3.2 5.6
Weighted N = 1,643 189 168 179 207
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Condom Use in Last 12 Months b
TABLE 7-1b
Test for HIV, Lifetime and Last 12 Months
by Frequency of Condom Use
(Entries are percentages.)
among Respondents of Modal Age 35 in 2008–2017 a Combined
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Test for HIV: Lifetime and Last 12 Months Never Seldom Sometimes Most Times Always
Total
Yes, in the last 12 months 10.5 19.8 20.8 18.3 15.5
Yes, but not in the last 12 months 44.1 38.6 43.8 39.9 38.1
No, never 45.5 41.6 35.4 41.8 46.3
Weighted N = 4,484 323 346 351 479
Males
Yes, in the last 12 months 10.3 22.6 20.1 15.7 18.1
Yes, but not in the last 12 months 38.0 34.2 35.1 35.3 29.2
No, never 51.7 43.2 44.8 49.0 52.7
Weighted N = 2,114 179 191 194 247
Females
Yes, in the last 12 months 10.6 16.3 21.7 21.5 12.8
Yes, but not in the last 12 months 49.5 44.1 54.6 45.5 47.6
No, never 39.9 39.6 23.7 32.9 39.6
Weighted N = 2,370 144 154 158 232
Received HIV Test Results c
Total
Yes 93.9 94.2 94.4 95.7 92.8
No 6.1 5.8 5.6 4.3 7.2
Weighted N = 2,396 186 218 201 254
Males
Yes 91.7 94.6 94.3 92.2 88.5
No 8.3 5.4 5.7 7.8 11.5
Weighted N = 1,005 101 101 98 117
Females
Yes 95.4 93.8 94.6 99.0 96.3
No 4.6 6.2 5.4 1.0 3.7
Weighted N = 1,391 85 117 102 138
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' * ' indicates a prevalence rate of less than 0.05%.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when 
donating blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Condom Use in Last 12 Months b
TABLE 7-1c
Test for HIV, Lifetime and Last 12 Months
by Frequency of Condom Use
(Entries are percentages.)
among Respondents of Modal Age 40 in 2010–2017 a Combined
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Test for HIV: Lifetime and Last 12 Months Never Seldom Sometimes Most Times Always
Total
 Yes, in the last 12 months 24.7 31.3 31.9 29.4 20.5
 Yes, but not in the last 12 months 26.6 22.1 22.0 20.8 16.1
 No, never 48.8 46.6 46.1 49.9 63.4
Weighted N = 5,188 2,315 2,202 2,957 3,713
Male
Yes, in the last 12 months 16.7 22.7 23.3 23.3 18.0
Yes, but not in the last 12 months 24.2 20.8 21.2 20.4 14,5
No, never 59.2 56.5 55.5 56.3 67.6
Weighted N = 2,036 1,039 1,053 1,535 2,037
Female
Yes, in the last 12 months 29.8 38.4 39.7 35.9 23.7
Yes, but not in the last 12 months 28.2 23.1 22.8 21.1 18.1
No, never 42.0 38.5 37.5 43.0 58.2
Weighted N = 3,152 1,276 1,149 1,422 1,676
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
TABLE 7-1d
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Test for HIV, Lifetime and Last 12 Months
by Frequency of Condom Use
among Respondents who Report NOT Being Married 
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
Condom Use in Last 12 Months b
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Test for HIV: Lifetime and Last 12 Months
Never Seldom Sometimes Most Times Always
Total
 Yes, in the last 12 months 19.3 19.1 23.2 14.9 9.9
 Yes, but not in the last 12 months 30.0 25.5 25.2 28.1 25.1
 No, never 50.7 55.5 51.5 57.1 65.0
Weighted N = 4,766 1,003 854 623 586
Male
Yes, in the last 12 months 14.5 13.2 18.0 12.4 9.9
Yes, but not in the last 12 months 24.3 22.7 23.5 23.1 20.3
No, never 61.2 64.1 58.5 64.5 69.8
Weighted N = 1,935 484 401 307 239
Female
Yes, in the last 12 months 22.6 24.6 27.8 17.2 9.9
Yes, but not in the last 12 months 33.8 28.0 26.8 32.9 28.4
No, never 43.5 47.4 45.3 49.9 61.7
Weighted N = 2,831 519 453 316 347
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
TABLE 7-1e
by Frequency of Condom Use
Have you ever been tested for HIV/AIDS? (Do not 
Test for HIV, Lifetime and Last 12 Months
among Respondents who Report Being Married 
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
Condom Use in Last 12 Months b
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Chapter 8 
INTERSECTION OF RISK AND PROTECTIVE BEHAVIORS 
It is useful to know whether people who are at greatest risk of contracting or transmitting HIV are 
more likely than others to practice protective behaviors. In this chapter we examine the frequency 
of condom use as a function of three known risk factors: (1) the number of sex partners the 
respondent reported having in the last 12 months, (2) the gender of those partners, and (3) a history 
of sharing needles. We also look at the prevalence of getting tested for HIV/AIDS as a function of 
those same three risk factors. 
Frequency of Condom Use Related to Number of Partners 
• Among sexually active young adults (ages 21-30), both the prevalence and frequency of 
condom use rise with the number of sexual partners the respondent had in the last 12 
months; this holds true for both genders (Table 8-1a). The prevalence of using a condom 
at least once in the last 12 months rises from 49% among those having only one partner to 
77% for those having two partners, to 86% for those having three or four partners, and to 
89% among those reporting five or more partners. The prevalence is slightly higher among 
males than females (Table 8-1a).
• To the extent that consistent condom use is the goal, the results regarding frequency are 
less encouraging. As summarized in Chapter 6, only about one third (33%) of sexually 
active young adults said that they used a condom “most times” or “always”—37% of males 
and 29% of females (Table 6-1a). It is encouraging, however, that this statistic rises 
considerably for both genders as the number of partners reported rises (Table 8-1a).
• As might be expected, many of the young adults not using condoms are respondents who 
had only one partner during the year (Table 8-1a). Among those reporting only one partner 
(and these comprise the great majority of all respondents), 51% said they did not use 
condoms at all in the last 12 months. In sum, use of condoms, which help prevent 
transmission of HIV (and many other sexually transmitted diseases), is considerably more 
prevalent among young adults who are at heightened risk due to the number of sexual 
partners they have. That is the encouraging part of this finding. However, only 52% of 
those reporting five or more sexual partners in the last 12 months also report using 
condoms “most times” or “always,” leaving a considerable portion of this population at 
risk.
• Compared to young adults age 21-30, a lower proportion of 35- and 40-year-olds report 
having multiple partners; but there is a similar increase in the prevalence and frequency of 
condom use as a function of the number of sexual partners reported (Tables 8-1b and 
8-1c).
• The prevalence of condom use declines sharply with increasing age, very likely a result of 
more respondents being married or in another committed relationship at these later ages. 
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Among 35- and 40-year-olds, the case counts become quite low for people reporting a 
relatively high number of partners.  
Frequency of Condom Use Related to Gender of Partners 
• Extensive efforts have been made in past years to encourage the use of condoms by men 
who have sex with men, in an attempt to stem the spread of HIV/AIDS in this high-risk 
population. The numbers of such cases available for analysis so far are somewhat limited 
(among the 21- to 30-year olds, the weighted N is 500 men who report having sex with 
men exclusively; the case count of young adult males who report having sex with both 
genders is 104 at this point). Results suggest that the use of condoms in the last 12 months 
among men having sex exclusively with men (38% reporting “most times” or “always”) 
does not differ significantly from the use of condoms among men having sex exclusively 
with women (37% reporting “most times” or “always”). Similar proportions of both of 
these groups (39% and 36%, respectively, n.s.) report never using condoms (Table 8-2a).
(The rate of condom use among men having sex exclusively with women is likely 
suppressed some by the proportion trying to conceive a child.) Thus, the higher degree of 
risk among young adult men who have sex exclusively with men is not reduced by 
more frequent use of condoms. Fortunately, among young adult males who have had 
sex with both genders in the last 12 months, there do appear to be higher prevalence 
(almost 80%) and higher frequency (52% saying “most times” or “always”) of condom 
use than are found in either of the other two groups of men. Assuming this finding of 
higher prevalence and frequency of condom use holds as we gather more cases in future 
years, it suggests that this group’s higher risk behavior is met with more compensatory  
protective behavior than average against the transmission of the disease, including across 
genders.
• By way of contrast, among 35- and 40-year-olds, the prevalence and frequency of condom 
use among men having sex exclusively with men do appear to be higher than among men 
the same age who have sex exclusively with women, although the case counts for men who 
have sex with men exclusively are still quite low in those two age groups (Tables 8-2b and
8-2c). Whether this difference is an age effect or a cohort effect is not known at this point.
• As would be expected, the great majority of young adult women who had sex exclusively 
with women in the last 12 months’ report not using condoms during the prior year (84%) 
vs. 45% of those having sex exclusively with men. Among women reporting having sex 
with both genders during the year, only 26% report no use of condoms in the past 12 
months, and they report the highest frequency of using condoms “most times” or “always” 
of the three female groups, though still only 44% report using condoms that frequently.
• The case counts are still too small for 35- and 40-year-olds to make these comparisons 
among the three female respondent subgroups (Tables 8-2b and 8-2c). 
67
Frequency of Condom Use Related to Needle Sharing 
• The association between needle sharing and condom use is not very clear, particularly
given the small numbers of cases to date, even among the young adults (Table 8-3).
• There are too few cases for needle-sharing among 35- and 40-year-olds to report on
differences in condom use, so no tables are provided.
Getting Tested for HIV Related to Number of Sex Partners 
• Among young adults, the prevalence of getting tested for HIV rises with the number of sex
partners reported in the last 12 months (Table 8-4a). While only 6.1% of those reporting
no partners in the last 12 months say that they have been tested in the last 12 months, the
rate rises to 20% of those reporting one partner, 31% for those reporting two partners, and
40% for those reporting five or more partners.
• The proportion of young adults getting the results of their tests is very high in all groups,
but a bit higher among those with multiple sexual partners (Table 8-4a).
• In terms of protective behaviors, young adults at increased risk because of a higher number
of sexual partners are more likely to get tested and receive the results of the HIV test.
However, about two thirds of those reporting multiple partners did not have an HIV test in
the last 12 months (Table 8-4a).
• Among 35-year-olds and 40-year-olds, the proportion getting tested also rises with the
number of partners in the last 12 months (Tables 8-4b and 8-4c). Nearly half (48%) of 35-
year-olds reporting five or more partners in the last 12 months got tested in that interval,
while 42% of 40-year olds with  five or more partners did so.
Getting Tested for HIV Related to Gender of Partners 
• Because men who have sex with men are at particular risk for contracting and transmitting 
HIV, we examined whether HIV testing was more prevalent among those men reporting 
sex exclusively with men in the past year (Table 8-5a). While the number of young adult 
cases of men who have sex exclusively with men is limited (508 weighted cases), the 
results are suggestive of increased vigilance in this population. Two thirds (66%) of males 
having exclusively male partners in the last 12 months indicated being tested for HIV at 
some time, and about four in every ten (41%) said that they had been tested in the last 12 
months. These lifetime and 12-month rates compare to 38% and 17%, respectively, among 
men who had female partners exclusively during the last 12 months. Hardly any (2%) of 
the males reporting relations exclusively with other men in the last 12 months said that they 
failed to get the results of their most recent test, versus 8% of those who had only female 
partners.
• Similar large differences appear among 35- and 40-year-old men (Table 8-5b & 8-5c), 
though the case counts are still somewhat limited. 
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Getting Tested for HIV Related to Needle Sharing 
• Young adults who have shared needles in their lifetime are considerably more likely to
report having been tested for HIV both in their lifetime and in the last 12 months, compared
with those who have never shared needles. Those who have shared needles in the last 12
months are also more likely to report getting tested for HIV during the last 12 months by a
statistically significant amount than those who did not share needles during the last 12
months (Table 8-6).
Summary 
To conclude the intersection of risk and protective behaviors, those who have shared needles—
one of the highest risk groups for HIV infection—are among the most likely to exhibit the 
protective behavior of getting tested for HIV. Men having sex exclusively with men—another very 
high risk group—use condoms at about the same rate as men having sex exclusively with women; 
however, they do get tested for HIV/AIDS more frequently. Fortunately, another risk group—
those having multiple sex partners—are more likely to engage in both of these protective behaviors 
(using condoms and getting tested). 
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    Three   Five
Frequency of Condom Use in Last 12 Months b None One Two or Four or More
Total
    Never — 50.8 22.6 14.4 11.2
    Seldom — 12.7 16.6 17.0 15.1
    Sometimes — 10.1 16.5 19.2 22.3
    Most times — 9.5 20.8 31.0 35.3
    Always — 16.9 23.4 18.4 16.2
Weighted N = — 17,368 2,770 2,685 1,494
Male
    Never — 46.2 18.4 13.5 10.2
    Seldom — 13.1 15.7 16.0 14.1
    Sometimes — 10.9 14.8 18.0 21.6
    Most times — 10.9 21.5 30.4 35.1
    Always — 18.9 29.5 22.1 18.9
Weighted N = — 7,533 1,244 1,350 977
Female
    Never — 54.4 26.0 15.2 12.9
    Seldom — 12.4 17.3 18.1 16.9
    Sometimes — 9.6 17.9 20.5 23.6
    Most times — 8.4 20.3 31.6 35.5
    Always — 15.3 18.5 14.6 11.0
Weighted N = — 9,834 1,526 1,335 517
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a 
third questionnaire form.
partners are omitted.  
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no  
TABLE 8-1a
Condom Use by Number of Sex Partners in Last 12 Months
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
Number of Partners in Last 12 Months
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This includes 
vaginal and anal sex, but not oral sex.)
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    Three   Five
Frequency of Condom Use in Last 12 Months b None One Two or Four or More
Total
Never — 71.8 36.4 24.6 11.8
Seldom — 7.3 14.9 13.7 22.4
Sometimes — 6.8 14.8 15.6 16.9
Most times — 5.5 16.2 28.0 34.8
Always — 8.5 17.7 18.0 14.1
Weighted N = — 6,212 396 356 204
Males
Never — 68.5 36.4 21.7 9.8
Seldom — 8.7 15.8 15.0 24.6
Sometimes — 7.9 14.7 14.5 16.6
Most times — 6.5 11.7 28.5 32.4
Always — 8.4 21.4 20.3 16.5
Weighted N = — 2,894 183 200 145
Females
Never — 74.8 36.4 28.3 16.8
Seldom — 6.1 14.2 12.0 16.9
Sometimes — 5.9 14.9 17.1 17.5
Most times — 4.6 20.0 27.5 40.7
Always — 8.6 14.5 15.2 8.1
Weighted N = — 3,318 214 156 59
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
are omitted.  
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners 
TABLE 8-1b
Condom Use by Number of Sex Partners in Last 12 Months
(Entries are percentages.)
Number of Partners in Last 12 Months
among Respondents of Modal Age 35 in 2008–2017 a Combined
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
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    Three   Five
Frequency of Condom Use in Last 12 Months b None One Two or Four or More
Total
Never — 80.1 44.5 32.3 23.5
Seldom — 4.2 14.5 17.5 9.8
Sometimes — 4.2 12.2 22.0 21.0
Most times — 4.2 13.0 16.8 31.7
Always — 7.3 15.8 11.3 14.0
Weighted N = — 5,280 325 239 147
Males
Never — 78.9 40.3 27.6 21.4
Seldom — 4.5 16.7 18.9 10.8
Sometimes — 4.9 10.1 22.7 19.6
Most times — 4.5 14.2 16.1 31.7
Always — 7.2 18.8 14.8 16.5
Weighted N = — 2,526 151 140 113
Females
Never — 81.2 48.2 38.9 30.4
Seldom — 3.8 12.5 15.7 6.5
Sometimes — 3.6 14.1 21.2 25.6
Most times — 4.0 12.0 17.9 31.9
Always — 7.4 13.2 6.3 5.5
Weighted N = — 2,753 174 99 34
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
are omitted.  
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners 
TABLE 8-1c
Condom Use by Number of Sex Partners in Last 12 Months
(Entries are percentages.)
Number of Partners in Last 12 Months
among Respondents of Modal Age 40 in 2010–2017 a Combined
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Frequency of Condom Use in Last 12 Months b
    Never 36.0 38.7 20.8 45.0 84.1 26.3
    Seldom 13.9 11.0 15.6 13.9 4.6 12.7
    Sometimes 13.2 11.9 11.2 12.3 2.6 16.7
    Most times 16.4 18.8 31.8 13.2 2.9 25.7
    Always 20.6 19.6 20.5 15.6 5.8 18.6
Weighted N = 10,516 500 104 12,644 308 271
Source.  The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no  
partners are omitted.
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This includes 
vaginal and anal sex, but not oral sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-2a
Condom Use by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Frequency of Condom Use in Last 12 Months b
Never 62.5 40.9 † 69.9 † †
Seldom 9.9 12.7 † 7.1 † †
Sometimes 8.9 8.9 † 7.1 † †
Most times 8.7 23.8 † 7.0 † †
Always 10.0 13.8 † 9.0 † †
Weighted N = 3,274 122 24 3,630 78 33
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' † ' indicates that the sample size is too limited to provide reliable estimates.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. In 2009
and after, these questions were included in all questionnaires for this group.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are 
omitted.
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-2b
Condom Use by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Frequency of Condom Use in Last 12 Months b
Never 73.3 53.6 † 77.4 † †
Seldom 5.9 8.4 † 4.8 † †
Sometimes 6.5 7.8 † 5.0 † †
Most times 6.1 18.2 † 5.1 † †
Always 8.2 12.0 † 7.5 † †
Weighted N = 2,801 110 20 2,969 60 35
Source. The Monitoring the Future study, the University of Michigan.
Notes  ' †  '  indicates that the sample size is too limited to provide reliable estimates.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are 
omitted.
When you had sexual intercourse during the LAST 
12 MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-2c
Condom Use by Gender of Sex Partners in Last 12 Months 
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
 
75
Yes, in Last Yes, but not in 
Frequency of Condom Use in Last 12 Months b 12 Months Last 12 Months No, Never 
Never 33.0 47.8 41.1
Seldom 33.5 24.8 13.7
Sometimes 13.4 10.4 12.6
Most times 19.4 11.2 14.8
Always 0.9 5.8 17.8
Weighted N = 40 81 23,990
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bThose respondents who report never having sex in the last 12 months are excluded from these percentages. 
Needle Sharing
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
TABLE 8-3
Condom Use by Needle Sharing
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
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Three   Five   
Test for HIV: Lifetime and Last 12 Months None One Two or Four or More
    Yes, in the last 12 months 6.1 19.6 31.0 35.6 40.4
    Yes, but not in the last 12 months 9.6 25.4 20.9 20.4 18.6
    No, never 84.3 55.0 48.1 44.0 41.0
Weighted N = 4,624 17,555 2,794 2,699 1,497
Received HIV Test Results b
    Yes 90.0 93.6 92.0 93.5 96.2
    No 10.0 6.4 8.0 6.5 3.8
Weighted N = 718 7,805 1,431 1,504 867
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a  
third questionnaire form.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not include tests 
that you may have had when donating blood or blood plasma.)
Did you receive the results of your most recent HIV/AIDS test? 
(We don’t want to know your test results.)
Number of Partners in Last 12 Months
TABLE 8-4a
Test for HIV, Lifetime and Last 12 Months
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
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Three   Five   
Test for HIV: Lifetime and Last 12 Months None One Two or Four or More
Yes, in the last 12 months 9.3 14.8 34.5 33.9 47.6
Yes, but not in the last 12 months 25.8 40.2 34.3 33.1 32.8
No, never 64.9 45.0 31.2 33.0 19.6
Weighted N = 746 6,271 398 357 203
Received HIV Test Results b
Yes 93.7 94.7 95.7 96.7 92.8
No 6.3 5.3 4.3 3.3 7.2
Weighted N = 251 3,394 273 236 162
Source. The Monitoring the Future study, the University of Michigan.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Number of Partners in Last 12 Months
TABLE 8-4b
Test for HIV, Lifetime and Last 12 Months
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
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Three   Five   
Test for HIV: Lifetime and Last 12 Months None One Two or Four or More
Yes, in the last 12 months 7.3 9.9 25.5 34.0 41.3
Yes, but not in the last 12 months 34.0 43.2 45.8 42.1 32.4
No, never 58.7 46.9 28.8 23.9 26.3
Weighted N = 709 5,337 324 241 146
Received HIV Test Results b
Yes 93.3 94.4 88.0 93.9 97.4
No 6.7 5.6 12.0 6.1 2.6
Weighted N = 287 2,777 224 181 104
Source. The Monitoring the Future study, the University of Michigan.
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Number of Partners in Last 12 Months
TABLE 8-4c
Test for HIV, Lifetime and Last 12 Months
by Number of Sex Partners in Last 12 Months
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Test for HIV: Lifetime and Last 12 Months
Yes, in the last 12 months 17.0 41.4 35.8 28.3 23.8 48.6
Yes, but not in the last 12 months 20.9 24.9 17.3 26.4 23.7 24.3
No, never 62.1 33.7 46.9 45.2 52.5 27.1
Weighted N = 10,573 508 104 12,736 328 273
Received HIV Test Results b
Yes 92.3 97.9 82.5 94.2 92.3 95.7
No 7.7 2.1 17.5 5.8 7.7 4.3
Weighted N = 3,953 329 54 6,906 156 194
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-5a
Test for HIV, Lifetime and Last 12 Months 
by Gender of Sex Partners in Last 12 Months
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Test for HIV: Lifetime and Last 12 Months
Yes, in the last 12 months 13.3 43.2 † 20.3 25.4 †
Yes, but not in the last 12 months 34.3 38.3 † 43.9 41.8 †
No, never 52.4 18.5 † 35.8 32.7 †
Weighted N = 3,287 127 24 3,640 83 33
Received HIV Test Results b
Yes 92.2 97.6 † 96.3 98.1 †
No 7.8 2.4 † 3.7 1.9 †
Weighted N = 1,538 103 17 2,309 55 27
Source. The Monitoring the Future study, the University of Michigan.
Notes. ' † ' indicates that the sample size is too limited to provide reliable estimates. ' * ' indicates a prevalence rate of less 
than 0.05%.
aIn 2008, the HIV questions were added to one half of the questionnaires administered to the 35-year-old respondents. 
In 2009 and after, these questions were included in all questionnaires for this group.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-5b
Test for HIV, Lifetime and Last 12 Months 
by Gender of Sex Partners in Last 12 Months
among Respondents of Modal Age 35 in 2008–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Female Male Male and Male Female Male and
Only Only Female Only Only Female
Test for HIV: Lifetime and Last 12 Months
Yes, in the last 12 months 11.5 46.3 † 11.8 † †
Yes, but not in the last 12 months 36.4 37.1 † 49.3 † †
No, never 52.1 16.6 † 38.9 † †
Weighted N = 2,812 112 20 2,974 63 35
Received HIV Test Results b
Yes 91.8 95.6 † 95.6 † †
No 8.2 4.4 † 4.4 † †
Weighted N = 1,323 93 15 1,775 38 27
Source. The Monitoring the Future study, the University of Michigan.
Notes.  ' †  '  indicates that the sample size is too limited to provide reliable estimates. 
aThe HIV questions were added to the questionnaires for 40-year-olds beginning in 2010.
bThose respondents who report never having been tested for HIV are excluded from these percentages. 
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when 
donating blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don’t want to know your test 
results.)
Gender of Partner(s) Gender of Partner(s)
TABLE 8-5c
Test for HIV, Lifetime and Last 12 Months 
by Gender of Sex Partners in Last 12 Months
among Respondents of Modal Age 40 in 2010–2017 a Combined
(Entries are percentages.)
MALE RESPONDENTS FEMALE RESPONDENTS
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Test for HIV: Lifetime and Last 12 Months
Yes, in the last 12 
months
Yes, but not in the last 
12 months No, never
    Yes, in the last 12 months 36.4 40.9 21.0
    Yes, but not in the last 12 months 22.3 38.4 21.6
    No, never 41.4 20.8 57.4
Weighted N = 44 95 28,811
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the HIV questions were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
TABLE 8-6
Testing for HIV by Needle Sharing
among Respondents of Modal Ages 21–30 in 2004–2017 a Combined
(Entries are percentages.)
Needle Sharing
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Chapter 9 
TRENDS IN THE PREVALENCE AND 
FREQUENCY OF RISK BEHAVIORS 
There is considerable value in tracking trends in the prevalence of the various risk and protective 
behaviors related to the spread of HIV. Ongoing annual data collections allow us to monitor the 
prevalence and frequency of these behaviors over time. While the numbers of cases available 
remain limited for estimating the intersection of some of the more rare behaviors like needle 
sharing and men having sex with men, continuing data collection is providing more in-depth 
consideration of these important subgroups and correlates. The 2017 MTF data collection is the 
thirteenth to include the set of questions on HIV risk and protective behaviors among young adults 
ages 21 to 30.1  
We now find some change in some of the risk behaviors under study from 2005 to 2017 among 
young adults ages 21–30 (Tables 9-1a, 9-2a, and top panels of Figures 9-1 through 9-5). Because 
35- and 40-year olds have lower case counts in the study, their trend data are less stable. These 
points are elaborated below.
Injection drug use  
• The prevalence of past-year injection drug use (Figure 9-2 and Table 9-1a) and lifetime 
needle sharing show little systematic change over the interval 2005–2017 among 21- to
30-year-olds, though among young adult males’ lifetime injection drug use did show some 
evidence of a peak around 2008 (past year injection drug use did not, Figure 9-1). The 
prevalence of these behaviors has consistently been quite low in this population drawn 
from high school graduates. The annual prevalence of injection drug use has consistently 
been below 1.0% among males and 0.4% among females since 2005.
• Among 35- and 40-year-olds the trend lines are less smooth (Table 9-1b and the lower 
panels in Figures 9-1 to 9-3).2 Nonetheless, some evidence suggests there may have been 
changes in certain rates. Among 35-year-olds, males showed an increase in the lifetime 
prevalence of injection drug use from 2.1% in 2011 to 3.8% in 2013 (p<.05) followed by 
a leveling through 2014 and then a decline back to 2.0% by 2017. They also showed an 
increase in the frequency of drug injection use, with the percent reporting using 20 or more 
times in their lifetime rising from 0.5% in 2012 to 1.6% in 2014 (p<0.05) followed by a 
non-significant decline to 0.7% by 2017. 
1 We present the trend data in this chapter and the next using two-year moving averages in order to smooth the trend estimates and reduce fluctuations 
due primarily to sampling error. This is done by taking an arithmetic average of (a) the results for the year labeled at the top of each column in 
Tables 9-1 and 9-2, and (b) the results from the prior year. The annual sample size increased in 2007 due to the inclusion of this set of questions in 
an additional questionnaire form; but the 2006 and 2007 data are weighted equally in calculating the two-year moving average for 2007. 
2 The numbers of cases that underlie the annual estimates for both age groups may be found in the trend tables (e.g., Tables 9-2a and 9-2ab). They 
show that the estimates for young adults are based on 3,400 to 4,900 cases each year whereas the estimates for 35-year-olds are based on 1,400 to 
1,900 cases, and the estimates for 40-year-olds are based on 1,500 to 1,800 cases. 
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The 40-year-old males and females showed rather little change in lifetime prevalence of 
injecting drugs between 2011, when data were first gathered on them, and 2017           
(Figure 9-1, lower panel). Annual injection prevalence has been very low in these two age 
groups, but has generally been higher among males than among females (Figure 9-2, Tables 
9-1b and 9-1c).
Needle sharing  
• Among young adults the rates of lifetime needle sharing were consistently very low during
the 2005 to 2017 interval, and were even lower among females in 2013 and 2014 (not
statistically significant; Figure 9-3 and Table 9-1a). The past-year overall rates of needle
sharing were quite flat across the entire interval, ranging from 0.1% to 0.2% for all young
adults. Among young adult males, rates showed small, non-significant increases in 2013
and 2014, when annual prevalence was 0.3%; in all other years, annual prevalence was
0.1% or 0.2% (Table 9-1a).
• Among the 35- and 40-year-olds lifetime needle sharing has been well under 1.0% for both
genders in all years, with none of the year-to-year changes reaching statistical significance.
Number of sex partners 
• In Table 9-2a and Figure 9-5 young adult males show some decline over the interval 2005–
2017 in the prevalence of having more than one sex partner in the prior year; the average 
rate for 2012–2015 of 25.2% is significantly lower than the earlier average rate of 27.5%
for 2005–2011 (p<.05). In fact, the decline continued after 2015 and now the lowest 
observation for males is in 2017, at which point the rates for the two genders have crossed 
with 21.9% of males saying they had more than one partner in the prior 12 months 
compared with 22.9% of females. One reason for this change among males is that more of 
them indicate having no sex partners during the year, rising from a low of 14.4% in 2008 
to a high of 23.1% in 2017 (p<.001).
• While the percent of young adult males reporting multiple sex partners has been declining, 
the percent of young adult females reporting multiple partners in the prior year may have 
risen slightly, from 20.8% in 2011 to 22.9% in 2017 (a nonsignificant difference, even 
when testing across multiple years as described above for young adult males). Interestingly, 
this has been occurring at much the same time that the percent of young adult females 
reporting zero partners has risen from 12.3% in 2005 to 16.1% in 2017 (p<.001) and the 
proportion reporting just one partner has fallen a bit. The general shift from one partner to 
zero partners can be observed in the data for both genders (see Table 9-2a). The net effect 
of these changes since about 2011 is that the difference between the genders in the 
prevalence of having multiple sex partners has been eliminated, as can be seen most clearly 
in Figure 9-5. But there still remains a gender difference in having four or more partners 
(Table 9-2a). In 2017, 9.3% of the males reported having four or more partners in the prior 
12 months compared to 7.6% of the females.
• Among 35-year-olds (Table 9-2b and Figure 9-5, lower panel) there is rather little evidence 
of systematic change in number of sex partners reported in the last 12 months. Each year, 
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over 75% of 35-year-old males and over 78% of the females report having only one partner 
in the prior year—higher proportions than among young adults. And in the eight years 
shown, only 10–13% of all 35-year-olds and under 11% of the 40-year-olds (in the six 
years shown) have indicated that they had multiple partners, compared with about 23% 
among the young adults. Thus, this risk factor clearly declines with age. 
Same Gender sex partners 
• The proportions of young adult male respondents reporting sex with partners of the same
gender (including those reporting sex with both genders) during the prior year have been
quite stable over time (Table 9-2a and Figure 9-6). Each year between 4.7% and 6.7% of
the men indicated having sex with other men with no clear trending over time. Among
women, between 3.6% and 6.0% indicated having sex with other women (although this
behavior by women is not a risk behavior for HIV transmission). There has been a gradual,
statistically significant increase since 2009 in the percentage of young adult women having
sex exclusively with women, from 1.8% in 2009 to 3.1% in 2017 (Table 9-2a).
• Among 35-year-olds, compared to young adults, the rates of same-gender sex are slightly
lower for males (between 3.2% and 5.0%) and females (between 2.3% and 4.2%). Figure
9-6 suggests that there has been little systematic change among 35-year-olds over the eight-
year interval studied; and the same is true for the 40-year-olds over the six-year interval
studied (Tables 9-2a and 9-2b, Figure 9-6).
To summarize, in the young adult population (ages 21–30) and among 35- and 40-year-olds there 
has been considerable stability in recent years in the major risk behaviors under study here—drug 
injecting, sharing needles, having multiple sex partners, and men having sex with men. One 
exception may be a possible increase in 2013 and 2014 in past-year needle sharing among young 
adult males (Figures 9-1 and 9-2). Men age 35 have shown some increase in both prevalence and 
frequency of injecting drugs, quite possibly reflecting the resurgence in heroin use in recent years 
among this age group (CDC, 2018).  
With regard to the numbers of sex partners reported, there are some positive developments from 
the perspective of HIV/AIDS transmission risk. Males have shown a significant increase in the 
percent reporting having no sex partners in the past 12 months, with abstention  rising from 2008 
(14.4%) through 2017 (23.1%). They have also shown a significant decline in the percent having 
multiple sex partners. Young adult females also showed a significant increase in abstention over 
the same interval, but a more modest one, from 12.8% to 16.1%. 
However, working against these improvements in the situation, a significantly increasing percent 
of young adult females report having multiple sex partners. In combination these changes have led 
to a reversal of gender differences in having multiple sex partners. Among young adult females 
there has been a significant rise in the prevalence of having multiple partners, whereas among 
young adult males there has been a significant decline; the net effect is an elimination and perhaps 
even a slight reversal of the gender gap on this risk factor. There remains a considerable gap in the 
prevalence of having four or more partners, however, with males more likely to report this many.  
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One important risk behavior for HIV/AIDS transmission is men having sex with other men. We 
do not see significant change in the prevalence of this behavior in any of the three age groups in 
the intervals under study. There has been a statistically significant increase in the reporting by 
women of having sex with other women, but that is not a risk behavior for the spread of the disease. 
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Lifetime Frequency of Injecting Drugs 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 98.5 98.5 98.3 98.2 98.4 98.5 98.4 98.5 98.4 98.6 98.7 98.7 98.8
    1–2 —  0.5  0.5  0.6  0.5  0.5  0.5  0.4  0.4  0.4  0.2  0.1  0.2  0.3
    3–5 —  0.2  0.2  0.3  0.3  0.2  0.2  0.2  0.2  0.2  0.2  0.2  0.2  0.2
    6–9 —  0.1  0.2  0.2  0.2  0.1  0.2  0.2  0.1 * 0.1  0.2  0.1  0.1
    10–19 —  0.3  0.2  0.2  0.2  0.2  0.1  0.1  0.1  0.2  0.2  0.1  0.1  0.1
    20–39 —  0.1  0.1  0.1  0.2  0.2  0.1  0.1  0.2  0.1  0.1  0.1  0.1 *
    40+ Occasions —  0.4  0.3  0.3  0.4  0.4  0.5  0.6  0.6  0.7  0.6  0.7  0.6  0.4
Weighted N = — 3,643 3,441 4,076 4,846 4,819 4,751 4,624 4,510 4,384 4,243 4,101 3,826 3,693
Annual Frequency of Injecting Drugs
    0 Occasions — 99.5 99.6 99.6 99.5 99.5 99.5 99.5 99.5 99.4 99.4 99.4 99.5 99.5
    1–2 —  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.2
    3–5 — * 0.1 * * 0.1  0.2  0.1  0.1 * 0.1  0.1  0.1  0.1
    6–9 — * 0.1  0.1  0.2  0.1 * * 0.1  0.1  0.1  0.1 * *
    10–19 —  0.1  0.1  0.1  0.1 * * 0.1  0.1 * * * * *
    20–39 — * * *  0.1  0.1  0.1  0.1 * 0.1 * 0.1 * *
    40+ Occasions —  0.2  0.1  0.1  0.1  0.2  0.1  0.2  0.2  0.2  0.3  0.3  0.2  0.2
Weighted N = — 3,644 3,441 4,077 4,847 4,821 4,753 4,630 4,515 4,385 4,244 4,101 3,814 3,681
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months —  0.1  0.1  0.1  0.1  0.2  0.2  0.1  0.2  0.2  0.2  0.2  0.1  0.1
    Yes, but not in the last 12 months —  0.3  0.4  0.4  0.4  0.3  0.3  0.5  0.4  0.3  0.2  0.3  0.5  0.4
    No, never — 99.7 99.5 99.5 99.5 99.5 99.6 99.4 99.4 99.5 99.6 99.5 99.4 99.5
Weighted N = — 3,610 3,387 4,032 4,813 4,783 4,716 4,587 4,475 4,349 4,214 4,066 3,786 3,670
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth. The questions were contained in
 two questionnaire forms in 2004 through 2006 and three forms beginning in 2007.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) in your 
lifetime? Do not include anything you took under a 
doctor ’s orders.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) during the 
last 12 months? Do not include anything you took 
under a doctor ’s orders.
Have you ever taken such drugs using a needle 
that you knew (or suspected) had been used by 
someone else before you used it?
TABLE 9-1a
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Total
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Lifetime Frequency of Injecting Drugs 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 97.9 97.7 97.4 97.3 97.6 97.9 97.6 97.8 97.7 98.1 98.1 97.9 98.0
    1–2 —  0.6  0.6  0.7  0.7  0.7  0.5  0.4  0.4  0.6  0.4  0.2  0.3  0.5
    3–5 —  0.2  0.3  0.5  0.5  0.4  0.3  0.3  0.4  0.4  0.3  0.1  0.2  0.4
    6–9 —  0.1  0.3  0.4  0.3  0.2  0.3  0.4  0.1 * 0.1  0.2  0.3  0.1
    10–19 —  0.5  0.4  0.4  0.4  0.3  0.2  0.2  0.2  0.3  0.3  0.2  0.2  0.2
    20–39 —  0.2  0.2  0.3  0.4  0.3  0.1  0.3  0.3  0.2  0.1  0.2  0.2  0.1
    40+ Occasions —  0.5  0.5  0.4  0.4  0.5  0.6  0.8  0.9  0.9  0.9  1.1  1.0  0.7
Weighted N = — 1,727 1,615 1,904 2,277 2,285 2,247 2,154 2,099 2,027 1,954 1,902 1,780 1,717
Annual Frequency of Injecting Drugs
    0 Occasions — 99.2 99.3 99.2 99.3 99.3 99.2 99.2 99.2 99.1 99.1 99.1 99.2 99.1
    1–2 —  0.2  0.2  0.2  0.1  0.1  0.1  0.1  0.1  0.2  0.2  0.1  0.2  0.3
    3–5 — * 0.1  0.1 * 0.1  0.3  0.3  0.1  0.1  0.2  0.2  0.1  0.2
    6–9 — * 0.1  0.2  0.3  0.2 * * 0.1  0.2 * 0.1  0.1 *
    10–19 —  0.2  0.2  0.1  0.1 * * 0.1  0.1 * * * * *
    20–39 —  0.1 * * 0.1  0.1  0.2  0.2  0.1  0.1 * * *  0.1
    40+ Occasions —  0.2  0.1  0.1  0.1  0.2  0.2  0.3  0.3  0.3  0.5  0.5  0.4  0.3
Weighted N = — 1,727 1,615 1,905 2,277 2,285 2,249 2,156 2,101 2,027 1,954 1,902 1,771 1,707
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months —  0.1  0.2  0.2  0.1  0.2  0.1  0.1  0.2  0.3  0.3  0.2  0.1  0.2
    Yes, but not in the last 12 months —  0.3  0.4  0.3  0.4  0.3  0.4  0.6  0.5  0.4  0.2  0.5  0.6  0.4
    No, never — 99.6 99.4 99.4 99.5 99.5 99.5 99.3 99.4 99.4 99.4 99.4 99.3 99.3
Weighted N = — 1,708 1,582 1,888 2,266 2,264 2,231 2,135 2,078 2,008 1,939 1,887 1,764 1,709
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth. The questions were contained in
 two questionnaire forms in 2004 through 2006 and three forms beginning in 2007.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) in your 
lifetime? Do not include anything you took under a 
doctor ’s orders.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) during the 
last 12 months? Do not include anything you took 
under a doctor ’s orders.
Have you ever taken such drugs using a needle 
that you knew (or suspected) had been used by 
someone else before you used it?
TABLE 9-1a (cont.)
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Male
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Lifetime Frequency of Injecting Drugs 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 99.1 99.2 99.0 99.1 99.1 99.0 99.0 99.1 99.0 99.1 99.2 99.4 99.4
    1–2 —  0.3  0.5  0.5  0.3  0.3  0.4  0.4  0.4  0.3  0.1  0.1  0.2  0.2
    3–5 —  0.2  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.2  0.2  0.1  0.1
    6–9 — * * * * * 0.1  0.1 * * 0.1  0.1 * 0.1
    10–19 — * * 0.1  0.1  0.1 * * *  0.2  0.2 * * *
    20–39 — * * *  0.1  0.1 * * * * * 0.1 * *
    40+ Occasions —  0.3  0.2  0.2  0.4  0.4  0.4  0.4  0.5  0.4  0.3  0.3  0.3  0.2
Weighted N = — 1,916 1,826 2,172 2,569 2,534 2,504 2,471 2,412 2,358 2,289 2,199 2,045 1,976
Annual Frequency of Injecting Drugs
    0 Occasions — 99.7 99.9 99.8 99.7 99.7 99.7 99.8 99.7 99.6 99.6 99.7 99.8 99.9
    1–2 —  0.1 * 0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1  0.1 * *
    3–5 — * * * * * * * * * * 0.1 * *
    6–9 — * * * * * * * *  0.1  0.1 * * *
    10–19 — * * * * * * * * * * * * *
    20–39 — * * * *  0.1  0.1 * * *  0.1  0.1  0.1 *
    40+ Occasions —  0.2  0.1 * 0.1  0.1  0.1  0.1  0.1  0.2  0.1 * 0.1  0.1
Weighted N = — 1,917 1,826 2,172 2,570 2,535 2,505 2,473 2,415 2,358 2,289 2,199 2,043 1,974
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months —  0.1  0.1  0.1  0.2  0.2  0.2  0.2  0.2  0.1  0.1  0.2  0.2  0.1
    Yes, but not in the last 12 months —  0.3  0.3  0.4  0.3  0.3  0.2  0.3  0.3  0.2  0.1  0.2  0.3  0.3
    No, never — 99.7 99.6 99.6 99.5 99.6 99.6 99.5 99.5 99.7 99.8 99.6 99.5 99.6
Weighted N = — 1,902 1,805 2,144 2,547 2,519 2,485 2,453 2,396 2,340 2,275 2,179 2,023 1,962
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth. The questions were contained in
 two questionnaire forms in 2004 through 2006 and three forms beginning in 2007.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) in your 
lifetime? Do not include anything you took under a 
doctor ’s orders.
On how many occasions (if any) have you taken 
any drugs by injection with a needle (like heroin, 
cocaine, amphetamines, or steroids) during the 
last 12 months? Do not include anything you took 
under a doctor ’s orders.
Have you ever taken such drugs using a needle 
that you knew (or suspected) had been used by 
someone else before you used it?
TABLE 9-1a (cont.)
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Female
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Lifetime Frequency of Injecting Drugs 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 98.7 98.4 98.5 98.4 97.6 97.8 98.3 98.2 98.5
    1–2 —  0.8  0.8  0.5  0.6  0.8  0.6  0.7  0.6  0.4
    3–5 —  0.1  0.1  0.2  0.2  0.2  0.1  0.1  0.1  0.2
    6–9 — * 0.1  0.1  0.1  0.2  0.2  0.1  0.1  0.1
    10–19 — * 0.1  0.3  0.3  0.3  0.3  0.2  0.2  0.3
    20–39 —  0.1 0.1  0.1 * 0.2  0.2  0.1  0.1  0.1
    40+ Occasions —  0.2 0.4  0.4  0.4 0.6  0.7  0.6  0.6  0.5
Weighted N = — 1,453 1,908 1,796 1,770 1,750 1,648 1,544 1,497 1,487
Annual Frequency of Injecting Drugs
    0 Occasions — 99.8 99.6 99.6 99.7 99.5 99.3 99.6 99.6 99.7
    1–2 —  0.1  0.1  0.1 * * * * * 0.1
    3–5 — * * * *  0.1  0.1 * * *
    6–9 — * 0.1 0.2  0.2  0.1  0.2 * * *
    10–19 — * * * *  0.0  0.1 * * *
    20–39 — * 0.1 0.1  0.1  0.1 * 0.1  0.1  0.1
    40+ Occasions —  0.1 0.1 * * 0.2  0.3 0.2  0.2  0.1
Weighted N = — 1,453 1,909 1,797 1,772 1,753 1,649 1,544 1,497 1,487
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months — * 0.1 * * *  0.1  0.1  0.1 *
    Yes, but not in the last 12 months —  0.1 0.2  0.4  0.4  0.4  0.4  0.3  0.4  0.5
    No, never — 99.9 99.7 99.6 99.6 99.6 99.6 99.6 99.6 99.5
Weighted N = — 1,455 1,911 1,790 1,763 1,749 1,647 1,543 1,496 1,485
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor ’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor ’s 
orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The questions were 
contained in three of the six questionnaire forms.
TABLE 9-1b
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Age 35 
(Entries are percentages.)
Total
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Lifetime Frequency of Injecting Drugs 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 97.9 97.6 97.9 97.7 96.2 96.4 97.7 97.7 98.0
    1–2 —  1.4  1.1  0.3  0.9  1.3  0.7  0.7  0.7  0.4
    3–5 —  0.2  0.2  0.3  0.2  0.2  0.2 * 0.0  0.3
    6–9 —  0.1  0.2  0.1  0.0  0.4  0.4  0.2 0.2  0.1
    10–19 — * 0.1  0.5  0.7  0.7  0.7  0.3 0.3  0.5
    20–39 —  0.2 0.2  0.1 * 0.3  0.4  0.1 0.3  0.2
    40+ Occasions —  0.3 0.7  0.7  0.5 1.0  1.2  0.9 0.8  0.5
Weighted N = — 711 923 843 824 819 774 745 736 709
Annual Frequency of Injecting Drugs
    0 Occasions — 99.7 99.4 99.1 99.6 99.2 98.9 99.5 99.6 99.8
    1–2 —  0.1  0.1  0.1 * * * *  0.1  0.1
    3–5 — * * * *  0.2  0.2 * * *
    6–9 — * 0.2 0.5  0.4  0.2  0.3  0.1 * *
    10–19 — * * * *  0.1  0.1 * * *
    20–39 — * 0.1 0.1 * * *  0.1  0.2  0.1
    40+ Occasions —  0.1 0.2 0.1 * 0.2 0.5  0.3  0.1 *
Weighted N = — 711 923 843 825 821 775 745 736 709
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months — * * * * * 0.0  0.1  0.1 *
    Yes, but not in the last 12 months —  0.1  0.3  0.7  0.7  0.4 0.4  0.3  0.6  0.7
    No, never — 99.9 99.7 99.3 99.3 99.5 99.6 99.6 99.4 99.3
Weighted N = — 711 924 841 822 818 773 746 734 709
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor ’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor ’s 
orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The questions were 
contained in three of the six questionnaire forms.
TABLE 9-1b (cont.)
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Age 35 
(Entries are percentages.)
Male
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Lifetime Frequency of Injecting Drugs 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    0 Occasions — 99.6 99.2 98.9 99.0 98.9 99.1 98.9 98.6 98.9
    1–2 —  0.3  0.6  0.7  0.3  0.5  0.5  0.7  0.6  0.4
    3–5 — * * 0.2  0.3  0.1 * 0.1  0.1 *
    6–9 — * * *  0.1  0.1 * * *  0.1
    10–19 — * 0.1 0.1 * * *  0.1  0.1  0.1
    20–39 — * * *  0.1 0.1 * * * *
    40+ Occasions —  0.1 0.1 0.1  0.3  0.3  0.3  0.3  0.5  0.4
Weighted N = — 742 985 954 946 932 874 799 761 777
Annual Frequency of Injecting Drugs
    0 Occasions — 99.9 99.8 99.9 99.9 99.7 99.7 99.7 99.6 99.6
    1–2 — * * * * * * * *  0.1
    3–5 — * 0.1 0.1 * * * * * 0.1
    6–9 — * * * * * * * * *
    10–19 — * * * * * * 0.1  0.1 *
    20–39 — * * *  0.1  0.1  0.1  0.1  0.1  0.1
    40+ Occasions —  0.1 0.1 * * 0.1  0.2  0.2  0.3  0.1
Weighted N = — 743 986 954 947 932 874 799 761 777
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months —  0.1  0.1  0.1 * * 0.1  0.1 * *
    Yes, but not in the last 12 months — * 0.1  0.1  0.1  0.3  0.4  0.3  0.2  0.3
    No, never — 99.9 99.8 99.8 99.9 99.7 99.6 99.6 99.7 99.7
Weighted N = — 744 987 949 941 931 874 798 762 776
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor ’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor ’s 
orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The questions were 
contained in three of the six questionnaire forms.
TABLE 9-1b (cont.)
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Age 35 
(Entries are percentages.)
Female
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Lifetime Frequency of Injecting Drugs 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017
    0 Occasions 98.7 98.5 98.3 98.4 98.5 98.7 98.4 98.1 97.9 97.7 97.9 97.7 97.7 97.5 99.3 99.1 99.0 98.9 99.2 99.5 99.1
    1–2 0.7 0.5 0.5 0.8 0.7 0.3 0.5 0.9 0.6 0.5 0.8 1.0 0.6 0.7 0.4 0.4 0.5 0.8 0.4 0.1 0.4
    3–5 0.2 0.3 0.3 0.1 0.0 0.2 0.2 0.2 0.5 0.5 0.2 0.0 0.3 0.4 0.2 0.1 0.1 0.1 0.0 0.1 0.1
    6–9 0.2 0.1 0.0 0.0 0.1 0.2 0.4 0.4 0.1 0.1 0.1 0.2 0.4 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.1
    10–19 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.2 0.5 0.4 0.1 0.2 0.2 0.0 0.0 0.1 0.0 0.1 0.1 0.0
    20–39 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    40+ Occasions 0.1 0.5 0.5 0.4 0.6 0.4 0.4 0.1 0.7 0.7 0.6 0.9 0.7 0.5 0.1 0.3 0.2 0.2 0.3 0.2 0.3
Weighted N = 1813 1719 1693 1752 1706 1575 1597 873 856 850 869 827 738 743 940 864 843 883 879 837 854
Annual Frequency of Injecting Drugs
    0 Occasions 99.9 99.8 99.7 99.7 99.6 99.7 99.6 99.8 99.6 99.4 99.5 99.4 99.5 99.6 100.0 100.0 100.0 99.9 99.9 99.9 99.7
    1–2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1
    3–5 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0
    6–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    10–19 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    20–39 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
    40+ Occasions 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.3 0.2 0.2 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2
Weighted N = 1814 1720 1693 1752 1707 1577 1597 874 857 850 869 828 739 743 940 864 843 883 879 838 854
Lifetime and Annual Needle Sharing
    Yes, in the last 12 months 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0
    Yes, but not in the last 12 months 0.1 0.3 0.6 0.4 0.3 0.4 0.2 0.2 0.4 0.7 0.5 0.6 0.6 0.3 0.1 0.3 0.5 0.3 0.1 0.2 0.1
    No, never 99.9 99.7 99.4 99.6 99.6 99.5 99.8 99.9 99.6 99.3 99.5 99.4 99.3 99.7 99.9 99.7 99.5 99.7 99.8 99.7 99.9
Weighted N = 1811 1718 1685 1747 1710 1573 1589 873 857 852 870 829 739 738 939 861 833 877 881 835 851
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
TABLE 9-1c
Trends a in Injection Drug Use and Needle Sharing
Total and by Gender among Respondents of Modal Age 40
(Entries are percentages.)
Total Males Females
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) in your lifetime? Do not 
include anything you took under a doctor ’s orders.
On how many occasions (if any) have you taken any 
drugs by injection with a needle (like heroin, cocaine, 
amphetamines, or steroids) during the last 12 months? 
Do not include anything you took under a doctor ’s 
orders.
Have you ever taken such drugs using a needle that you 
knew (or suspected) had been used by someone else 
before you used it?
aData presented in this table are two-year moving averages. The 2011 data is 2010 and 2011 combined and so forth.  
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Number of Partners in Last 12 Months 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None — 14.5 14.6 13.7 13.5 14.0 14.5 15.9 16.7 16.9 17.3 17.8 18.9 19.3
    One — 61.2 61.5 61.9 62.2 61.3 61.0 60.1 59.0 58.8 58.9 59.0 59.1 58.2
    Two — 10.1  9.3  9.5  9.5  9.2  9.9 10.0  9.7  9.9  9.9  9.8  8.6  8.3
    Three —  5.9  6.2  5.8  5.9  5.9  5.9  5.2  4.9  5.5  5.8  5.2  5.1  5.8
    Four —  3.2  3.4  4.0  4.1  4.0  3.3  3.5  4.0  3.9  3.8  3.7  3.3  3.1
    5–10 —  3.9  4.1  4.2  4.0  4.3  4.4  4.2  4.4  4.1  3.7  3.7  3.5  3.8
    11–20 —  0.9  0.7  0.6  0.7  0.8  0.5  0.7  0.9  0.7  0.4  0.5  0.9  1.0
    21–100 —  0.2  0.2  0.2  0.3  0.3  0.4  0.4  0.3  0.3  0.3  0.4  0.4  0.3
    More than 100 —  0.1  0.2  0.1  0.1  0.2  0.2  0.1 * 0.1  0.1 * 0.1  0.1
Weighted N = — 3,628 3,432 4,066 4,833 4,810 4,741 4,618 4,505 4,370 4,238 4,103 3,825 3,685
Gender of Partners in Last 12 Months b
    Exclusively male? — 53.4 54.0 54.0 53.4 52.8 52.9 54.0 54.7 55.1 55.1 54.3 54.3 54.7
    Both male and female? —  1.5  1.4  1.4  1.3  1.4  1.3  1.4  1.6  1.4  1.5  1.7  1.9  2.2
    Exclusively female? — 45.1 44.6 44.6 45.3 45.8 45.8 44.6 43.7 43.5 43.4 44.0 43.8 43.1
Weighted N = — 3,103 2,935 3,504 4,171 4,129 4,049 3,881 3,748 3,631 3,500 3,369 3,100 2,966
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The 2007 data is a simple  
average of 2006 and 2007, because these questions were included in two questionnaire forms in 2006 and three forms beginning in 2007. 
During the LAST 12 MONTHS, how many 
sex partners have you had? (This includes 
vaginal, oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
TABLE 9-2a
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Total
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Number of Partners in Last 12 Months 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None — 16.9 16.6 14.7 14.4 14.6 15.3 17.5 19.4 19.8 20.2 20.6 22.3 23.1
    One — 56.3 56.2 57.0 58.6 57.7 56.4 55.0 54.3 54.1 54.0 54.3 55.2 55.0
    Two — 10.1  8.7  8.9  8.8  9.2 10.3  9.6  8.5  9.1  9.4  9.7  8.1  7.4
    Three —  6.1  7.5  7.2  6.4  6.0  6.3  5.9  5.1  5.4  6.3  5.4  4.6  5.2
    Four —  3.5  4.3  4.8  4.4  4.7  3.7  4.3  5.0  4.3  3.9  3.6  2.9  3.0
    5–10 —  5.2  5.3  5.8  5.5  5.8  6.4  6.1  5.8  5.6  5.0  4.8  4.6  3.9
    11–20 —  1.5  0.9  0.9  1.2  1.2  0.7  0.9  1.4  1.2  0.6  0.8  1.6  1.8
    21–100 —  0.4  0.4  0.5  0.5  0.4  0.6  0.6  0.6  0.5  0.5  0.6  0.5  0.4
    More than 100 —  0.1  0.2  0.1  0.2  0.3  0.3  0.2 * 0.1  0.1  0.1  0.2  0.2
Weighted N = — 1,720 1,611 1,902 2,270 2,277 2,238 2,147 2,093 2,019 1,956 1,908 1,782 1,709
Gender of Partners in Last 12 Months b
    Exclusively male? —  3.9  4.3  4.6  4.1  4.2  3.9  4.6  5.1  4.7  4.8  4.8  4.9  5.4
    Both male and female? —  1.0  0.8  1.0  0.9  0.8  0.8  0.7  0.9  0.8  0.9  1.0  1.0  1.3
    Exclusively female? — 95.0 94.9 94.4 95.0 94.9 95.3 94.8 94.0 94.6 94.3 94.3 94.0 93.4
Weighted N = — 1,432 1,344 1,616 1,944 1,950 1,897 1,773 1,689 1,617 1,555 1,511 1,380 1,315
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many 
sex partners have you had? (This includes 
vaginal, oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The 2007 data is a simple  
average of 2006 and 2007, because these questions were included in two questionnaire forms in 2006 and three forms beginning in 2007. 
TABLE 9-2a (cont.)
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Male
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Number of Partners in Last 12 Months 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None — 12.3 12.8 12.7 12.8 13.5 13.8 14.6 14.4 14.4 14.8 15.4 15.9 16.1
    One — 65.6 66.1 66.2 65.3 64.6 65.2 64.6 63.1 62.8 63.0 63.0 62.6 61.0
    Two — 10.2  9.8 10.1 10.0  9.2  9.5 10.3 10.8 10.6 10.3  9.8  9.1  9.1
    Three —  5.6  5.1  4.5  5.4  5.8  5.5  4.6  4.7  5.7  5.4  5.1  5.6  6.2
    Four —  2.9  2.6  3.3  3.7  3.4  2.9  2.8  3.2  3.5  3.7  3.7  3.7  3.3
    5–10 —  2.7  3.0  2.8  2.6  2.9  2.7  2.6  3.2  2.7  2.5  2.7  2.6  3.7
    11–20 —  0.4  0.5  0.4  0.2  0.3  0.3  0.5  0.5  0.3  0.3  0.1  0.2  0.4
    21–100 —  0.1 * * 0.1  0.2  0.2  0.1  0.1  0.1 * 0.1  0.3  0.1
    More than 100 —  0.1  0.1 * * * * * * * * * 0.1  0.1
Weighted N = — 1,908 1,821 2,163 2,563 2,532 2,503 2,471 2,412 2,350 2,282 2,195 2,044 1,977
Gender of Partners in Last 12 Months b
    Exclusively male? — 95.8 96.0 96.3 96.4 96.3 96.0 95.6 95.4 95.5 95.3 94.6 94.0 94.0
    Both male and female? —  1.9  1.9  1.7  1.7  1.9  1.8  2.0  2.2  2.0  2.0  2.2  2.5  2.9
    Exclusively female? —  2.3  2.1  2.0  1.9  1.8  2.2  2.4  2.4  2.5  2.7  3.2  3.5  3.1
Weighted N = — 1,672 1,590 1,888 2,226 2,180 2,153 2,108 2,059 2,014 1,945 1,858 1,720 1,651
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable. ' * ' indicates a prevalence rate of less than 0.05%. 
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many 
sex partners have you had? (This includes 
vaginal, oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The 2007 data is a simple  
average of 2006 and 2007, because these questions were included in two questionnaire forms in 2006 and three forms beginning in 2007. 
TABLE 9-2a (cont.)
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Female
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Number of Partners in Last 12 Months 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None —  9.5  9.7  8.8  8.7  9.6 10.4 10.0  9.7  9.2
    One — 78.5 78.2 79.1 80.3 79.5 77.5 76.8 78.8 78.7
    Two —  4.9  5.1  4.4  4.3  5.0  5.2  5.5  5.1  5.1
    Three —  3.1  3.4  3.5  2.7  2.2  2.4  2.6  2.3  2.6
    Four —  1.6  1.6  2.0  2.1  1.6  1.5  1.8  1.6  1.4
    5–10 —  1.6  1.3  1.5  1.4  1.6  2.3  2.3  1.4  2.1
    11–20 —  0.5  0.3  0.3  0.3  0.3  0.4  0.7  0.7  0.7
    21–100 —  0.2  0.3  0.3  0.4  0.2  0.2  0.3  0.2  0.2
    More than 100 —  0.1  0.1 * * * *  0.1  0.1  0.1
Weighted N = — 1,449 1,902 1,784 1,763 1,748 1,645 1,535 1,489 1,485
Gender of Partners in Last 12 Months b
    Exclusively male? — 51.7 52.2 53.8 53.3 51.8 52.8 52.0 50.7 52.4
    Both male and female? —  0.6  1.0  1.1  0.7  0.5  0.4  0.7  0.8  1.0
    Exclusively female? — 47.7 46.8 45.1 46.0 47.7 46.8 47.3 48.5 46.6
Weighted N = — 1,307 1,701 1,611 1,605 1,578 1,469 1,374 1,338 1,343
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.  ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The 
questions were contained in three of the six questionnaire forms.
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
TABLE 9-2b
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Total
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Number of Partners in Last 12 Months 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None —  9.9  9.8  9.6  8.5  8.4  9.6  9.2  9.6 10.1
    One — 76.4 77.0 76.0 78.9 79.6 75.3 75.1 76.7 75.8
    Two —  4.9  4.3  4.1  3.8  4.4  5.6  5.1  5.4  5.9
    Three —  2.9  4.0  4.0  2.9  2.6  2.7  2.5  2.2  2.5
    Four —  1.9  2.0  3.3  3.2  2.0  2.1  2.8  2.2  1.5
    5–10 —  2.5  1.8  2.0  1.6  2.2  3.6  3.4  2.0  2.7
    11–20 —  1.0  0.6  0.3  0.3  0.5  0.7  1.3  1.2  1.0
    21–100 —  0.3  0.4  0.5  0.7  0.4  0.3  0.4  0.5  0.5
    More than 100 —  0.2  0.1  0.1  0.1 * * 0.1  0.2  0.1
Weighted N = — 707 918 837 821 819 775 742 730 706
Gender of Partners in Last 12 Months b
    Exclusively male? —  3.5  3.3  3.7  3.8  2.9  3.7  4.3  3.7  4.2
    Both male and female? —  0.5  1.0  1.3  0.5  0.3  0.4  0.7  0.8  0.7
    Exclusively female? — 95.9 95.6 95.0 95.7 96.9 96.0 95.0 95.5 95.2
Weighted N = — 634 818 753 754 752 700 671 660 636
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.  ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The 
questions were contained in three of the six questionnaire forms.
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
TABLE 9-2b (cont.)
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Male
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Number of Partners in Last 12 Months 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    None —  9.1  9.5  8.1  8.8 10.6 11.2 10.8  9.8  8.4
    One — 80.5 79.4 81.8 81.4 79.5 79.4 78.4 80.9 81.4
    Two —  4.9  5.8  4.8  4.8  5.6  4.9  5.8  4.9  4.3
    Three —  3.2  2.8  3.0  2.4  1.8  2.2  2.7  2.3  2.6
    Four —  1.3  1.3  0.8  1.1  1.3  1.0  0.8  1.0  1.3
    5–10 —  0.8  0.9  1.0  1.1  1.0  1.2  1.3  0.8  1.6
    11–20 —  0.1  0.1  0.2  0.2  0.1  0.1  0.1  0.2  0.4
    21–100 — * 0.2  0.2  0.1  0.1  0.1  0.1 * *
    More than 100 — * * * * * * * * *
Weighted N = — 742 984 947 942 929 871 793 758 778
Gender of Partners in Last 12 Months b
    Exclusively male? — 97.0 97.6 97.7 97.1 96.4 97.4 97.5 96.5 95.8
    Both male and female? —  0.6  1.0  1.0  0.8  0.7  0.4  0.7  0.8  1.2
    Exclusively female? —  2.3  1.5  1.3  2.1  2.8  2.1  1.8  2.7  3.0
Weighted N = — 673 882 858 851 825 769 703 678 707
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.  ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2009 data is 2008 and 2009 combined and so forth.  The 
questions were contained in three of the six questionnaire forms.
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
TABLE 9-2b (cont.)
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Female
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Number of Partners in Last 12 Months 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017
    None 11.1 11.1 9.9 9.4 10.2 10.8 11.0 9.7 9.0 8.4 8.2 9.3 10.7 10.8 12.4 13.2 11.5 10.6 11.0 10.8 11.1
    One 79.2 78.0 78.6 79.1 79.2 78.8 78.8 79.4 77.0 76.2 78.0 78.6 77.4 78.2 79.0 79.0 81.0 80.2 79.7 80.0 79.2
    Two 4.5 5.2 5.0 5.2 4.8 4.5 5.0 4.1 5.4 5.2 4.8 4.6 4.6 4.4 4.8 5.0 4.9 5.6 4.9 4.4 5.4
    Three 1.9 2.1 2.7 2.7 2.4 2.7 2.4 2.3 3.0 4.1 3.8 2.7 2.7 2.2 1.6 1.3 1.3 1.5 2.0 2.7 2.5
    Four 1.2 1.0 1.3 1.5 1.4 1.0 1.0 1.3 1.5 1.6 1.7 1.5 1.2 1.4 1.2 0.4 0.9 1.3 1.2 0.9 0.6
    5–10 1.4 1.7 1.6 1.6 1.6 1.4 1.4 2.2 2.6 2.8 2.4 2.3 1.9 1.8 0.6 0.8 0.5 0.7 1.0 0.9 1.0
    11–20 0.6 0.4 0.2 0.2 0.4 0.4 0.2 0.7 0.5 0.4 0.4 0.7 0.7 0.3 0.5 0.2 0.0 0.0 0.2 0.3 0.1
    21–100 0.2 0.3 0.4 0.3 0.1 0.3 0.5 0.3 0.5 0.9 0.6 0.2 0.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1
    More than 100 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Weighted N = 1,813 1,723 1,690 1,740 1,698 1,566 1,587 872 860 850 864 825 734 739 942 863 840 876 873 831 848
Gender of Partners in Last 12 Months b
    Exclusively male? 52.1 49.6 49.2 50.0 51.1 53.0 52.6 4.7 4.1 3.8 3.7 3.3 3.5 3.2 97.6 97.5 96.8 96.7 97.0 96.9 95.8
    Both male and female? 0.7 0.8 0.7 0.8 1.2 1.1 1.2 0.1 0.8 1.0 0.5 1.2 1.2 0.5 1.2 0.7 0.4 1.0 1.1 1.1 1.8
    Exclusively female? 47.2 49.6 50.1 49.2 47.7 45.9 46.2 95.1 95.0 95.2 95.8 95.5 95.3 96.4 1.2 1.8 2.9 2.3 1.9 2.1 2.4
Weighted N = 1,601 1,525 1,515 1,566 1,513 1,391 1,411 784 782 775 786 741 654 658 817 743 741 780 772 738 754
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.  ' * ' indicates a prevalence rate of less than 0.05%. 
aData presented in this table are two-year moving averages. The 2011 data is 2010 and 2011 combined and so forth.   
bBased on those reporting sex with one or more partners during the past year. Those reporting no partners are omitted.
During the LAST 12 MONTHS, how many sex 
partners have you had? (This includes vaginal, 
oral, or anal sex.)
During the LAST 12 MONTHS, have your sex 
partner or partners been …
TABLE 9-2c
Trends a in Number of Sex Partners and Gender of Sex Partners
 Total and by Gender among Respondents of Modal Age 40
(Entries are percentages.)
Total Males Females
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Source.  The Monitoring the Future study, the University of Michigan.
FIGURE 9-1
Trends (2-year average) in Lifetime Injection Drug Use 
by Gender among Respondents of Modal Ages 21-30
Trends (2-year average) in Lifetime Injection Drug Use 
by Gender among Respondents of Modal Age 35/40
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Source.  The Monitoring the Future study, the University of Michigan.
Trends (2-year average) in Annual Injection Drug Use 
by Gender among Respondents of Modal Age 35/40
FIGURE 9-2
Trends (2-year average) in Annual Injection Drug Use 
by Gender among Respondents of Modal Ages 21-30
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Source.  The Monitoring the Future study, the University of Michigan.
by Gender among Respondents of Modal Age 35/40
FIGURE 9-3
Trends (2-year average) in Lifetime Needle Sharing 
by Gender among Respondents of Modal Ages 21-30
Trends (2-year average) in Lifetime Needle Sharing 
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Source.  The Monitoring the Future study, the University of Michigan.
FIGURE 9-4
Trends (2-year average) in Annual Needle Sharing 
by Gender among Respondents of Modal Ages 21-30
Trends (2-year average) in Annual Needle Sharing 
by Gender among Respondents of Modal Age 35/40
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Source.  The Monitoring the Future study, the University of Michigan.
FIGURE 9-5
Trends (2-year average) in Having 
by Gender a among Respondents of Modal Ages 21-30
More than One Sex Partner in the Last Year 
Trends (2-year average) in Having 
More than One Sex Partner in the Last Year 
by Gender a among Respondents of Modal Age 35/40
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Source.  The Monitoring the Future study, the University of Michigan.
aBased on those reporting sexual activity with one or more partners during the past year. Those 
reporting no partners are omitted.
Sex Partner of the Same/Both Genders in the Last Year
by Gender a among Respondents of Modal Age 35/40
Trends (2-year average) in Having a
Sex Partner of the Same/Both Genders in the Last Year
FIGURE 9-6
by Gender a among Respondents of Modal Ages 21-30
Trends (2-year average) in Having a
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Chapter 10 
 
TRENDS IN THE PREVALENCE AND  
FREQUENCY OF PROTECTIVE BEHAVIORS 
 
The behaviors that can help to protect against the spread of HIV have not shown a great deal of 
change in the 2005–2017 interval among young adults, but there has been some change.  
 
Condom Use  
Past-year prevalence of using condoms “most times or always” among young adults did not change 
much from 2005 to 2017 (Table 10-1a and Figure 10-1). The proportion indicating having used 
condoms at all when having sex in the past 12 months has remained fairly flat for both genders 
since 2005, with prevalence levels among males (ranging between 62% and 67%) considerably 
higher than among females (ranging between 50% and 58%). The only change in Figure 10-1 to 
reach statistical significance was the decline in annual prevalence in condom use among females 
from 2014-2017. Among 35- and 40-year-olds, there is little evidence of systematic change since 
they were added to the study (35-year-olds in 2009 and 40-year-olds in 2011). At age 35 males 
have been consistently more likely than females to report having used condoms in the past 12 
months; that has not been the case among 40-year-olds, where there has been little gender 
difference. 
 
Table 10-1d makes clear that the prevalence and frequency of using condoms declines with age 
across the young adult years. Averaged across the 2004-2017 surveys, it can be seen in the right 
hand column that 75% of the 21- to 22-year-olds reported they used a condom at least once in the 
past 12 months, but that the rate falls to 46% among those ages 29 to 30. And, in 2017 specifically, 
while 35% of the 21- to 22-year-olds said they have used condoms most times or always, that rate 
falls to 25% among the 29- to 30-year-olds, in considerable part due to the rising proportion who 
are married (as is documented in Tables 6-1e and 6-1f). Use of condoms declines further by age 
35, and still further by age 40 (Tables 10-1b and 10-1c).  
 
Getting Tested for HIV/AIDS 
The lifetime prevalence of getting tested for HIV/AIDS has shown a small but significant decline 
(p<05) among young adult females (50.2% in 2005; 47.7% in 2017, Table 10-1a), and a larger 
decline among young adult males (from 37.9% to 30.9%; p<.05, Table 10-1a). Despite some 
decline in lifetime testing, among females the prevalence of getting tested in the past 12 months 
was at 23.7% in 2005 , but then rose gradually and somewhat unevenly,  reaching   27.0% by 2017 
(p<.05). Among males, the prevalence of getting tested in the past 12 months declined slightly 
between 2005 (16.7%) to 2017 (15.1%), n.s. These different changes produced a widening gap 
between the genders in the prevalence of getting tested in the past 12 months, with females trending 
toward higher levels, especially through 2010, and becoming even more likely than males to get 
tested since then (Figure 10-2). The change in the gap is significant (p<.001). 
 
Since 2005 the percentages of young adults receiving the test results have been stable and very 
high (92%–94%) with females being very slightly higher than males prior to 2012, after which the 
small gender gap nearly disappeared (Table 10-1a and Figure 10-3). 
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Among 35-year-olds both genders showed some increase between 2012 and 2014 in the annual 
prevalence of getting tested; but both showed some decline between 2014 and 2016, followed by 
an increase among females only in 2017  (Figure 10-2). Females have consistently had higher rates 
of getting tested than males at age 35, as is true among the young adults, but there has been little 
difference between the genders among those age 40 (Figure 10-3). Both genders have shown a 
very slight increase in the high proportions who do receive the results—a positive development 
(Figure 10-3 and Table 10-1b). 
 
Among 40-year-olds, 12-month prevalence of getting tested has been lower than among 35-year-
olds, ranging between 8% and 13% from 2011 to 2017, with no significant gender differences 
(Table 10-1c, Figure 10-2). The rates of receiving the test results have been consistently high (93% 
to 96%) with females consistently slightly more likely than males to get test results (Table 10-1c, 
Figure 10-3). 
 
Summary 
It is clear that condom use is a protective behavior that occurs relatively infrequently among young 
and middle-aged adults. On average only about 55-60% of sexually active young adults indicate 
any use of condoms in the last 12 months—more males than females—and there has been little 
change in this practice since 2005 among young adult males. Young adult females have shown 
some gradual falloff in condom use, particularly in the past two years.  It is clear that the use of 
condoms declines considerably between the ages of 21-22 to 29-30 and then declines further 
through age 40. Using condoms “most times” or “always” is substantially less likely to be reported, 
with an annual prevalence of about 30% to 33% of young adults giving these answers. 
 
Only between 40% and 50% of all young adults report getting tested for HIV/AIDS at some time 
in their lives, with females being more likely than males to do so. The rate of getting tested in the 
prior year showed some increase among females between 2006 and 2010 and then a more gradual 
increase; the 2005-2017 increase, which was  statistically significant, helped to open a somewhat 
greater difference between the genders among young adults. On the other hand, among 35-year-
olds the gender difference appeared to diminish between 2012 and 2014 as both genders showed 
increasing proportions of testing, but with males rising faster. Failing to obtain the test results after 
being tested is rare, and thus seems not to be a serious problem.  
 
As we have seen in the previous chapter, males have considerably higher risks of contracting 
HIV/AIDS, but they are somewhat less likely to adopt the protective behavior of getting tested for 
HIV/AIDS, leaving them even more vulnerable to being unaware that they have the disease. They 
are, however, more likely than females to report having used condoms, perhaps in part because 
more of them have a large number of sex partners. 
 
Over the interval covered so far for young adults and the shorter intervals for 35- and 40-year-olds, 
we note a limited amount of systematic movement in these protective factors. The modest increase 
in getting tested observed among young adult females is probably the most positive development 
in terms of protective behaviors. The fact that nearly all people tested in any of these age groups 
do secure their test results is also encouraging.  
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Frequency of Condom Use in Last 12 Months b 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 42.1 41.6 40.5 40.7 40.1 39.5 40.2 40.0 39.4 40.4 42.3 44.3 44.3
    Seldom — 13.7 13.2 13.6 13.1 13.3 14.0 14.4 14.4 14.6 14.3 13.7 12.6 12.8
    Sometimes — 12.4 13.3 13.5 13.0 13.0 13.0 12.2 12.6 12.8 12.4 11.9 11.9 12.4
    Most times — 15.5 15.2 15.2 15.0 14.4 14.0 14.6 15.3 14.8 14.5 14.6 14.3 14.3
    Always — 16.4 16.7 17.2 18.2 19.2 19.6 18.6 17.7 18.4 18.4 17.6 16.9 16.0
Weighted N = — 3,076 2,905 3,476 4,151 4,096 4,009 3,847 3,719 3,600 3,472 3,347 3,077 2,946
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 20.4 19.6 20.1 20.9 21.5 21.0 20.9 22.1 21.5 20.7 21.4 20.8 21.5
    Yes, but not in the last 12 months — 24.0 23.9 23.5 23.0 22.9 23.3 22.4 21.4 20.9 19.9 18.9 18.9 18.4
    No, never — 55.7 56.5 56.4 56.1 55.6 55.7 56.7 56.5 57.7 59.4 59.7 60.3 60.2
Weighted N = — 3,664 3,459 4,098 4,872 4,835 4,774 4,647 4,520 4,399 4,255 4,099 3,820 3,695
Received HIV Test Results c
    Yes — 92.2 92.8 92.5 92.7 93.1 93.7 94.2 94.1 93.7 93.7 93.7 93.5 94.4
    No —  7.8  7.2  7.5  7.3  6.9  6.3  5.8  6.0  6.3  6.3  6.3  6.5  5.6
Weighted N = — 1,610 1,486 1,764 2,117 2,125 2,088 1,982 1,937 1,836 1,707 1,631 1,507 1,463
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were 
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1a
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Total
When you had sexual intercourse during the LAST 
12 MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
 
111
Frequency of Condom Use in Last 12 Months b 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 37.0 36.4 35.8 36.1 35.2 36.1 36.2 34.7 33.0 34.6 36.8 38.0 37.7
    Seldom — 13.7 12.8 13.3 13.7 13.3 13.0 13.7 14.3 15.0 14.3 14.4 13.3 13.4
    Sometimes — 12.8 13.0 13.3 13.2 13.3 13.2 12.7 13.6 13.6 13.5 12.9 12.7 12.9
    Most times — 17.8 18.0 16.8 15.7 15.6 15.7 16.8 17.2 17.1 16.9 15.5 16.1 17.5
    Always — 18.8 19.9 20.7 21.3 22.6 22.1 20.7 20.3 21.3 20.7 20.4 20.0 18.6
Weighted N = — 1,423 1,330 1,607 1,941 1,937 1,878 1,760 1,684 1,610 1,545 1,503 1,369 1,307
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 16.7 16.0 16.0 16.4 16.4 15.0 15.3 17.1 16.3 15.0 15.8 14.3 15.1
    Yes, but not in the last 12 months — 21.2 20.8 21.2 20.9 20.3 20.2 19.1 18.9 17.5 16.1 15.8 15.4 15.8
    No, never — 62.2 63.2 62.8 62.7 63.3 64.8 65.6 64.0 66.3 68.9 68.4 70.3 69.1
Weighted N = — 1,738 1,629 1,919 2,288 2,290 2,257 2,166 2,102 2,034 1,963 1,904 1,782 1,719
Received HIV Test Results c
    Yes — 89.8 91.2 92.2 91.9 91.4 91.5 92.6 93.5 92.9 93.8 93.5 92.7 93.1
    No — 10.2  8.8  7.8  8.1  8.6  8.6  7.4  6.5  7.1  6.2  6.5  7.3  6.9
Weighted N = — 655 591 701 845 830 775 727 744 673 602 593 520 525
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
When you had sexual intercourse during the LAST 
12 MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were 
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1a (cont.)
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Male
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Frequency of Condom Use in Last 12 Months b 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 46.5 46.1 44.4 44.8 44.5 42.4 43.6 44.3 44.5 45.1 46.8 49.3 49.6
    Seldom — 13.7 13.5 13.7 12.6 13.2 14.9 15.0 14.5 14.3 14.2 13.2 12.1 12.4
    Sometimes — 12.0 13.5 13.7 12.8 12.8 12.8 11.8 11.7 12.1 11.6 11.0 11.3 12.1
    Most times — 13.5 12.9 13.9 14.3 13.4 12.5 12.8 13.8 13.0 12.6 13.8 12.9 11.9
    Always — 14.3 14.0 14.3 15.5 16.1 17.5 16.9 15.6 16.1 16.5 15.3 14.4 14.0
Weighted N = — 1,653 1,574 1,869 2,210 2,159 2,131 2,087 2,035 1,990 1,927 1,844 1,708 1,639
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 23.7 22.9 23.8 24.9 26.0 26.4 25.8 26.4 25.9 25.6 26.2 26.4 27.0
    Yes, but not in the last 12 months — 26.5 26.6 25.5 24.9 25.2 26.1 25.3 23.6 23.9 23.2 21.7 22.1 20.7
    No, never — 49.8 50.6 50.7 50.1 48.8 47.5 48.9 50.0 50.2 51.3 52.1 51.5 52.3
Weighted N = — 1,927 1,830 2,179 2,584 2,545 2,517 2,480 2,418 2,364 2,292 2,194 2,038 1,976
Received HIV Test Results c
    Yes — 93.9 93.8 92.7 93.2 94.2 95.1 95.1 94.4 94.2 93.7 93.8 93.9 95.1
    No —  6.1  6.2  7.3  6.8  5.8  5.0  4.9  5.6  5.8  6.3  6.3  6.1  4.9
Weighted N = — 955 895 1,063 1,273 1,295 1,312 1,255 1,193 1,163 1,105 1,037 987 938
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
When you had sexual intercourse during the LAST 
12 MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were 
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1a (cont.)
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Ages 21–30
(Entries are percentages.)
Female
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Frequency of Condom Use in Last 12 Months b 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 66.5 64.8 63.5 65.5 66.9 66.9 65.7 67.2 66.3
    Seldom —  8.0  8.6  8.4  9.2  8.9  7.6  8.2  7.7 8.9
    Sometimes —  8.6  9.3  9.1  7.6  7.8  7.9  7.4  7.3 7.0
    Most times —  6.9  8.0  9.2  9.1  8.2  7.9  7.6  7.3 8.2
    Always — 10.0  9.2  9.7  8.6  8.1  9.7 11.1 10.5 9.6
Weighted N = — 1,306 1,702 1,605 1,595 1,570 1,462 1,375 1,333 1,327
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 15.0 15.0 15.4 15.3 16.7 19.5 19.2 16.5 18.6
    Yes, but not in the last 12 months — 38.6 38.1 41.1 41.8 38.6 35.3 36.2 37.6 35.1
    No, never — 46.4 46.9 43.5 42.9 44.7 45.2 44.6 45.9 46.2
Weighted N = — 1,452 1,903 1,787 1,767 1,752 1,651 1,546 1,496 1,485
Received HIV Test Results c
    Yes — 92.4 93.2 94.8 94.2 94.3 95.1 95.3 95.5 96.7
    No —  7.6  6.8  5.2  5.8  5.7  4.9  4.7  4.5  3.3
Weighted N = — 764 1,000 996 991 948 883 844 800 788
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
 contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1b
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Total
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were
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Frequency of Condom Use in Last 12 Months b 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 65.4 61.8 58.4 59.0 62.4 62.6 60.1 63.2 60.9
    Seldom —  7.4  8.6 10.3 12.6 10.9  8.9 11.1  9.8 11.1
    Sometimes —  8.9 10.2 11.2  9.1  8.6  8.8  7.8  7.8  8.6
    Most times —  8.0  9.4 11.0 11.1  9.3  8.8  8.8  8.6  8.5
    Always — 10.2 10.0  9.2  8.3  8.9 10.9 12.1 10.6 10.8
Weighted N = — 637 823 747 745 749 698 675 657 625
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 11.8 12.1 12.3 12.2 15.2 18.1 17.4 14.6 14.7
    Yes, but not in the last 12 months — 32.5 32.2 35.8 39.2 34.7 30.0 31.4 30.0 28.7
    No, never — 55.7 55.8 51.9 48.6 50.1 51.9 51.2 55.4 56.7
Weighted N = — 707 918 840 825 820 775 748 736 708
Received HIV Test Results c
    Yes — 89.3 89.6 91.1 89.6 91.9 94.3 94.1 94.6 95.7
    No — 10.7 10.4  8.9 10.4  8.1  5.7  5.9  5.4  4.3
Weighted N = — 310 402 397 415 400 364 358 323 304
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
 contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1b (cont.)
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Male
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Frequency of Condom Use in Last 12 Months b 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
    Never — 67.5 67.7 68.1 71.3 71.1 70.8 71.1 71.1 71.1
    Seldom —  8.6  8.6  6.8  6.3  7.1  6.5  5.5  5.7  6.9
    Sometimes —  8.3  8.5  7.3  6.2  7.1  7.0  6.9  6.8  5.6
    Most times —  5.9  6.7  7.6  7.3  7.2  7.2  6.4  6.1  7.9
    Always —  9.8  8.5 10.2  8.9  7.4  8.6 10.1 10.3  8.5
Weighted N = — 670 879 857 850 822 764 700 676 702
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months — 18.1 17.7 18.1 18.0 18.0 20.7 20.9 18.3 22.3
    Yes, but not in the last 12 months — 44.3 43.7 45.9 44.1 42.0 39.9 40.7 45.0 41.1
    No, never — 37.6 38.6 36.1 37.9 40.0 39.4 38.3 36.7 36.7
Weighted N = — 745 985 947 942 932 876 798 760 777
Received HIV Test Results c
    Yes — 94.5 95.6 97.2 97.5 96.0 95.7 96.1 96.1 97.3
    No —  5.5  4.4  2.8  2.5  4.0  4.3  3.9  3.9  2.7
Weighted N = — 454 598 599 577 549 519 486 477 484
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
 contained in two questionnaire forms in 2004–2006 and three forms beginning in 2007.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2005 data is 2004 and 2005 combined and so forth.  The questions were
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1b (cont.)
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Age 35
(Entries are percentages.)
Female
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Frequency of Condom Use in Last 12 Months b 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017
    Never 74.7 74.7 74.1 73.5 74.9 76.0 76.0 72.1 72.9 70.3 69.9 73.3 74.6 73.4 77.2 76.5 78.0 77.1 76.4 77.3 78.3
    Seldom 5.4 4.9 4.8 6.4 6.0 4.9 5.3 5.8 5.5 5.7 7.1 6.5 5.5 6.5 5.0 4.2 3.9 5.7 5.5 4.3 4.3
    Sometimes 5.8 6.6 6.8 5.5 5.8 5.8 4.8 6.4 7.7 8.3 6.7 7.0 6.3 4.3 5.2 5.4 5.2 4.2 4.6 5.4 5.2
    Most times 6.0 6.0 5.7 6.3 6.2 5.0 5.5 6.6 6.3 6.6 6.9 6.6 5.9 6.8 5.5 5.8 4.8 5.6 5.9 4.3 4.5
    Always 8.1 7.9 8.6 8.3 7.1 8.2 8.4 9.1 7.6 9.1 9.4 6.6 7.7 9.2 7.2 8.1 8.1 7.3 7.6 8.7 7.7
Weighted N = 1,593 1,523 1,504 1,553 1,508 1,387 1,397 782 781 767 778 741 654 646 810 742 737 775 768 733 751
Testing for HIV: Lifetime and Last 12 Months
    Yes, in the last 12 months 11.8 8.4 8.4 8.1 12.5 11.7 12.3 12.6 8.2 8.5 7.8 12.6 10.4 10.5 11.1 8.6 8.3 8.4 12.3 12.9 13.9
    Yes, but not in the last 12 months 43.4 45.9 45.6 45.0 41.1 42.5 41.5 37.8 49.7 47.2 46.5 33.7 36.4 37.2 48.6 42.2 43.9 43.5 48.0 47.9 45.2
    No, never 44.8 45.7 46.0 46.9 46.4 45.8 46.2 49.6 42.1 44.3 45.7 53.6 53.2 52.3 40.3 49.2 47.8 48.1 39.6 39.2 40.9
Weighted N = 1,808 1,720 1,686 1,744 1,707 1,578 1,594 868 859 847 866 830 740 740 940 861 839 878 878 838 854
Received HIV Test Results c
    Yes 93.5 93.5 92.7 92.7 94.1 94.0 95.6 91.7 92.6 90.9 89.7 91.9 91.0 93.2 94.9 94.2 94.1 94.8 95.8 96.0 97.3
    No 6.5 6.5 7.3 7.3 5.9 6.0 4.4 8.3 7.4 9.1 10.3 8.1 9.0 6.8 5.1 5.8 5.9 5.2 4.2 4.0 2.7
Weighted N = 973 893 871 905 901 843 840 429 401 380 380 381 342 348 544 492 491 525 520 501 491
Source.  The Monitoring the Future study, the University of Michigan.
Notes. ' — ' indicates not applicable.
cThose respondents who report never having been tested for HIV are excluded from these percentages. 
bPercentages based on those reporting sex with one or more partners during the last 12 months. Those reporting no partners are omitted.
TABLE 10-1c
Trends a in Frequency of Condom Use and Testing for HIV
Total and by Gender among Respondents of Modal Age 40
(Entries are percentages.)
Total Males Females
When you had sexual intercourse during the LAST 12 
MONTHS, how often were condoms used? (This 
includes vaginal and anal sex, but not oral sex.)
Have you ever been tested for HIV/AIDS? (Do not 
include tests that you may have had when donating 
blood or blood plasma.)
Did you receive the results of your most recent 
HIV/AIDS test? (We don ’t want to know your test 
results.)
aData presented in this table are two-year moving averages. The 2011 data is 2010 and 2011 combined and so forth.  
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2004–
Age 21–22 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2017
Frequency of Condom Use in Past Year:
    Never 26.1 26.6 26.8 23.5 23.4 23.8 22.7 25.9 19.3 22.2 25.4 29.9 33.4 31.4 25.4
    Seldom/Sometimes 32.5 30.7 29.8 28.7 28.7 28.7 29.0 30.6 31.0 29.5 29.6 27.1 23.8 33.5 29.4
    Most times/Always 41.4 42.6 43.4 47.8 47.9 47.5 48.3 43.5 49.7 48.3 45.0 43.0 42.8 35.1 45.2
Weighted N = 307 266 266 376 424 419 394 351 365 312 336 278 255 263 4,495
Age 23–24
Frequency of Condom Use in Past Year:
    Never 36.8 36.2 31.1 30.1 33.2 30.2 31.8 34.3 32.0 33.7 36.1 35.5 39.1 35.5 33.6
    Seldom/Sometimes 28.8 30.8 28.8 29.0 31.7 24.7 27.2 28.5 29.8 27.4 22.4 27.3 29.0 29.5 28.1
    Most times/Always 34.4 33.0 40.1 40.9 35.1 45.1 41.1 37.2 38.2 38.9 41.5 37.2 31.9 35.0 38.3
Weighted N = 322 316 284 398 422 394 398 399 400 336 351 298 291 280 4,871
Age 25–26
Frequency of Condom Use in Past Year:
    Never 43.1 39.5 41.6 40.1 40.4 40.6 40.8 38.0 39.8 38.3 39.8 44.9 48.1 42.6 40.9
    Seldom/Sometimes 23.5 27.1 29.2 27.8 21.6 29.4 30.5 26.3 28.5 27.8 29.9 26.6 22.5 23.9 26.9
    Most times/Always 33.4 33.4 29.3 32.1 37.9 30.0 28.7 35.7 31.7 33.9 30.3 28.5 29.4 33.6 32.3
Weighted N = 331 299 273 408 387 392 417 355 360 365 360 322 302 274 4,866
Age 27–28
Frequency of Condom Use in Past Year:
    Never 47.0 55.2 50.2 49.6 53.3 47.7 46.7 50.6 51.7 45.6 48.8 48.2 48.9 51.1 49.4
    Seldom/Sometimes 27.1 19.8 24.2 25.6 22.9 28.4 26.1 24.0 25.2 25.4 24.9 23.8 23.7 21.8 24.5
    Most times/Always 33.4 25.0 25.6 24.8 23.9 23.8 27.2 25.4 23.2 29.0 26.3 28.0 27.4 27.1 26.0
Weighted N = 308 320 312 413 409 387 388 365 382 343 334 315 319 338 5,006
Age 29–30
Frequency of Condom Use in Past Year:
    Never 54.3 53.8 51.3 54.8 53.7 51.8 55.9 53.4 53.5 54.0 57.3 57.8 55.6 51.6 54.1
    Seldom/Sometimes 21.4 19.4 25.8 23.1 23.1 24.6 21.9 22.0 24.7 26.7 25.9 19.6 22.9 23.9 23.3
    Most times/Always 24.3 26.8 22.9 22.1 23.2 23.6 22.2 24.6 21.8 19.3 16.8 22.6 21.5 24.5 22.6
Weighted N = 319 287 281 464 459 416 405 379 378 368 372 299 311 312 5,149
Source. The Monitoring the Future study, the University of Michigan.
aIn 2004–2006, the questions about condom use were included in two questionnaire forms. In 2007, these questions were added to a third 
questionnaire form.
Year of Administration
TABLE 10-1d
Use of Condoms in Past Year by 2-Year Age Groupsa
(Entries are percentages.)
among Young Adults
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Source.  The Monitoring the Future study, the University of Michigan.
aBased on those reporting sexual activity with one or more partners during the past year.  Those 
reporting no partners are omitted.
(most times or always)
FIGURE 10-1
by Gender a among Respondents of Modal Ages 21-30
Trends (2-year average) in Annual Condom Use 
by Gender a among Respondents of Modal Age 35/40
(most times or always)
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Source.  The Monitoring the Future study, the University of Michigan.
Trends (2-year average) in Having an 
HIV/AIDS Test in the Past Year 
by Gender among Respondents of Modal Age 35/40
FIGURE 10-2
Trends (2-year average) in Having an 
HIV/AIDS Test in the Past Year 
by Gender among Respondents of Modal Ages 21-30
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Source.  The Monitoring the Future study, the University of Michigan.
aThose respondents who report never having been tested for HIV are excluded from these percentages.
Trends (2-year average) in Receiving HIV/AIDS Test Results 
FIGURE 10-3
Trends (2-year average) in Receiving HIV/AIDS Test Results 
by Gender a among Respondents of Modal Ages 21-30
by Gender a among Respondents of Modal Age 35/40
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Chapter 11 
SUMMARY AND CONCLUSIONS 
Risk behaviors for the spread of HIV/AIDS are all too prevalent among today’s young adults. 
Sharing needles, engaging in sex with multiple partners, and having unprotected male-to-male sex 
are perhaps the most important ones.  
Based on our 2004 through 2017 national surveys combined, about one quarter (24.0%) of young 
adults aged 21 to 30 indicated having more than one sex partner in the prior 12 months (26.3% of 
males and 21.9% of females). However, trend data show that previously observed differences 
between males and females on this statistic have been virtually eliminated by 2017 (21.9% for 
males vs. 22.9% for females) as having multiple sex partners has declined significantly among 
young adult males. However, males are still somewhat more likely than females to report having 
four or more partners (9.3% of males, 7.6% of females, and 8.3% overall). Some 5.2% said they 
had five or more partners (6.3% of males and 4.3% of females). Thus young adult men on average 
are still at higher risk than young adult women based on number of sex partners they have, but the 
gender difference has narrowed as the proportion of males having more than one partner has 
declined considerably along with a significantly increasing abstention rate. The percent of young 
adult males indicating they had no sex partners in the prior 12 months rose from 14.4% in 2008 to 
23.1% in 2017 (p<.001). Females also have shown an increase in abstention in the prior 12 months, 
albeit a smaller one, from 12.3% in 2005 to 16.1% in 2017 (p<.001). These reductions in the 
number of sex partners are important changes in a risk factor for HIV/AIDS.  
Young adult men reporting sex exclusively with men are considerably more likely to have multiple 
partners than men reporting sex exclusively with women, thus compounding their already higher 
risk. Among sexually active male respondents in 2017 almost one in twenty (4.5%) indicated 
having had sex exclusively with male partners in the prior 12 months (and another 0.9% indicated 
having sex with both genders); slightly over half of them reported having multiple male partners, 
including 21% of them reporting five or more male partners. Among 35- and 40-year-old men 
slightly lower proportions had sex exclusively with men in the prior year (4.2% and 3.2%, 
respectively) and another 0.7% and 0.5% respectively had sex with both genders. Men in these 
older age groups who have sex with men are also more likely to have multiple sex partners during 
the year. Among 35-year-olds who had sex exclusively with men in the prior year 54% had 
multiple partners, and among 40-year-olds 50% did—much higher rates than among men the same 
age who have exclusively female partners. So, these two risk factors—men having sex with men 
and having multiple sex partners—combine to create even higher risk than either alone. 
While young adult men who have sex exclusively with men use condoms about as frequently as 
men who have sex exclusively with women; the differences are small and not statistically 
significant—38% of the former group say they use condoms “most times” or “always” versus 37% 
in the latter group. Among the 35- and 40-year-olds, men who have sex exclusively with men 
actually have a lower prevalence of using condoms than those having sex exclusively with women; 
but it is also the case that 30–40% of them use condoms “most times” or “always.” So, there is 
some evidence in these two older age groups of compensatory protective behavior for the 
heightened risk involved in men having sex with men. 
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Among all young adults the protective behavior of using condoms rises considerably with the 
number of sex partners reported, and that is true among 35- and 40-year-olds as well. The higher 
the number of partners, the higher the rate of condom use; this holds true for both genders. So, 
there is some compensatory protective behavior here, as well, associated with the increased risk 
derived from having more sex partners, but certainly not enough to fully offset that added risk. 
Some 41% of young adult men who report having sex exclusively with men in the prior 12 months 
indicate having been tested for HIV/AIDS in the same interval. This compares with only 17% of 
young adult men who report having sex exclusively with women. Men who have sex exclusively 
with men are also more likely to obtain the results of their tests. Thus there is evidence of some 
further compensatory protective behavior indicated in this high risk group.  
Among all respondents, the proportion getting tested for HIV/AIDS rises with the number of sex 
partners reported—again indicating some compensatory protective behavior related to increased 
risk—though even among those with five or more partners during the year, only 39% indicate 
being tested in that interval.  
These data suggest that a number of people recognize that their sexual practices put them at greater 
risk and take action to determine whether or not they are already infected. That can be particularly 
important because it can allow a person testing positive to initiate treatment and protect against 
spreading the disease to others by refraining from risky sexual contact, using condoms if they do 
have sex, and avoiding sharing needles with others if they are drug injectors. Their partners can 
also be alerted to use pre-exposure prophylaxis (PrEP) because they are at heightened risk (CDC, 
2018). Interestingly, condom use and HIV testing—two risk-reduction behaviors—do not seem to 
correlate with each other. 
Only about 0.5%, or one in every 200, of 21- to 30-year-old respondents surveyed in 2004–2017 
(combined) admitted to ever sharing needles in their lifetime—0.2% in the prior 12 months. 
Importantly, one-third of young adults who ever injected drugs (1.5%) reported having ever shared 
needles (0.5%). Of those injecting drugs in just the prior 12 months (0.5%) nearly half (0.2%) 
indicated that they shared needles in that time interval. Although those who have shared needles 
represent a small proportion of the population, they are at particularly high risk for contracting and 
for transmitting HIV. Furthermore, we believe it likely that we underestimate the size of this group. 
Of those few respondents in the samples who have ever shared needles, about 40% indicate having 
been tested for HIV in the prior 12 months—roughly twice the rate among all young adults who 
have never shared needles—indicating some compensatory protective behavior for this serious 
risk behavior. Those who have shared needles, however, carry increased risk from being more 
likely than others to have multiple sex partners and from having a lower prevalence of condom use 
than those who have not shared needles, thus increasing the risk that they acquire HIV and/or 
transmit it to others. 
Findings reported here for young adults are based on the fourteen annual data collections 
combined; and, as we have stated at various points in this monograph, even then the numbers of 
cases often are not sufficient to provide statistical confidence for relatively rare behaviors or 
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especially for the intersection of rare behaviors. Nevertheless, the prevalence data tend to replicate 
across years, giving us increased confidence in their validity. 
The extent to which these HIV/AIDS risk and protective behaviors are changing over time is of 
great importance to the country, and the evidence here from the most recent twelve-year interval 
suggests that only limited change is taking place in the general population of young adults who 
have completed high school. One of the changes large enough to reach statistical significance was 
a gradual decline in the proportion of young adult males who reported ever getting tested for 
HIV/AIDS—a change in the wrong direction. To illustrate, the percent of young adult males who 
had never been tested for HIV rose from 62% in 2005 to 69% in 2017. On the other hand, rates of 
past-year young adult female testing appear to have risen gradually and significantly from 2005 
(23.7%)  through 2017 (27.0%), and that combined with the reduction in testing by males during 
that period has resulted in a larger gender difference in recent years (Figure 10-2; the increase in 
the gap is significant: p<.001). Thus, in 2017, 27% of young adult females reported getting tested 
in the prior 12 months compared to 15% of young adult males; this is despite the fact that the males 
are at considerably higher risk of contracting HIV. Among the 35- and 40-year-olds, there is some 
evidence of an increase in recent years among both males and females in the prevalence of getting 
tested, but the changes do not reach statistical significance (see Figure 10-2).    
One positive development is that the proportion of all young adults who fail to secure their test 
results started out quite low at about 8% among those tested in 2004—the beginning year for this 
study—and became still lower (about 6% of those tested) by 2011 by a statistically significant 
amount. It remained at 6% in 2017. 
The data from 35- and 40-year-olds present a less clear picture due to the smaller samples and 
shorter time intervals covered so far. Consistent with what we know about the opioid epidemic, 
the only trends that were statistically significant were an increase among 35-year-old males in their 
lifetime injection drug use between 2011 and 2013, as well as in the frequency of their injection 
drug use, with the percent reporting using on 20 or more occasions in their lifetime rising from 
0.5% in 2012 to 1.6% in 2014 (p<.05). They also showed some increase in needle sharing from 
2009 to 2011, followed by a leveling; and there appeared to be some upward drift in needle sharing 
from 2011 to 2013 among 35-year-old females and 40-year-old males and females, though not a 
significant one.1 
As we have argued in the context of drug abuse, there is always a danger of generational 
forgetting—that through generational replacement combined with reduced attention to the topic in 
media and with fewer casualties, younger cohorts may not acquire the knowledge and concern 
about risks that earlier cohorts possessed and that motivated them to avoid risky behaviors. It seems 
likely that there has been a considerable shift over the past two decades in the perceived dangers 
of HIV/AIDS. Some reduction in perceptions of risk may be due to improvements in treatment 
effectiveness, but this likely left recent cohorts of young adults more vulnerable to taking the kinds 
of risks associated with both contracting and transmitting the disease. In particular, survival rates 
for those having AIDS have increased, starting around 1996 with the introduction of antiretroviral 
1 It should be noted that we have not been able to make separate estimates for some of the highest risk subgroups in the population as identified by 
the Centers for Disease Control and Prevention (March 14, 2012): These include (in order after White men who have sex with men [MSM]) Black 
MSM, Hispanic/Latino MSM, Black heterosexual women, Black heterosexual men, Hispanic/Latina heterosexual women, (followed by White 
heterosexual women), etc. To be able to make meaningful estimates for these subgroups would require much larger annual samples. 
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therapy (Crum et al., 2006; see also http://www.cdc.gov/media/pressrel/aids-d1.htm). This 
improvement in survival rates is certainly a very favorable development—but one that also carries 
the risk of reduced perceptions of the dangers of AIDS for incoming cohorts of young adults. This 
underscores the importance of continued education and prevention efforts. 
Although great progress has been made in HIV risk reduction in recent decades, in large part 
through medical advances, the MTF results show that there has been only limited progress over 
the past decade in key behaviors in the population related to acquiring HIV/AIDS, and thus, there 
is little room for complacency.2 There appears to be a substantial portion of the population that 
current HIV policies and interventions are not reaching. These MTF results suggest that efforts to 
reduce HIV risk beyond current levels will require further effort, research, and innovation in HIV 
prevention. 
2 A number of efforts are still being made, of course, to further improve biomedical approaches to the prevention of HIV (HIV.gov, 2018). 
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APPENDIX 
OTHER RELEVANT STUDIES OF THE GENERAL POPULATION 
Seven other studies that generate information on risk and protective behaviors on national samples 
of the U.S. general population are described below. The degree of overlap with MTF is discussed 
for each. 
National Longitudinal Study of Adolescent Health (Add Health). The Add Health study is a 
nationally representative, longitudinal study of U.S. youth who were in grades 7–12 during the 
1994–1995 school year. The original panel, surveyed in-home, initially comprised around 21,000 
individuals, with about 15,000 interviewed at waves 2, 3, and 4. This set of class cohorts has been 
followed into adulthood, with additional data collection waves in 1996, 2001/2002, and 
2008/2009, and (most recently) 2016-18 (Carolina Population Center, 2018; Harris et al., 2008). 
Collected data include measures on perceived risk of HIV/AIDS, sexual behavior history, 
contraceptive use, sexually transmitted disease (STD) history, and substance use including 
injection drug use (IDU) and needle sharing. Not all of the HIV/AIDS risk behavior measures are 
asked at each wave of data collection. A wide range of analyses focusing on risk behaviors for 
HIV and other sexually-transmitted infections have been published with Add Health data (for a 
listing of publications, see https://www.cpc.unc.edu/projects/addhealth/publications). These 
studies provide important data based on the six adjacent class cohorts included in Add Health; 
however, MTF continually adds cohorts and can thus track historical trends for fixed age groups 
and also for many cohorts over time. For more information on Add Health, see 
https://www.cpc.unc.edu/projects/addhealth. 
General Social Survey (GSS). Conducted by the National Opinion Research Center at the 
University of Chicago, GSS began in 1972 as an annual survey (although no surveys were 
conducted in 1979, 1981, or 1992) and went to a biennial format beginning in 1994. Prior to 2008, 
the study used cross-sectional surveys of the U.S. non-institutionalized adult household population 
(ages 18 and over). Starting in 2008, the design was changed to a rotating panel, with each entering 
cohort to be followed up for the next two consecutive surveys (e.g., the 2006 cohort was re-
interviewed in 2008 and 2010; National Opinion Research Center, 2018). Most items on sexual 
risk and protective factors were added to the GSS starting in 1988, and the survey now includes 
measures such as number and type of sex partners, ever paying for sex, heterosexual and 
homosexual sex, condom use, and HIV/AIDS testing. A limited number of substance use items 
are asked, including injection drug use (but not needle sharing) and crack cocaine use (both lifetime 
and past 30-day use). However, the only other item on substance use (use of any illegal drugs in 
the past 12 months) has not been asked since 2004 (Davis & Smith, 2007). GSS data are collected 
in a face-to-face interview context: paper-and-pencil questionnaires were used through 2000; 
collection via computer-assisted personal interviewing (CAPI) has been used since 2002. As part 
of the CAPI format, the respondent is handed the interviewer’s laptop computer to self-complete 
the more sensitive sections using computer-assisted self-interviewing (CASI). Because MTF uses 
self-administered, mailed questionnaires, and thus does not have an interviewer present, a higher 
level of perceived privacy may exist for respondents when answering HIV/AIDS risk behavior–
related items (Brener et al., 2006) resulting in more valid data. HIV/AIDS publications from the 
GSS have reported on sexual risk behaviors (e.g., Anderson, 2003; Anderson et al., 2003; Choi et 
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al., 1994; Johnen et al., 1995; Twenge et al., 2017), HIV testing (e.g., Oraka et al., 2018; Pitasi et 
al., 2018), and HIV diagnoses rates (Jones et al., 2018). Given that substance use behaviors are not 
consistently collected in the GSS and needle sharing is not measured, MTF provides an important 
additional source for both cross-sectional and longitudinal data that look at the intersection of these 
behaviors with other HIV/AIDS risk and protective factors. For more information about GSS, see 
http://www.norc.org/Research/Projects/Pages/general-social-survey.aspx. 
National Epidemiological Survey on Alcohol and Related Conditions (NESARC). During 
2001-2002, NESARC surveyed a nationally representative sample of approximately 
43,000 U.S. civilian, noninstitutionalized adults aged 18 and older (Hasin & Grant, 
2016). The initial participants were surveyed again in 2004-2005 through NESARC-II. Most 
recently, a new large-scale nationally representative sample was surveyed in 2012-2013 through 
NESARC-III (Grant et al., 2015). Data collection involved face-to-face computer-assisted 
personal interviewing (CAPI). The NESARC studies examine detailed measures of alcohol, 
drug, and psychiatric disorders; sex risk behaviors; substance use (including injection drug 
use); and HIV diagnosis and testing. Publications using NESARC data have addressed 
prevalence and correlates of HIV testing (Blanco et al., 2018) and associations between a 
range of psychological and substance use/disorder measures and risk behaviors associated 
with HIV (e.g., Lopes et al., 2012; O’Leary et al., 2006; Reisner et al., 2011; Sareen et al., 2009; 
Thompson et al., 2014). While NESARC provides detailed data in these areas, the survey is 
time-limited, and has involved only one 3-year longitudinal component. MTF provides an 
important broad-based range of risk and protective factors using a continued cohort-sequential 
longitudinal design, with potentially higher perceived privacy due to not utilizing in-person 
interviewing. For more information on NESARC, see https://
www.niaaa.nih.gov/research/nesarc-iii. 
National Survey on Drug Use and Health (NSDUH). Begun in 1971, the NSDUH study is now an 
annual, cross-sectional survey of the civilian, non-institutionalized U.S. population ages 12 
and older (SAMHSA, 2017). Approximately 67,500 persons are interviewed in NSDUH each 
year. In 1999, NSDUH was redesigned to allow state-level estimates. As suggested by the study 
name, a major focus is on measures related to substance use, including injection drug use (IDU). 
Published findings utilizing NSDUH data related to IDU have reported national IDU 
prevalence levels, demographic and geographic variation in such use, and correlates of risky 
injection practices (Novak & Kral, 2011; Ropelewski et al., 2011; SAMHSA, 2007). Data 
are also collected on lifetime and past-year HIV/AIDS diagnoses as well as related health 
conditions such as hepatitis and sexually transmitted diseases (e.g., SAMHSA, 2010). However, 
data on participation in high-risk sexual behaviors are not collected, which distinguishes MTF 
from NSDUH. In addition, MTF collects longitudinal data on individuals over time as part of its 
cohort-sequential design. For more information about NSDUH, see https://nsduhweb.rti.org/
respweb/homepage.cfm. 
National Health and Nutrition Examination Survey (NHANES). NHANES began in the early 
1960s as a series of surveys initiated by the National Center for Health Statistics, focusing on 
different population groups and health topics. In 1999, NHANES began to be conducted on a 
continuous basis with a nationally representative cross-sectional sample of approximately 5,000 
individuals per year (CDC, 2017a). Data on number and type of sexual partners and 
behaviors (including condom use) are collected from respondents aged 14–69. Through 2004, 
only limited drug use data were collected. However, beginning in 2005, age at first use, lifetime, 
and past 30-day use of 
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marijuana, cocaine, heroin, methamphetamine, and injection drug use were collected from 
individuals aged 12–69 (needle sharing is not included). NHANES data for these items are 
collected using audio computer-assisted self-interviewing (ACASI) at NHANES mobile 
examination centers. With ACASI, the interviewer is unaware of the highly sensitive questions as 
they are asked or of the answers being given, thus providing respondents with a high level of 
privacy similar to self-administered questionnaires like those used in MTF (Brener et al., 2006). 
Studies using NHANES data have focused on HIV testing (Guo & Sims, 2017) and prevalence 
(McQuillan et al., 2006), as well as characteristics of sub-groups at high risk for sexually-
transmitted diseases (e.g., Esie et al., 2018; Martinez et al., 2017; Xu et al., 2010). NHANES is 
the only national survey that collects and tests blood samples from participants aged 18–49 for the 
HIV antibody (CDC, 2016b). A longitudinal component of NHANES is underway that follows up 
a sub-sample of participants in the 2007-2014 continuous NHANES surveys (CDC 2017b). MTF 
includes a broader range of substance use measures, including needle sharing, and is able to utilize 
on-going panel data to examine individual change over time in HIV/AIDS risk and protective 
behaviors. For more information on NHANES, see https://www.cdc.gov/nchs/nhanes/index.htm. 
 
National Survey of Family Growth (NSFG). Sponsored by the National Center for Health Statistics, 
NSFG was begun in 1973 and was initially designed to be a periodic national fertility study of U.S. 
females. In 2002, the survey provided nationally representative cross-sectional samples of both 
males and females ages 15–44. In mid-2006, the NSFG began continuous interviewing utilizing a 
rolling, cumulating yearly nationally representative sample of U.S. households (Lepkowski et al., 
2006), with a target of approximately 5,000 interviews among individuals ages 15-44 per year. 
The NSFG gathers detailed data on sexual risk behaviors of many kinds, including number of sex 
partners and condom use, heterosexual anal and oral sex, sexual health risks and formal sex 
education, and homosexual sex (CDC, 2016a). The NSFG contains some items on substance use, 
including injection drug use and needle sharing; it also asks about testing and diagnoses of sexually 
transmitted diseases including HIV. The most sensitive questions are asked using ACASI in order 
to provide respondents with a high level of privacy. Published NSFG data have addressing HIV 
risk and protective factors including condom use (Nasrullah et al., 2017), number of sex partners 
(Harper et al., 2017) and sexual behaviors (Copen et al., 2016).  Longitudinal panel data are not 
collected on NSFG respondents. MTF uses self-administered, mailed questionnaires, which should 
also provide respondents with a high level of privacy similar to that in ACASI and thus provide 
similarly valid data (Brener et al., 2006). Further, the longitudinal component of the MTF study 
has allowed for examination of HIV/AIDS risk and protective behaviors from age 21 through 40 
among all U.S. high school graduating cohorts since 2004. Further, MTF is capable of correcting 
for the recanting of earlier reported drug using behaviors (Johnston & O’Malley, 1997; Johnston 
et al., 2015). For more information on NSFG, see https://www.cdc.gov/nchs/nsfg/index.htm. 
 
National Youth Risk Behavior Survey (YRBS). YRBS is conducted every two years, and provides 
nationally representative, cross-sectional data on priority health risk behaviors for 9th- through 
12th-grade students in public and private U.S. schools (Brener et al., 2013). The number of 
respondents averages around 15,000 per survey (Brenner et al., 2013). Several HIV/AIDS-related 
risk behaviors have been measured since its inception in 1991, including substance use and sexual 
activity. YRBS data include national and sociodemographic group-specific prevalence measures 
of high school student licit and illicit substance use (including a measure of lifetime intravenous 
drug use), lifetime and current sexual activity (including number of partners), condom use, 
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substance use before sexual behavior, and HIV/AIDs education and testing (CDC, 2018a). YRBS 
data have been used to examine trends over time in such behaviors (CDC, 2018b; Harper et al., 
2018), as well as how substance use and sexual risk behaviors interrelate (Dunn & Yannessa, 2018; 
Santelli et al., 2009; Springer et al., 2007). The work of MTF complements that of the YRBS 
coverage of 14- through 18-year olds by covering respondents ages 21 to 40, a highly relevant age 
group for the spread of HIV/AIDS. MTF also contains a considerably more complete set of drug 
use measures, including annual and 30-day injection drug use, and lifetime and past-year needle 
sharing. In addition, the longitudinal nature of MTF allows an examination of how HIV/AIDS risk 
behaviors change over time across age within different cohorts. For more information on YRBS, 
see https://www.cdc.gov/healthyyouth/data/yrbs/index.htm. 
 
Key Distinctions among the Studies 
A review of these seven studies shows that, although key data are provided by each, none of the 
studies allows for the ongoing, cohort-sequential prospective examination of both substance use 
and other risk and protective behaviors for HIV/AIDS among the U.S. young adult population. 
YRBS does not cover age groups above 18 or 19; GSS does not broadly examine substance use 
behaviors; NSDUH does not cover high-risk sexual behaviors; Add Health covers only six class-
cohorts; NESARC is not a yearly survey; NSDUH, NSFG, and YRBS do not gather longitudinal 
panel data on their respondents, and NHANES has only recently introduced a longitudinal follow-
up component. Further, most of these studies do not include all of the measures of risk and 
protective behaviors covered in MTF. Thus, along with these other national studies, MTF is an 
essential component of the nation's efforts to monitor and understand HIV/AIDS risk behaviors in 
the general population, as opposed to specially selected high risk populations.  
 
Whatever changes occur in the proportions of American young adults choosing to engage in these 
risk and risk-reduction behaviors will, of course, have very important consequences for the course 
of the nation’s HIV/AIDS epidemic. MTF findings thus stand to make important contributions to 
our understanding of this major health problem and our ability to deal with it effectively. 
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